[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes TDP-43, a protein critical for RNA processing and stress granule dynamics. Mutations in TARDBP are a major cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive motor neuron loss. The network provided includes components of complex I of the mitochondrial respiratory chain, which is involved in ATP production. While TARDBP itself is not part of complex I, its dysfunction can lead to mitochondrial dysfunction, oxidative stress, and neuronal death, contributing to ALS pathology. TDP-43 mislocalization and aggregation are hallmark features of ALS, particularly in familial cases. The interaction between TARDBP and mitochondrial proteins suggests a link between RNA metabolism and mitochondrial function, both of which are disrupted in ALS. Therefore, TARDBP mutations contribute to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes TDP-43, a protein critical for RNA processing and stress granule dynamics. Mutations in TARDBP are associated with mislocalization and aggregation of TDP-43, leading to neurodegeneration. This contributes to amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. TDP-43 pathology is also observed in frontotemporal lobar degeneration (FTLD), particularly FTLD with ubiquitin-positive bodies (FTLD-U). The disruption of TARDBP affects RNA metabolism and protein homeostasis, leading to neuronal dysfunction and death. TARDBP mutations are one of the most common genetic causes of familial ALS, and TDP-43 aggregation is a hallmark of both ALS and FTLD. Therefore, the biological effect of this TARDBP allele is the contribution to amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a critical RNA-binding protein involved in RNA processing and stress granule dynamics. Mutations in TARDBP are a major cause of **frontotemporal lobar degeneration (FTLD)**, particularly **FTLD with ubiquitinated TDP-43 (FTLD-TDP)**. These mutations lead to the aberrant aggregation of TDP-43 protein, which disrupts RNA metabolism and causes neuronal dysfunction. TDP-43 pathology is also observed in **amyotrophic lateral sclerosis (ALS)**, where it contributes to motor neuron degeneration. The interaction between TARDBP and complex I subunits (CxI) suggests a link between mitochondrial dysfunction and neurodegeneration. Overall, TARDBP mutations are strongly associated with **frontotemporal dementia** and **ALS**, highlighting its role in neurodegenerative diseases. \n\n\\boxed{Frontotemporal Dementia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is part of a pathway involving VHL, RBX1, ELOC, ELOB, and CUL2, which targets HIF1A for degradation under normoxic conditions. Under hypoxia, VHL dysfunction leads to HIF1A stabilization, activating downstream genes such as VEGFA, PDGFB, and TGFB, promoting angiogenesis and cell proliferation. This pathway is critical in tumor progression. Mutations in VHL disrupt this regulation, leading to constitutive HIF1A activation, a hallmark of certain cancers. This contributes to the development of clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. The stabilization of HIF1A under normoxia promotes tumor angiogenesis, cell survival, and metastasis. Therefore, VHL dysfunction is a key driver in ccRCC, making it a critical gene in the disease's pathogenesis.\n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, when mutated, disrupts the VHL-RBX1-ELOC-ELOB-CUL2 E3 ubiquitin ligase complex, which targets HIF1A for proteasomal degradation under normoxia. In the absence of functional VHL, HIF1A accumulates, leading to constitutive activation of hypoxia-inducible genes. This pathway includes ARNT, forming the HIF1A-ARNT transcription factor complex, which drives the expression of genes such as VEGFA, PDGFB, and TGF\u03b2 family members. This leads to uncontrolled angiogenesis, cell proliferation, and tissue remodeling, hallmark features of vascular tumors. The most well-characterized disease associated with VHL mutations is **Von Hippel-Lindau disease**, a hereditary disorder characterized by the development of benign and malignant tumors in multiple organs, including hemangioblastomas, renal cell carcinomas, and pheochromocytomas. The dysregulation of the VHL pathway is central to the pathogenesis of this syndrome.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele in this genomic pathway is part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, which is critical for ubiquitination and degradation of HIF1A under normoxic conditions. In the absence of functional VHL, this complex fails to degrade HIF1A, leading to its stabilization and activation. HIF1A then drives the transcription of genes such as VEGFA, PDGFB, and TGFs, promoting angiogenesis, cell proliferation, and fibrosis. This dysregulation is a hallmark of hypoxia-inducing pathways and is strongly associated with tumor progression. The VHL mutation leads to constitutive activation of the HIF pathway, contributing to the development and progression of clear cell renal cell carcinoma (ccRCC). This disease is characterized by the loss of VHL function, leading to uncontrolled cell growth and angiogenesis. The pathway described is central to the pathogenesis of this malignancy. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the regulation of the p53 tumor suppressor pathway. CDKN2A encodes for p14ARF, which inhibits MDM2, a negative regulator of TP53. This allows TP53 to remain active, promoting cell cycle arrest and apoptosis in response to DNA damage. CDKN2A also directly inhibits CDK4/6 and cyclins D1/D2/D3, preventing the phosphorylation of RB1 and subsequent activation of E2F transcription factors, which drive cell cycle progression. Loss or mutation of CDKN2A disrupts this regulatory network, leading to unchecked cell proliferation and genomic instability. This contributes to the development of various cancers, particularly melanoma and pancreatic cancer. The impairment of this pathway is a key driver in the pathogenesis of these diseases. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the regulation of the p53 tumor suppressor pathway. CDKN2A encodes INK4a, which inhibits CDK4/6, preventing the phosphorylation of RB1. This inhibition blocks E2F-driven cell cycle progression, thereby suppressing cell proliferation. Mutations or inactivation of CDKN2A lead to loss of this inhibitory function, allowing unchecked cell division. This disruption contributes to genomic instability and uncontrolled cell growth, hallmarks of cancer. Specifically, CDKN2A inactivation is a key driver in melanoma, where it impairs the p53 pathway, reducing the ability of cells to respond to DNA damage. It is also frequently altered in other cancers, including pancreatic neuroendocrine tumors and bladder cancer. The loss of CDKN2A results in the activation of cyclins D and CDK4/6, leading to RB1 inactivation and E2F-mediated transcription of genes promoting cell cycle progression. Thus, the biological effect of CDKN2A inactivation is oncogenic, contributing to the development of melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4/6, which regulates the cell cycle by preventing the phosphorylation of RB1. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and degrades TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions, including the induction of CDKN1A and inhibition of E2F-driven cell cycle progression. Loss or mutation of CDKN2A disrupts this checkpoint, leading to uncontrolled cell proliferation. This contributes to several cancers, most notably melanoma, pancreatic adenocarcinoma, and prostate cancer. CDKN2A mutations are also implicated in Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. Therefore, the biological effect of CDKN2A loss is the promotion of tumorigenesis by compromising the p53-mediated cell cycle arrest and DNA repair pathways. \n\n\\boxed{(Melanoma)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent downstream signaling through GNAQ, PLCB, IP3, and calcium release from the endoplasmic reticulum (ER) and mitochondria. The mitochondrial calcium overload via MCU leads to the opening of the mitochondrial permeability transition pore (MPTP), releasing cytochrome c and triggering apoptosis. This pathway is central to Alzheimer's disease (AD) pathology, as the accumulation of amyloid-beta is a hallmark of AD and is linked to neuronal dysfunction and death. The involvement of mAChRs and calcium dysregulation further supports the role of this pathway in AD. The genetic components listed are all implicated in AD through their roles in amyloid metabolism, neurotransmission, and mitochondrial function. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the amyloid beta precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). This Abeta binds to muscarinic acetylcholine receptors (mAChR), specifically CHRM1, CHRM3, and CHRM5. The activation of these receptors leads to the activation of GNAQ, which triggers phospholipase C beta (PLCB) to generate IP3. IP3 releases calcium from the endoplasmic reticulum (ITPR1-3), and calcium enters mitochondria via MCU and voltage-dependent anion channels (VDAC1-3). The accumulation of mitochondrial calcium can lead to the opening of the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis. This pathway is central to Alzheimer's disease pathology, where APP processing and Abeta accumulation contribute to neurodegeneration, mitochondrial dysfunction, and neuronal death. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the release of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and downstream activation of GNAQ, PLCB, and IP3. The IP3 receptor allows the release of calcium ions (Ca2+), which are further transported into mitochondria via the MCU. This mitochondrial calcium overload triggers the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c (CYCS) and ultimately apoptosis. This pathway is central to neurodegeneration, particularly in Alzheimer\u2019s disease. The accumulation of amyloid-beta and subsequent mitochondrial dysfunction are key contributors to neuronal death in Alzheimer\u2019s. Thus, alterations in this pathway, especially involving the APP gene, are strongly associated with the development of **Alzheimer\u2019s disease**.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel (Kv3.4), which plays a critical role in repolarizing cardiac cells during action potentials. Mutations in KCNC3 can disrupt normal ion homeostasis, leading to arrhythmias. Specifically, gain-of-function mutations in KCNC3 have been associated with **long QT syndrome type 1 (LQTS1)**, a cardiac disorder characterized by prolonged QT interval on ECG, increased risk of torsades de pointes, and potentially sudden cardiac death. These mutations result in prolonged action potentials in cardiac myocytes, increasing the likelihood of life-threatening arrhythmias. KCNC3 is also implicated in other neurological and cardiac conditions, but its most well-documented disease association is LQTS1. The altered function of the Kv3.4 channel due to KCNC3 mutations disrupts the delicate balance of ion currents essential for normal cardiac electrophysiology. \\boxed{Long QT syndrome type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **KCNC3** gene encodes a voltage-gated potassium channel subunit (Kv3.3), which plays a critical role in repolarizing neurons by allowing the efflux of potassium ions. Mutations in **KCNC3** disrupt normal ion homeostasis, leading to impaired neuronal excitability. This contributes to hyperexcitability in the nervous system. Specifically, gain-of-function mutations in **KCNC3** are associated with **myoclonic epilepsy with eyelid myokymia (MIM 604315)**, a rare neurological disorder characterized by myoclonic seizures and continuous eyelid myokymia. These mutations result in increased potassium channel activity, causing excessive neuronal firing and seizure activity. The disease is typically inherited in an autosomal dominant manner. The altered ion flux due to the **KCNC3** allele disrupts normal neural function, leading to the clinical manifestations observed in this condition.\n\n\\boxed{Myoclonic epilepsy with eyelid myokymia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a neuronal potassium voltage-gated channel subunit, which plays a critical role in regulating action potential repolarization in neurons. Mutations in KCNC3 can disrupt normal ion channel function, leading to altered neuronal excitability. This contributes to neurodevelopmental and neurological disorders. Specifically, pathogenic variants in KCNC3 have been associated with **epilepsy** and **cognitive impairments**, often as part of neurodevelopmental syndromes. These mutations can result in hyperexcitability of neurons, increasing the risk of seizures. Additionally, KCNC3 mutations have been linked to **developmental and progressive encephalopathy** with seizures and intellectual disability. The disruption of potassium homeostasis in neurons due to KCNC3 dysfunction can lead to a range of neurological manifestations, underscoring its importance in neuronal physiology. The precise disease contribution of KCNC3 depends on the type and location of the mutation, but it is most notably associated with **epilepsy**.\n\n\\boxed{Epilepsy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid-beta precursor protein (APP), leading to the release of calcium ions from the mitochondria and ultimately contributing to mitochondrial dysfunction. The involvement of APP in the production of amyloid-beta peptides is central to this process. Accumulation of these peptides disrupts cellular homeostasis, particularly in neurons, leading to neurodegeneration. The pathway culminates in the release of cytochrome c, which is a key mediator of apoptosis. This mechanism is strongly associated with Alzheimer's disease, where the accumulation of amyloid-beta plaques and mitochondrial dysfunction play pivotal roles in neuronal death. The genes involved in this pathway are implicated in the pathogenesis of Alzheimer's disease, highlighting the contribution of the APP allele to this condition. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the **APP (amyloid beta precursor protein)** gene, which is critical in Alzheimer\u2019s disease. The pathway involves the cleavage of APP to produce **Abeta**, a key pathological protein in Alzheimer\u2019s. Abeta then interacts with **mAChR (muscarinic acetylcholine receptors)**, leading to activation of **GNAQ** and downstream signaling through **PLCB** (phospholipase C beta), resulting in **IP3** production. IP3 binds to **ITPR** (inositol 1,4,5-trisphosphate receptors), releasing **Ca\u00b2+** into the cytoplasm. This calcium then enters the mitochondria via **MCU** (mitochondrial calcium uniporter), leading to mitochondrial dysfunction and the opening of **MPTP** (mitochondrial permeability transition pore). This ultimately releases **cytochrome c (CYCS)**, triggering apoptosis. This pathway is central to **Alzheimer\u2019s disease**, as it contributes to neurodegeneration through amyloid accumulation, calcium dysregulation, and mitochondrial damage. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is the production of amyloid-beta (Abeta), which activates muscarinic acetylcholine receptors (mAChR), leading to activation of GNAQ and downstream signaling via PLCB, IP3, and calcium release from the endoplasmic reticulum (IP3 receptor) and mitochondria (MCU). This mitochondrial calcium overload triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which initiates apoptosis. This pathway is central to neurodegeneration. Mutations in APP are strongly associated with early-onset Alzheimer's disease (AD), where abnormal Abeta accumulation leads to synaptic dysfunction, neuronal death, and hallmark neuropathology. The mitochondrial cascade involving calcium and MPTP contributes to neuronal apoptosis, a key mechanism in AD progression. Therefore, this pathway directly contributes to the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the genomic pathway starting from glutamate signaling through GRM1, GNAQ, and PLCB, leading to IP3 production and subsequent calcium release via ITPR1. This calcium influx triggers mitochondrial calcium uptake via MCU, contributing to mitochondrial calcium overload. This process is linked to the opening of the MPTP (mitochondrial permeability transition pore), leading to the release of cytochrome c (CYCS), a key initiator of apoptosis. Mutations in ATXN3 are associated with ataxia-telangiectasia-like disorder (ATLD), a neurodegenerative disease characterized by progressive ataxia, pigmentary changes, and telangiectases. ATXN3 mutations also contribute to spinocerebellar ataxia type 2 (SCA2), a hereditary ataxia caused by polyglutamine expansions in the ATXN3 gene. The pathogenic mechanism involves toxic gain-of-function due to misfolded ATXN3 protein, leading to neuronal dysfunction and degeneration. The biological effect of the ATXN3 allele is thus directly linked to neurodegeneration and specific ataxic disorders.\n\n\\boxed{Spinocere", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and transcriptional regulation. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins and subsequent neurodegeneration. This contributes to spinocerebellar ataxia type 2 (SCA2), a progressive neurodegenerative disorder characterized by impaired coordination, speech difficulties, and cognitive decline. The pathway involving ATXN3 is part of a calcium signaling cascade that regulates mitochondrial function and apoptosis. Dysregulation of this pathway due to ATXN3 mutations disrupts calcium homeostasis, leading to mitochondrial dysfunction and neuronal death. These molecular alterations are central to the pathogenesis of SCA2. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. In the provided pathway, ATXN3 is implicated in the IP3-Ca\u00b2+ signaling cascade, which regulates mitochondrial calcium levels and contributes to apoptosis through the MPTP and CYCS pathway. Mutations in ATXN3 are well-documented in Spinocerebellar Ataxia Type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. These mutations lead to the production of an abnormal ataxin-3 protein that accumulates in neurons, disrupting cellular function and causing neuronal death, particularly in the cerebellum. The altered calcium dynamics and mitochondrial stress associated with ATXN3 mutations exacerbate neuronal damage, contributing to the pathophysiology of SCA2. Therefore, the biological effect of the ATXN3 allele is the contribution to Spinocerebellar Ataxia Type 2.\n\n\\boxed{Spinocerebellar Ataxia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving stress response and protein folding. SOD1, a copper-zinc superoxide dismutase, catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen, playing a key role in oxidative stress defense. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The pathway involving SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3 highlights the connection between oxidative stress, endoplasmic reticulum (ER) stress, and the unfolded protein response. These processes are disrupted in ALS, leading to neuronal dysfunction and death. Mutant SOD1 proteins misfold, aggregate, and disrupt cellular homeostasis, contributing to neurotoxicity. This pathway is critical in understanding the molecular mechanisms underlying ALS. The biological effect of the SOD1 allele in this context is therefore a key contributor to the pathogenesis of $\\boxed{Amyotrophic Lateral Sclerosis}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described pathway, is involved in oxidative stress response and endoplasmic reticulum (ER) stress signaling. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway involving SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3 reflects the cellular response to oxidative and ER stress, which is dysregulated in ALS. The accumulation of misfolded proteins and oxidative damage, driven by mutant SOD1, leads to neuronal death. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). The pathway involving SOD1, HSPA5, EIF2AK3, EIF2S1, ATF4, and DDIT3 reflects a stress response mechanism. SOD1, a copper/zinc superoxide dismutase, normally detoxifies reactive oxygen species. Mutant SOD1 proteins misfold and aggregate, leading to oxidative stress and neurotoxicity. These aggregates disrupt cellular homeostasis, impair protein folding (via HSPA5), and activate the integrated stress response through EIF2AK3 and EIF2S1. This leads to ATF4 activation, which upregulates DDIT3, promoting cell death. Mutant SOD1 is a well-established cause of familial ALS, characterized by progressive motor neuron degeneration. Thus, the biological effect of the SOD1 allele in this context is the contribution to amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene plays a central role in the pathogenesis of Alzheimer's disease. The pathway described involves the proteasomal degradation of APP and the production of amyloid-beta (Abeta), a key protein in Alzheimer's pathology. The proteasome subunits listed, including those of the 20S and 26S proteasomes, are essential for the degradation of misfolded or damaged proteins, including Abeta. Impaired proteasomal function, as indicated by the involvement of these subunits, can lead to the accumulation of Abeta, contributing to amyloid plaque formation, a hallmark of Alzheimer's disease. Mutations or dysfunction in APP or its degradation pathway can result in increased Abeta production and reduced clearance, exacerbating neurodegeneration. This pathway is critical for maintaining protein homeostasis and is directly linked to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele, as part of a pathway involving proteasome subunits, is central to the formation of amyloid-beta (Abeta) peptides. The pathway describes the processing of APP by proteasomal machinery, specifically the 26S proteasome, which includes ATPases and non-ATPase subunits. Impaired proteasomal function or dysfunction in this pathway leads to the accumulation of misfolded or aggregated proteins, including Abeta. This accumulation is a hallmark of Alzheimer's disease, where Abeta peptides aggregate into plaques, contributing to neurodegeneration. Mutations or dysregulation in APP or proteasome subunits such as PSMA and PSMB genes are linked to increased Abeta production or impaired clearance, accelerating disease progression. Thus, this pathway is critically involved in the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as defined by the pathway APP -> Abeta -| 26S, is central to Alzheimer's disease. The amyloid precursor protein (APP) is cleaved to produce amyloid-beta (Abeta), a key component of plaques found in Alzheimer's brains. The pathway involves the 26S proteasome, which is responsible for degrading misfolded or damaged proteins. Impaired proteasome function leads to the accumulation of Abeta, contributing to neurodegeneration. Mutations in APP or its processing enzymes are well-documented in familial Alzheimer's disease. The involvement of multiple proteasome subunits (PSMA and PSMB) suggests a dysfunction in protein degradation, exacerbating Abeta accumulation. This pathway is critical in the pathogenesis of Alzheimer's disease, making it a key contributor to the disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation. Activating mutations in FGFR3 lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in uncontrolled cell growth and impaired differentiation. In the context of chromosome 4, mutations in FGFR3 are most notably associated with **blastic plasmacytoid dendritic cell neoplasm (BPDCN)**, a rare aggressive myeloid neoplasm. These mutations drive aberrant signaling through the FGFR3 receptor, leading to oncogenic transformation and disease progression. The pathway's involvement in MYC activation further promotes cell cycle progression and tumorigenesis. Thus, FGFR3 mutations on chromosome 4 are a key driver in BPDCN, contributing to its pathogenesis.\n\n\\boxed{Blastic plasmacytoid dendritic cell neoplasm}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation, differentiation, and survival. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in uncontrolled cell growth and proliferation. Mutations in FGFR3 are most notably associated with **bladder urothelial carcinoma** (also known as urothelial cancer), where they drive tumor progression by promoting cell survival and proliferation. These mutations are particularly common in low-grade bladder cancers and are linked to a better prognosis compared to high-grade tumors. Additionally, FGFR3 mutations can also be found in other cancers, such as chondrosarcoma and some lymphomas, but their most prominent and well-characterized association is with bladder cancer. The biological effect is the disruption of normal growth control mechanisms, leading to oncogenic transformation. \n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is central to cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of the downstream MAPK/ERK cascade, promoting uncontrolled cell growth. This dysregulation is implicated in various diseases, most notably **Klein syndrome**, a rare form of achondroplasia, a type of short-limbed short stature disorder. However, the most well-known disease associated with FGFR3 mutations is **bladder cancer**, particularly **bladder urothelial carcinoma**, where activating mutations in FGFR3 drive tumorigenesis by promoting cell proliferation and inhibiting apoptosis. Additionally, FGFR3 mutations are linked to **myeloid malignancies**, such as **myelodysplastic syndromes** and **acute myeloid leukemia**, through aberrant activation of downstream oncogenic pathways. The specific disease contributed by the FGFR3 allele depends on the mutation type and context, but **bladder cancer** is the most prominent association. \n\n\\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in neuronal function. In the given pathway, HTT interacts with STX1A and activates VGCC (N-type), leading to increased intracellular Ca\u00b2\u207a levels. Mutations in HTT, particularly expansions of the CAG repeat, result in the production of an abnormally long huntingtin protein. This toxic protein disrupts cellular processes, including calcium homeostasis, synaptic function, and protein degradation. The accumulation of mutant huntingtin leads to neuronal loss and dysfunction, primarily in the basal ganglia. This mechanism is central to Huntington\u2019s disease, a neurodegenerative disorder characterized by motor, cognitive, and psychiatric impairments. The disrupted pathway contributes to the pathological features of the disease, making HTT a key gene in its etiology.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the gene HTT (huntingtin), which encodes the huntingtin protein. The pathway shows HTT interacting with STX1A (syntaxin 1A) and CACNA1B (a subunit of the N-type voltage-gated calcium channel), leading to an increase in intracellular calcium (Ca\u00b2+). Mutations in HTT, particularly those causing an abnormal expansion of CAG repeats, result in the production of a toxic form of huntingtin. This leads to neuronal dysfunction and degeneration, primarily in the basal ganglia. The accumulation of mutant huntingtin disrupts synaptic function and calcium homeostasis, contributing to neurodegeneration. This is the molecular basis for Huntington\u2019s disease, a progressive neurological disorder characterized by motor, cognitive, and psychiatric symptoms. The pathway described is central to the pathogenesis of this disease. The HTT allele with expanded CAG repeats is the causative genetic mutation in Huntington\u2019s disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, specifically the mutant form of the huntingtin gene, contributes to Huntington's disease. In this pathway, HTT interacts with STX1A and activates VGCC (N-type), leading to increased intracellular Ca\u00b2\u207a levels. The mutant HTT protein forms aggregates that disrupt normal cellular function, including synaptic transmission, which is critical for neuronal health. The dysregulation of calcium homeostasis due to this pathway dysfunction exacerbates neuronal toxicity and leads to progressive neurodegeneration. This results in the hallmark features of Huntington's disease, including cognitive decline, motor dysfunction, and psychiatric symptoms. The accumulation of mutant HTT is the primary genetic cause of this autosomal dominant disorder. The pathway highlights how HTT dysfunction disrupts calcium signaling, contributing to neuronal death. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for mitochondrial quality control and proteasomal degradation. Mutations in PRKN lead to impaired ubiquitin-mediated degradation of damaged proteins and mitochondria, resulting in the accumulation of toxic aggregates. This dysfunction is a key driver in neurodegenerative diseases, particularly Parkinson's disease. PRKN mutations disrupt mitophagy, leading to mitochondrial dysfunction, oxidative stress, and neuronal death, especially in dopamine-producing neurons. The pathway involving UBCH7/8 (ubiquitin-conjugating enzymes) and CDCREL1 supports ubiquitin conjugation, a process essential for PRKN-mediated protein degradation. Disruption of this pathway exacerbates the loss of parkin function, contributing to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN encodes parkin, an RBR E3 ubiquitin ligase critical for proteasomal degradation of misfolded or damaged proteins. Mutations in PRKN lead to impaired ubiquitin-mediated protein degradation, resulting in the accumulation of toxic proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN mutations are a leading cause of autosomal recessive Parkinson's disease, specifically juvenile-onset forms. The pathway involving PRKN, UBE2L3, UBE2L6, and SEPTIN5 is involved in ubiquitin-mediated proteolysis, and dysfunction in this pathway disrupts protein quality control. This disruption is implicated in the pathogenesis of Parkinson's disease. Mutations in PRKN are also associated with other neurodegenerative disorders, but the most well-characterized is Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN lead to impaired ubiquitin ligase activity, disrupting protein quality control and mitochondrial homeostasis. This dysfunction is linked to the accumulation of damaged proteins and mitochondria, contributing to neuronal loss. The pathway includes UBE2L3 and UBE2L6, which are ubiquitin-conjugating enzymes essential for ubiquitination processes. The involvement of SEPTIN5 suggests roles in cytoskeletal dynamics and cell division. PRKN mutations are a primary cause of autosomal recessive Parkinson\u2019s disease. Loss-of-function mutations in PRKN result in reduced ubiquitination of target proteins, including alpha-synuclein and Pael-R, leading to neurodegeneration. This pathway is critical for maintaining cellular homeostasis, and its disruption is a hallmark of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a critical component of the Wnt/\u03b2-catenin signaling pathway, acting as a scaffold that promotes the degradation of \u03b2-catenin. In the given pathway, AXIN1 functions in parallel with GSK3B and APC to regulate \u03b2-catenin stability. Mutations or dysfunction in AXIN1 can lead to the stabilization and nuclear accumulation of \u03b2-catenin, resulting in aberrant activation of TCF/LEF transcription factors. This dysregulation drives the expression of oncogenes such as MYC and CCND1, which promote cell proliferation and inhibit apoptosis. This pathway is frequently disrupted in cancers, particularly colorectal cancer, where loss-of-function mutations in AXIN1 contribute to uncontrolled cell growth. Therefore, the biological effect of AXIN1 dysfunction is the promotion of tumor formation, and it contributes to \\boxed{Colorectal Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a critical component of the WNT signaling pathway, functioning as a scaffold protein that promotes the degradation of \u03b2-catenin (CTNNB1). In the given pathway, AXIN1 is part of a regulatory complex with GSK3B and APC, which inhibits the stabilization and nuclear translocation of \u03b2-catenin. When AXIN1 is mutated or inactivated, this repression is lost, leading to the accumulation of \u03b2-catenin and its transcriptional activation of TCF/LEF target genes such as MYC and CCND1. This dysregulation drives uncontrolled cell proliferation and is a hallmark of several cancers. Specifically, mutations in AXIN1 contribute to the development of **colorectal cancer** by promoting aberrant WNT signaling, which is a key driver in the pathogenesis of this disease.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 allele plays a critical role in the WNT/\u03b2-catenin signaling pathway. AXIN1 acts as a scaffold protein that promotes the degradation of \u03b2-catenin by forming a destruction complex with APC and GSK3B. This prevents the accumulation of \u03b2-catenin in the cytoplasm, which would otherwise translocate to the nucleus and activate TCF/LEF transcription factors, leading to the expression of downstream genes such as MYC and CCND1. Mutations or loss-of-function in AXIN1 disrupt this regulatory process, resulting in \u03b2-catenin stabilization and aberrant cell proliferation. This contributes to the development of colorectal cancer, where WNT signaling is frequently dysregulated. Thus, the biological effect of a dysfunctional AXIN1 allele is the promotion of uncontrolled cell growth, a hallmark of colorectal cancer.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a critical role in prostate biology. The pathway described involves androgenic hormones such as testosterone (T), dihydrotestosterone (DHT), and estradiol (E2), which bind to AR, leading to the activation of downstream genes like KLK3 (kallikrein-related peptidase 3). This pathway is central to prostate growth and function. Mutations or aberrant activation of AR can disrupt normal hormonal regulation, leading to uncontrolled cell proliferation. This contributes to the development and progression of prostate cancer, where increased AR activity promotes tumor growth and resistance to therapy. The expression of KLK3, a prostate-specific serine protease, is often elevated in prostate cancer and is associated with disease aggressiveness. Therefore, alterations in the AR pathway are strongly linked to prostate cancer. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the androgen receptor (AR) and its downstream activation leading to the expression of KLK3, a gene associated with prostate cancer. The pathway includes androgen ligands such as DHT, E2, and others, indicating a hormonal regulation mechanism. The AR allele in this context is likely a variant that enhances AR activity, promoting the transcription of KLK3. Increased KLK3 expression is strongly linked to the progression and aggressiveness of prostate cancer. This pathway highlights the role of androgen signaling in prostate malignancy. Therefore, the biological effect of this AR allele is the promotion of prostate cancer development and progression. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) pathway involves genes such as AR and KLK3, with ligands including testosterone (T), dihydrotestosterone (DHT), estriol (E2), and others. Activation of the AR by these ligands leads to the expression of KLK3, a gene encoding prostate-specific antigen (PSA). Mutations or aberrant activation of the AR can disrupt normal prostate development and function. Specifically, gain-of-function mutations in AR are associated with increased KLK3 expression, which promotes prostate cell proliferation and tumor growth. This contributes to the development and progression of prostate cancer. The AR pathway is a key driver in prostate carcinogenesis, making AR mutations a significant factor in disease onset and progression. The biological effect of this AR allele is the promotion of prostate cancer. \n\n\\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of the amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). These mutations disrupt the normal processing of APP, leading to increased production of toxic amyloid-\u03b242 peptides, which aggregate into plaques in the brain. This pathological accumulation contributes to neuronal toxicity, synaptic dysfunction, and ultimately neurodegeneration. The pathway described involves calcium signaling through the inositol 1,4,5-trisphosphate receptors (ITPRs), mitochondrial calcium uptake via MCU, and the release of cytochrome c via the mitochondrial permeability transition pore (MPTP), all of which are implicated in apoptosis and neurodegeneration. These processes are exacerbated by PSEN1 dysfunction, linking it to the progression of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). These mutations disrupt normal \u03b3-secretase function, leading to increased production of toxic amyloid-\u03b242 species, which aggregate into plaques in the brain. This pathological process contributes to neuronal dysfunction and death, hallmark features of Alzheimer's disease. Additionally, the pathway involving PSEN1, ITPR, MCU, and MPTP suggests a role in calcium homeostasis and mitochondrial dysfunction, which are also implicated in neurodegeneration. The disruption of calcium signaling via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDAC) further exacerbates cellular stress and apoptosis. Thus, PSEN1 mutations primarily contribute to Alzheimer's disease by promoting amyloid pathology and mitochondrial dysfunction. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), producing amyloid-\u03b2 peptides. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer's disease (AD). These mutations disrupt normal proteolytic processing, leading to increased production of toxic amyloid-\u03b242 species, which aggregate into plaques in the brain. The pathway described involves calcium signaling, mitochondrial dysfunction, and the release of cytochrome c, all of which contribute to neuronal damage and apoptosis. This cascade is consistent with the pathophysiology of Alzheimer's disease, where impaired calcium homeostasis and mitochondrial dysfunction exacerbate neurodegeneration. Thus, PSEN1 mutations primarily contribute to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a structural protein involved in maintaining cell membrane integrity and cytoskeletal organization. In the provided pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB isozymes, IP3, and ultimately Ca\u00b2\u207a release via ITPR. Mutations in SPTBN2 can disrupt this pathway, leading to altered calcium signaling and cytoskeletal dysfunction. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, SPTBN2 mutations are associated with **Mental Retardation, X-Linked 1 (MRX1)**, a condition characterized by intellectual disability, seizures, and motor dysfunction. The disruption of calcium homeostasis and neuronal connectivity underlies the pathophysiology of this disease. \\boxed{Mental Retardation, X-Linked 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a cytoskeletal protein involved in maintaining cell structure and membrane stability. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB isoforms, IP3, and Ca\u00b2\u207a release via ITPR. This pathway is critical for intracellular calcium regulation, which influences neuronal excitability, synaptic transmission, and cell survival. Mutations in SPTBN2 can disrupt this signaling, leading to altered calcium homeostasis and neuronal dysfunction. This contributes to neurodevelopmental disorders. Specifically, SPTBN2 mutations are associated with **Schwanner-Mai-Gruppe syndrome**, a rare autosomal dominant disorder characterized by intellectual disability, seizures, and structural brain abnormalities. The disruption of this pathway impairs neuronal development and connectivity, leading to the clinical manifestations observed in this condition.\n\n\\boxed{Schwanner-Mai-Gruppe syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 pathway involves the activation of GRM1, leading to a cascade including GNAQ, PLCB isoforms, IP3, and ultimately Ca\u00b2\u207a release via ITPR. SPTBN2 encodes spectrin beta non-erythrocytic 2, a cytoskeletal protein involved in maintaining cell structure and signaling. Mutations in SPTBN2 disrupt this structural integrity, impairing signaling downstream of metabotropic glutamate receptors. This leads to abnormal calcium dynamics, affecting neuronal excitability and synaptic transmission. These disruptions are implicated in neurodevelopmental and neurodegenerative disorders. Specifically, SPTBN2 mutations are associated with **familial hemiplegic migraine type 1 (FHM1)**, a genetic form of migraine with hemiplegic features. The pathway's role in calcium homeostasis and neuronal function directly links SPTBN2 dysfunction to migraine pathology. \n\n\\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which is critical for neuronal excitability and synaptic transmission. Mutations in **CACNA1A** disrupt calcium influx into neurons, leading to dysfunctional neurotransmitter release and altered neuronal signaling. This contributes to a range of neurological disorders, most notably **familial hemiplegic migraine (FHM)**, a genetic form of migraine with aura and motor weakness. Additionally, **CACNA1A** mutations are associated with **spinal cerebellar ataxia type 1 (SCA1)**, a neurodegenerative disorder characterized by progressive motor dysfunction. These mutations often result in gain-of-function or loss-of-function effects, leading to neuronal hyperexcitability or degeneration. The **CACNA1A** pathway is central to calcium homeostasis in neurons, and its disruption underlies both migratory and degenerative neurological conditions. The biological effect of the **CACNA1A** allele is therefore linked to **migraine and neurodegeneration**. \n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neuronal excitability and neurotransmitter release. Mutations in **CACNA1A** are associated with **familial hemiplegic migraine (FHM)**, a genetic disorder characterized by recurrent migraines with hemiplegia (temporary paralysis on one side of the body). These mutations typically cause gain-of-function effects, leading to abnormal calcium influx in neurons, which disrupts normal brain function and triggers migratory headaches. Additionally, **CACNA1A** mutations have been linked to **spinocerebellar ataxia type 2 (SCA2)**, a neurodegenerative disorder involving progressive loss of coordination. The pathway involving extracellular calcium and the calcium channel subunit **CACNA1A** underscores its role in calcium homeostasis and neuronal signaling, with dysfunction contributing to both migraine and neurodegeneration. \n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in calcium influx during neuronal action potentials. Mutations in CACNA1A are associated with impaired calcium homeostasis, leading to neurodevelopmental and neurodegenerative disorders. Specifically, alterations in this gene contribute to **Familial Hemiplegic Migraine (FHM)**, a genetic form of migraine with hemiparesis. These mutations disrupt normal calcium signaling in neurons, leading to abnormal neuronal excitability and vascular dysfunction. Additionally, CACNA1A mutations have been linked to other neurological conditions, including some forms of ataxia and epilepsy. The primary disease directly associated with CACNA1A is \\boxed{Familial Hemiplegic Migraine}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor molecule essential for the proper folding and activity of lysosomal enzymes involved in sphingolipid metabolism. Mutations in PSAP lead to reduced levels of functional enzymes, including beta-glucosidase (GBA) and galactosylceramidase (GALC), which are critical for breaking down specific lipids. This disruption causes the accumulation of toxic lipids in lysosomes, leading to progressive neuronal damage. The primary disease associated with PSAP mutations is metachromatic leukodystrophy (MLD), a rare inherited neurological disorder. MLD results in the demyelination of nerve cells, causing severe neurological deterioration, often beginning in childhood. The pathogenic mechanism involves impaired sphingolipid metabolism due to the defective enzymes downstream of PSAP. This highlights the central role of PSAP in maintaining lysosomal function and neural integrity. \n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele, along with GBA, GBA2, and GALC, is involved in the lysosomal breakdown of glycosphingolipids. Mutations in PSAP, which encodes prosaposin, lead to a deficiency in saposins\u2014proteins essential for the activity of lysosomal enzymes like GBA (beta-glucocerebrosidase) and GALC (galactocerebrosidase). This deficiency results in the accumulation of sphingolipids in neurons, leading to neurodegeneration. The most notable disease associated with PSAP mutations is **Sphingolipidosis**, specifically **Kufs disease** when GBA is also mutated. Kufs disease is a rare, inherited neurological disorder characterized by progressive mental deterioration, seizures, and movement disorders. It is classified as a type of lysosomal storage disorder and is often linked to mutations in the GBA gene, with PSAP playing a supportive role in the functional integrity of the lysosomal enzyme complex. \\boxed{Kufs disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele is involved in the metabolism of sphingolipids and is part of a pathway that includes GBA, GBA2, and GALC. PSAP, or prosaposin, is a precursor protein that is essential for the proper folding and trafficking of lysosomal enzymes such as GBA (beta-glucocerebrosidase) and GALC (galactocerebrosidase). Mutations in PSAP can lead to impaired activation of these enzymes, resulting in the accumulation of toxic sphingolipids in lysosomes. This contributes to the pathogenesis of metachromatic leukodystrophy (MLD), a severe lysosomal storage disorder. The loss of functional PSAP disrupts the activity of GALC, leading to demyelination of the central and peripheral nervous system. Therefore, defects in PSAP are a key contributor to MLD. \n\n\\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and proteasomal function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation. Mutations in ATXN3 are linked to spinocerebellar ataxia type 3 (SCA3), also known as Machado\u2013Joseph disease. This is a neurodegenerative disorder characterized by progressive cerebellar atrophy and motor dysfunction. The disease results from an expansion of CAG repeats in the ATXN3 gene, leading to toxic accumulation of mutant ataxin-3 protein. This disrupts cellular processes, including protein degradation and autophagy, contributing to neuronal loss. The involvement of autophagy-related genes in this pathway underscores the role of impaired autophagy in disease progression. Therefore, the biological effect of the ATXN3 allele is the development of spinocerebellar ataxia type 3.\n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 cause **spinocerebellar ataxia type 2 (SCA2)**, a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process crucial for protein homeostasis. Dysregulation of this pathway can lead to the accumulation of misfolded proteins, contributing to neuronal dysfunction. In SCA2, expansions of the CAG repeat in ATXN3 result in the production of an unstable ataxin-3 protein, which aggregates and disrupts neuronal function. This genetic mutation is therefore directly linked to the development of SCA2, a form of hereditary ataxia.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine tracts, resulting in protein misfolding and aggregation. This contributes to neurodegeneration. The pathway includes genes involved in autophagy (BECN1, PIK3C3, ATG14, PIK3R4, AMBRA1), suggesting a role for autophagy in clearing misfolded proteins. The ATXN3 allele, particularly with CAG repeat expansions, is the primary genetic cause of **Spinocerebellar Ataxia Type 3 (SCA3)**. This dominantly inherited disorder leads to progressive degeneration of cerebellar and brainstem neurons, causing ataxia, motor dysfunction, and cognitive decline. The involvement of autophagy-related genes implies that impaired autophagy exacerbates protein toxicity in SCA3. Thus, the ATXN3 allele contributes to **Spinocerebellar Ataxia Type 3**.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and mutations in PRNP are well-documented as the primary cause of prion diseases. These are transmissible, protein misfolding disorders characterized by the conversion of normal prion protein (PrP^C) into a pathogenic form (PrP^Sc), leading to neurodegeneration. The pathway described, PRNP \u2192 CAV \u2192 FYN \u2192 PI3K \u2192 PRKCD \u2192 NOX2 \u2192 ROS, highlights a mechanism linking prion protein to oxidative stress via the activation of NADPH oxidase (NOX2), which generates reactive oxygen species (ROS). This oxidative stress contributes to neuronal damage and disease progression. The most prominent disease associated with PRNP mutations is **Creutzfeldt-Jakob Disease (CJD)**, a rapidly progressive and invariably fatal neurodegenerative disorder. Other related conditions include variant CJD (vCJD), kuru, and Gerstmann-Str\u00e4ussler-Scheinker syndrome. These diseases are all classified as transmissible spongiform encephalopathies (TSEs).\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the given pathway, PRNP activates a cascade involving CAV1/2/3, FYN, PI3K subunits, PRKCD, NOX2, and ultimately ROS production. This pathway is implicated in oxidative stress and cellular damage. Mutations in PRNP are most famously associated with **Creutzfeldt-Jakob Disease (CJD)**, a rapidly progressive and fatal neurodegenerative disorder caused by prion protein misfolding. The pathway's role in ROS generation suggests a mechanism linking prion dysfunction to oxidative stress and neuronal injury, which contributes to the pathogenesis of CJD. The involvement of NOX2 and related NCF genes highlights a connection between prion disease and inflammation, further supporting the link to neurodegeneration. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and mutations in this gene are associated with prion diseases. In the given pathway, PRNP activates a cascade involving CAV1/2/3, FYN, PI3K, PRKCD, and ultimately leads to NOX2-mediated ROS production. This pathway is linked to oxidative stress and neurodegeneration. The biological effect of a pathogenic PRNP allele is the misfolding and propagation of abnormal prion proteins, leading to neuronal damage. This contributes to neurodegenerative disorders characterized by spongiform encephalopathy. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal brain disorder. Other related diseases include variant CJD (vCJD), kuru, and Gerstmann-Str\u00e4ussler-Scheinker syndrome. These conditions are caused by the accumulation of misfolded prion proteins, leading to neuronal death and dementia. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway is part of the RAS oncogene family, which plays a central role in cell proliferation and survival. When mutated, NRAS leads to constitutive activation of the downstream PI3K-AKT pathway. This results in increased production of PIP3 and subsequent activation of AKT, which inhibits BAD, a pro-apoptotic protein. This pathway dysregulation promotes cell survival and resistance to apoptosis, driving uncontrolled cell growth. NRAS mutations are commonly associated with the development of **cancers** characterized by oncogenic RAS activation. Specifically, this mutation contributes to **non-small cell lung cancer (NSCLC)**, **colorectal cancer**, and **melanoma**, among others. These cancers often exhibit resistance to therapies targeting the PI3K-AKT pathway. The biological effect of the NRAS mutation is thus the promotion of tumorigenesis through sustained activation of survival signaling. \n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to dysregulation of cell survival and proliferation. NRAS, a Ras family GTPase, activates PI3K upon mutation, leading to increased PIP3 generation and subsequent activation of AKT. This inhibits BAD, a pro-apoptotic protein, thereby promoting cell survival and growth. Mutations in NRAS are commonly found in hematological malignancies, particularly in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These mutations drive oncogenesis by enhancing signaling through the PI3K-AKT pathway, which is critical for cell survival, proliferation, and resistance to apoptosis. The constitutive activation of this pathway due to NRAS mutations leads to uncontrolled cell growth and contributes to disease progression. Therefore, the biological effect of the NRAS allele is the promotion of malignancy through aberrant activation of the PI3K-AKT-BAD pathway, specifically contributing to \\boxed{Acute Myeloid Leukemia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS oncogene family, activates the PI3K-AKT pathway by promoting the conversion of PIP2 to PIP3, which leads to the activation of AKT. This activation inhibits BAD, a pro-apoptotic protein, thereby suppressing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, such as gain-of-function mutations, disrupt normal cellular proliferation control, leading to uncontrolled cell growth. This contributes to the development of various cancers. Specifically, NRAS mutations are frequently observed in melanoma, where they drive tumor progression by constitutively activating downstream signaling pathways. These mutations are also implicated in other malignancies, including certain subtypes of leukemia and lung cancer. The sustained activation of the PI3K-AKT-BAD axis by mutant NRAS promotes resistance to apoptosis and enhances cell survival, making it a key driver in oncogenesis. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins, disrupting cellular function and triggering neurodegeneration. This is the hallmark of spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3 links glutamate signaling to calcium homeostasis via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDACs), ultimately influencing apoptosis through the permeability transition pore (MPTP) and release of cytochrome c (CYCS). Dysregulation of this pathway contributes to neuronal death, a key feature of SCA2. Therefore, the biological effect of the ATXN3 allele is the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the glutamate signaling cascade leading to intracellular calcium release and mitochondrial dysfunction. ATXN3, an ataxin-3 protein, is part of the ITPr1 complex, which regulates calcium entry into mitochondria through MCU. Mutations in ATXN3 are well-known for causing spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. ATXN3 encodes a polyglutamine-containing protein that, when mutated, leads to protein misfolding, aggregation, and neuronal toxicity, particularly in cerebellar Purkinje cells. These aggregates disrupt calcium homeostasis and mitochondrial function, aligning with the pathway's role in calcium signaling and mitochondrial permeability. The dysfunction contributes to neuronal death and the clinical features of SCA2. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein quality control and transcription. In the given pathway, ATXN3 is part of the IP3-mediated calcium signaling cascade, which regulates mitochondrial calcium levels via the MCU and contributes to mitochondrial homeostasis. Mutations in ATXN3 are the primary cause of **spinocerebellar ataxia type 2 (SCA2)**, an autosomal dominant neurodegenerative disorder characterized by progressive coordination difficulties. SCA2 results from expansion of CAG repeats in the ATXN3 gene, leading to the production of an aberrant, polyglutamine-containing ataxin-3 protein. This toxic protein aggregates, disrupting cellular function, particularly in cerebellar neurons, which are critical for motor control. The resulting neuronal loss and dysfunction lead to the clinical features of SCA2, including ataxia, dysarthria, and sometimes ophthalmoplegia. Thus, the ATXN3 allele contributes to **spinocerebellar ataxia type 2**.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN allele plays a critical role in regulating the PI3K-AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. When PTEN is mutated or inactivated, PIP3 accumulates, leading to persistent activation of AKT. This promotes cell survival, proliferation, and resistance to apoptosis. The loss of PTEN function is associated with uncontrolled cell growth and tumor formation. This pathway is central to many cancers, particularly those involving the PTEN tumor suppressor gene. Mutations in PTEN are commonly found in cancers such as breast, endometrial, prostate, and glioblastoma. The resulting hyperactivation of AKT contributes to genomic instability, angiogenesis, and metastasis. Therefore, the biological effect of the PTEN allele is the promotion of tumorigenesis. \n\n\\boxed{Glioblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a phosphatase that negatively regulates the PI3K-AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. When PTEN is mutated or inactivated, PIP3 levels increase, leading to constitutive activation of AKT. This promotes cell survival, proliferation, and resistance to apoptosis. The loss of PTEN function is strongly associated with the activation of the PI3K/AKT/mTOR pathway, which drives uncontrolled cell growth. This dysfunction is a hallmark of several cancers. The most well-known disease linked to PTEN dysfunction is **Cowden syndrome**, a hereditary disorder characterized by an increased risk of developing benign and malignant tumors, particularly in the breast, thyroid, and skin. Additionally, PTEN mutations are frequently observed in **endometrial cancer**, **renal cell carcinoma**, and **brain tumors** such as glioblastoma. \\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a tumor suppressor phosphatase that negatively regulates the PI3K-AKT signaling pathway by dephosphorylating PIP3 to PIP2. In the given pathway, PTEN* inhibits the conversion of PIP3 to PIP2, thereby maintaining high levels of PIP3, which activates AKT. This leads to increased cell survival, proliferation, and resistance to apoptosis. Loss-of-function mutations in PTEN result in constitutive AKT activation, contributing to uncontrolled cell growth. This dysfunction is implicated in several cancers, including breast, prostate, and endometrial cancers. PTEN mutations are also associated with neurofibromatosis type 1 (NF1) and Cowden syndrome, which increase the risk of multiple cancer types. The biological effect of the PTEN allele is thus a key driver of tumorigenesis through aberrant activation of the PI3K-AKT pathway.\n\n\\boxed{Breast Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to neurodegeneration by disrupting cellular function, particularly in neurons. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation, a key process in maintaining cellular homeostasis and removing damaged proteins. Impaired autophagy due to ATXN3 dysfunction exacerbates protein aggregate accumulation, leading to neuronal loss. This is characteristic of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder marked by progressive motor dysfunction. The interplay between ATXN3 and autophagy-related genes underscores its role in disease progression. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA processing and ubiquitin-mediated proteolysis. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This pathological mechanism is central to the development of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a link between autophagy dysfunction and the accumulation of mutant ataxin-3. Impaired autophagy reduces the clearance of misfolded proteins, exacerbating neuronal damage. Thus, the ATXN3 allele contributes to SCA2 by disrupting proteostasis and autophagy, leading to neurodegeneration. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a cellular process critical for protein quality control and neuronal health. Dysfunction in this pathway can lead to the accumulation of damaged proteins and neuronal damage, contributing to the pathogenesis of SCA2. The expansion of polyglutamine repeats in ATXN3 is the primary genetic cause of SCA2, leading to protein misfolding and toxicity. This highlights the role of ATXN3 in maintaining neuronal function and its critical contribution to the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic amyloid-\u03b242 species, promoting amyloid plaque formation in the brain. The pathway described, involving PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects the cellular stress response triggered by neurotoxic amyloid accumulation. EIF2AK3 (PERK) activation in response to endoplasmic reticulum (ER) stress, leads to reduced protein translation via phosphorylation of EIF2S1, and subsequent upregulation of ATF4 and its downstream target DDIT3 (CHOP), which contributes to neuronal apoptosis. This pathway is central to the pathogenesis of Alzheimer's disease. Thus, the PSEN1 allele contributes to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of the amyloid precursor protein (APP). Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of amyloid-beta peptides, particularly the toxic A\u03b242 isoform, which aggregates into plaques in the brain. This pathological accumulation disrupts neuronal function and contributes to neurodegeneration. The pathway described involves PSEN1's connection to EIF2AK3, EIF2S1, ATF4, and DDIT3, which are involved in stress response and transcriptional regulation. This network likely modulates the cellular response to proteotoxic stress, further supporting the role of PSEN1 in neurodegeneration. Therefore, the biological effect of pathogenic PSEN1 alleles is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic amyloid-beta species, contributing to amyloid plaque formation in the brain, along with neurofibrillary tangles and neuronal loss. The pathway described, involving PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a cellular response to proteotoxic stress, including translational repression and the induction of stress-response genes. This pathway is dysregulated in neurodegenerative conditions. The biological effect of pathogenic PSEN1 alleles is therefore the promotion of Alzheimer's disease through enhanced amyloidogenesis and disruption of proteostasis. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP) and other substrates. The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 suggests a role in the unfolded protein response (UPR) via the ERN1-XBP1 axis. Mutations in PSEN1 are well-known to cause early-onset Alzheimer's disease (AD), as they lead to the accumulation of amyloid-\u03b2 plaques and neurodegeneration. The connection to ERN1 and XBP1 implies that PSEN1 may also modulate ER stress responses, which are implicated in AD pathology. Impaired ER homeostasis and increased ER stress are features of AD, and PSEN1 mutations may disrupt this balance, contributing to neuronal dysfunction and disease progression. Therefore, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (AD). The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 suggests a link between PSEN1 dysfunction and the unfolded protein response (UPR), mediated by ERN1 (IRE1) and XBP1. This connection implies that PSEN1 mutations may disrupt protein homeostasis, contributing to neurodegeneration. The accumulation of misfolded proteins and chronic ER stress are hallmarks of AD, supporting the role of PSEN1 in disease progression. Therefore, this PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of the amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 species, which aggregate into plaques in the brain. The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 reflects a stress response involving the unfolded protein response (UPR) in the endoplasmic reticulum (ER). ERN1 (PERK) activation via XBP1 contributes to cellular stress responses, which may exacerbate neurodegeneration in Alzheimer's disease. Therefore, the PSEN1 allele contributes to the development of Alzheimer's disease by promoting pathological amyloid accumulation and ER stress. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, functioning as a ubiquitin-binding adapter that facilitates the recruitment of damaged proteins and ubiquitinated cargo to autophagosomes for degradation. In the context of the provided pathway, SQSTM1 is linked to the PINK1-PRKN pathway, which is critical for mitochondrial quality control. Mutations in SQSTM1 disrupt autophagy and mitochondrial homeostasis, leading to the accumulation of damaged mitochondria and protein aggregates. This contributes to neurodegeneration. Specifically, SQSTM1 mutations are associated with Parkinson's disease, where impaired autophagy leads to the accumulation of alpha-synuclein and other toxic proteins, exacerbating neuronal loss. Therefore, the biological effect of this SQSTM1 allele is the contribution to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene encodes a key scaffolding protein involved in ubiquitin-mediated proteolysis and autophagy. In the context of the provided pathway, SQSTM1 interacts with components of the PINK1-PRKN pathway, which is critical for mitochondrial quality control. Mutations in SQSTM1 disrupt this pathway, impairing mitophagy and leading to the accumulation of damaged mitochondria. This dysfunction is strongly associated with neurodegenerative processes. SQSTM1 mutations are a known cause of autosomal recessive early-onset Parkinson's disease. The loss of SQSTM1 function impairs the degradation of damaged mitochondria, leading to oxidative stress, neuronal dysfunction, and ultimately, dopaminergic neuron loss. Therefore, the biological effect of SQSTM1 mutations is the disruption of mitochondrial homeostasis, contributing to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene plays a critical role in the autophagy pathway, acting as a scaffold for protein degradation and ubiquitin signaling. In the context of the provided pathway, SQSTM1 is linked to mitochondrial quality control via its interaction with PINK1 and PRKN, which are central to parkin-mediated mitophagy. Mutations in SQSTM1 disrupt this process, leading to the accumulation of damaged mitochondria and impaired cellular clearance of damaged proteins. This dysfunction contributes to neurodegeneration, particularly in Parkinson's disease (PD). SQSTM1 mutations are associated with early-onset PD and are implicated in the pathogenesis of the disease through the disruption of autophagy and mitochondrial homeostasis. The loss of SQSTM1 function also affects the ubiquitin-proteasome system, further exacerbating protein aggregation. Therefore, SQSTM1 mutations contribute to the development of Parkinson's disease by compromising neuronal survival through mitochondrial and protein quality control failure.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT-BAD signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of the RAS protein, which in turn continuously activates PI3K. This results in increased production of PIP3 and subsequent activation of AKT, which inhibits BAD, a pro-apoptotic protein. This suppression of apoptosis promotes cell survival and uncontrolled proliferation, key features of cancer. NRAS mutations are commonly found in cancers such as neurofibromatosis type 1 (NF1)-associated malignancies, melanoma, and certain leukemias. The sustained activation of this pathway disrupts normal cell cycle control and apoptosis, driving tumorigenesis. Therefore, NRAS mutations contribute to the development of **NF1-associated cancers** and other malignancies characterized by RAS pathway activation.\n\n\\boxed{NF1-associated cancers}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway activates the PI3K-AKT axis by promoting the conversion of PIP2 to PIP3, which in turn activates AKT. This leads to the inhibition of BAD, a pro-apoptotic protein, thereby preventing programmed cell death. This pathway is critical for cell survival, proliferation, and growth. Mutations in NRAS, such as gain-of-function mutations, result in constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development of various cancers. Specifically, NRAS mutations are commonly found in **melanoma**, where they drive tumor progression by promoting cell survival and resistance to apoptosis. These mutations are also implicated in **non-small cell lung cancer** and **colorectal cancer**, among others. The constitutive activation of the PI3K-AKT-BAD pathway by mutant NRAS is a key driver of oncogenesis in these malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-PI3K-AKT-BAD pathway, contributes to oncogenesis by promoting cell survival and proliferation. NRAS, a GTPase, activates PI3K upon oncogenic mutation, leading to increased production of PIP3. This activates AKT, which in turn inhibits BAD, a pro-apoptotic protein. This suppression of apoptosis and enhancement of cell survival drive uncontrolled cell growth, a hallmark of cancer. Mutations in NRAS are commonly found in cancers such as melanoma, non-small cell lung cancer, and colorectal cancer. These mutations result in constitutive activation of the downstream pathway, fostering tumor progression. The dysregulation of this pathway is central to the development and progression of these malignancies. Thus, NRAS mutations are significant contributors to the pathogenesis of melanoma. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin ligase pathway that targets hypoxia-inducible factors (HIFs) for degradation. In the absence of functional VHL, this pathway is disrupted, leading to the stabilization of HIF-1\u03b1, which drives the expression of genes like VEGFA, CXCL8, GLUT1, and EPO. This results in aberrant angiogenesis, inflammation, and erythropoiesis. The loss of VHL function is a key driver in the development of clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer. Mutations in VHL are also associated with von Hippel-Lindau disease, a hereditary syndrome characterized by the formation of benign and malignant tumors in multiple organs. The accumulation of HIF-1\u03b1 in VHL-defective cells promotes tumor growth and progression. Therefore, the biological effect of the VHL allele is the promotion of tumorigenesis, specifically contributing to \\boxed{Clear Cell Renal Cell Carcinoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is central to the von Hippel-Lindau (VHL) tumor suppressor pathway. This pathway plays a critical role in ubiquitin-mediated protein degradation, particularly targeting hypoxia-inducible factors (HIFs) like EPAS1 and ARNT under normoxic conditions. When VHL is mutated, this degradation process is impaired, leading to the stabilization of HIFs. This results in the aberrant activation of downstream genes such as VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. These effects are hallmarks of VHL-associated diseases. The most significant disease linked to VHL mutations is **Von Hippel-Lindau disease**, a hereditary disorder characterized by the development of benign and malignant tumors in multiple organs, including the brain, spinal cord, kidneys, and retinal hemangiomas. The disrupted pathway leads to uncontrolled cell growth and vascular abnormalities. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, when mutated, leads to the loss of function of the von Hippel-Lindau tumor suppressor protein. This results in the stabilization of hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT, which drive the expression of genes like VEGFA, CXCL8, GLUT1, and EPO. This pathway is critical for angiogenesis, cell survival, and erythropoiesis under hypoxic conditions. The dysregulation of this pathway is a hallmark of VHL syndrome, a hereditary cancer predisposition disorder. This condition is characterized by the development of various benign and malignant tumors, including renal cell carcinomas, hemangiomas, phaeochromocytomas, and pheochromocytomas. The stabilization of HIFs due to VHL loss promotes tumor growth by enhancing vascularization and metabolic adaptation. Thus, the biological effect of the VHL allele is the activation of a pro-angiogenic and pro-survival pathway, contributing to the development of VHL syndrome.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN allele, encoding parkin, is critical for mitochondrial quality control. Mutations in PRKN disrupt its E3 ubiquitin ligase activity, impairing the ubiquitination and degradation of mitofusins (MFN1/2), which are essential for mitochondrial fusion. This leads to mitochondrial dysfunction, impaired mitophagy, and accumulation of damaged mitochondria. These defects contribute to neuronal loss, a hallmark of neurodegenerative diseases. PRKN mutations are strongly associated with autosomal recessive Parkinson\u2019s disease. Loss of PRKN function disrupts mitochondrial dynamics and stress response pathways, exacerbating oxidative stress and cell death, particularly in dopaminergic neurons. This pathway is also implicated in other conditions, but the most well-characterized disease linked to PRKN dysfunction is Parkinson\u2019s disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through its role in ubiquitin-mediated degradation of damaged mitochondria, a process known as mitophagy. Mutations in PRKN, which encodes the E3 ubiquitin ligase parkin, disrupt this process, leading to the accumulation of dysfunctional mitochondria. This contributes to neuronal loss and is a key mechanism in neurodegenerative diseases. Specifically, mutations in PRKN are a major cause of Parkinson\u2019s disease, particularly in the juvenile or early-onset forms. The pathway also involves MFN1 and MFN2, which mediate mitochondrial fusion. Disruption of this pathway impairs mitochondrial dynamics, exacerbating oxidative stress and neuronal death. Thus, the PRKN allele contributes to the pathogenesis of Parkinson\u2019s disease by promoting mitochondrial dysfunction and neurodegeneration.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway, involving PRKN (parkin) and MFN1/MFN2, is critical for mitochondrial quality control. PRKN mediates mitophagy, the selective degradation of damaged mitochondria. Dysfunction in this pathway leads to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal damage. Mutations in PRKN are a primary cause of autosomal recessive Parkinson\u2019s disease. These mutations impair parkin's E3 ubiquitin ligase activity, disrupting mitophagy and contributing to neurodegeneration. The involvement of MFN1 and MFN2, which regulate mitochondrial fusion, further highlights the pathway\u2019s role in maintaining mitochondrial homeostasis. Impaired mitophagy results in the accumulation of toxic mitochondrial byproducts, which are particularly detrimental to dopaminergic neurons in the substantia nigra. Thus, PRKN mutations directly contribute to the pathogenesis of Parkinson\u2019s disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, which phosphorylates RB1, leading to the release of E2F transcription factors. This promotes cell cycle progression from G1 to S phase. The CDK4 allele, when mutated or overactive, leads to excessive phosphorylation of RB1, preventing its ability to inhibit E2F. This results in unchecked cell proliferation. Such dysregulation is a hallmark of several cancers. Specifically, hyperactivation of the CDK4/6-RB1-E2F pathway is strongly associated with **breast cancer**. Mutations or amplifications in CDK4 or its regulatory genes (e.g., CCND1) are commonly observed in breast cancer, contributing to uncontrolled cell division and tumor growth. Therefore, the biological effect of the CDK4 allele in this pathway is the promotion of neoplastic growth, contributing to **\\boxed{breast cancer}**.", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this pathway plays a critical role in cell cycle regulation. CDK4, when activated by cyclins D (CCND1, CCND2, CCND3), phosphorylates the retinoblastoma protein (RB1), inactivating it. This inactivation releases E2F transcription factors (E2F1-3), which drive the expression of genes necessary for DNA synthesis and cell division. Mutations or overexpression of CDK4 can lead to constitutive activation of this pathway, resulting in unchecked cell proliferation. This dysregulation is a hallmark of several cancers, particularly those characterized by loss of RB1 function. The CDK4 pathway is frequently altered in cancers such as osteosarcoma, melanoma, and breast cancer. However, the most well-documented association is with **retinoblastoma**, a childhood eye cancer, where inactivation of RB1 and dysregulation of CDK4/E2F contribute to tumor formation. \\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this genomic pathway plays a critical role in cell cycle regulation. CDK4, when activated by cyclins like CCND1-3, phosphorylates the retinoblastoma protein (RB1), leading to its inactivation. This inactivation releases E2F transcription factors, which drive the expression of genes necessary for DNA synthesis and cell division. Mutations or overexpression of CDK4 can result in aberrant phosphorylation of RB1, even in the absence of cyclins, leading to unchecked cell proliferation. This dysregulation is a hallmark of several cancers. The CDK4 pathway is frequently dysregulated in human tumors, particularly in melanoma, lung cancer, and certain leukemias. Notably, CDK4 amplification and mutations are strongly associated with retinoblastoma when combined with RB1 inactivation. However, the most well-characterized disease linked to CDK4 dysfunction is **retinoblastoma**, a rare eye cancer in children. \n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves NRAS, a RAS family GTPase, which, when mutated, leads to constitutive activation of downstream effectors such as PI3K and AKT. This results in the suppression of BAD, a pro-apoptotic protein, thereby promoting cell survival and resistance to apoptosis. The activation of AKT also leads to increased cell proliferation, angiogenesis, and metabolic reprogramming, all of which drive tumorigenesis. NRAS mutations are commonly found in cancers where RAS signaling is dysregulated. The most well-known disease associated with NRAS mutations is **Melanoma**, particularly in cases of cutaneous melanoma. These mutations contribute to uncontrolled cell growth and tumor progression by disrupting normal cell cycle regulation and apoptosis. NRAS mutations are also implicated in other cancers such as lung adenocarcinoma, bladder cancer, and certain leukemias. The hallmark of these mutations is their ability to activate the PI3K-AKT pathway, leading to oncogenic transformation and disease progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. This pathway is critical for cell survival, proliferation, and growth. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits pro-apoptotic proteins such as BAD. This results in uncontrolled cell growth and resistance to apoptosis. Such activation is a hallmark of several cancers. The most well-documented disease associated with NRAS mutations is **melanoma**, particularly in cases where NRAS is mutated. These mutations are also found in other malignancies, including certain subtypes of leukemia and colorectal cancer. However, the strongest and most recurrent association is with **melanoma**, where NRAS mutations are a major driver of tumorigenesis. Thus, the biological effect of this NRAS allele is the promotion of malignant growth, specifically contributing to **melanoma**.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway activates the PI3K-AKT-BAD signaling cascade. NRAS, a RAS family GTPase, functions as a molecular switch that, when mutated, remains in an active state, continuously stimulating PI3K. This leads to increased production of PIP3, which in turn recruits and activates AKT. Activated AKT inhibits BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. This dysregulated signaling contributes to uncontrolled cell growth and resistance to apoptosis, hallmark features of cancer. Mutations in NRAS are frequently observed in hematological malignancies, particularly in chronic myelomonocytic leukemia (CMML) and certain subtypes of acute myeloid leukemia (AML). Additionally, NRAS mutations are associated with melanoma and other solid tumors. The persistent activation of this pathway disrupts normal cellular homeostasis, driving tumorigenesis. \\boxed{Chronic Myelomonocytic Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor molecule essential for the proper folding and activity of glycosphingolipid hydrolases, including GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced production of functional enzymes, contributing to the pathogenesis of sphingolipid storage disorders. Specifically, PSAP mutations are a known cause of **Fabry disease**, a X-linked lysosomal storage disorder. In Fabry disease, the deficiency of alpha-galactosidase A (GLA), encoded by the GALC gene, results in the accumulation of glycosphingolipids in lysosomes, leading to multi-systemic damage. While PSAP mutations are less common than GLA mutations, they can also cause a milder form of the disease, often with later onset and variable clinical manifestations. Thus, the PSAP allele contributes to **Fabry disease** by affecting the stability and activity of the GLA enzyme.\n\n\\boxed{Fabry disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor for sphingolipid activator proteins. Mutations in PSAP lead to reduced production of these enzymes, including beta-glucosidase (GBA) and galactocerebrosidase (GALC), which are critical for breaking down sphingolipids. This results in the accumulation of toxic lipid byproducts in neurons, leading to progressive neurodegeneration. The dysfunction of these enzymes is central to the pathogenesis of metachromatic leukodystrophy (MLD), a severe lysosomal storage disorder. The pathway involving PSAP, GBA, GBA2, and GALC is essential for normal myelin maintenance. Defects in this pathway contribute to the clinical features of MLD, including intellectual disability, loss of motor function, and seizures. The PSAP allele's role in this pathway directly impacts the stability and function of these enzymes, making it a key contributor to the disease. \n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is involved in the lysosomal storage disorder metachromatic leukodystrophy (MLD). PSAP is a precursor protein that is processed into sphingolipid activator proteins, which are essential for the breakdown of complex lipids. Mutations in PSAP lead to reduced production of these enzymes, particularly GBA, GBA2, and GALC, which are involved in glycosphingolipid metabolism. The loss of functional PSAP results in the accumulation of undegraded lipids in neurons, leading to progressive neurodegeneration. This pathway is critical for myelin maintenance, and its dysfunction causes the severe neurological symptoms of MLD. The disease typically presents in childhood with developmental delay, motor dysfunction, and dementia. \\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway described (MET \u2192 GAB1 \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 BAD) is central to cell survival, proliferation, and migration. Activation of MET, a receptor tyrosine kinase, initiates downstream signaling through PI3K and AKT, which inhibits BAD, a pro-apoptotic protein. This promotes cell survival and resistance to apoptosis. Mutations or amplifications in MET or its downstream components, such as PIK3CA, can drive uncontrolled cell growth. This pathway is frequently dysregulated in cancers, particularly those involving cell proliferation and metastasis. The MET oncogene is implicated in various malignancies, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. Altered MET signaling can lead to tumor progression, resistance to therapy, and poor prognosis. Therefore, the biological effect of this MET allele is the promotion of cell survival and growth, contributing to the development and progression of **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with MET and proceeding through GAB1, PI3K (encoded by PIK3CA, PIK3CB, PIK3CD), PIP3, and AKT (AKT1/2/3), ultimately inhibits BAD, promoting cell survival. Mutations in MET or downstream components like PIK3CA can lead to constitutive pathway activation, driving uncontrolled cell growth and survival. This contributes to various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. In particular, MET amplification or mutations are strongly associated with NSCLC, especially in patients who are non-smokers and have adenocarcinoma histology. These genetic alterations enhance tumor progression, metastasis, and resistance to therapy. The activation of the PI3K-AKT pathway through MET also promotes angiogenesis and epithelial-mesenchymal transition, further supporting tumor aggressiveness. Therefore, the biological effect of this MET allele is oncogenic, contributing to the development and progression of \\boxed{Non-Small Cell Lung Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with MET and proceeding through GAB1, PI3K (encoded by PIK3CA, PIK3CB, and PIK3CD), PIP3, and AKT (AKT1, AKT2, AKT3), leads to the inhibition of BAD, promoting cell survival. Mutations or dysregulation in this pathway can drive uncontrolled cell growth and survival, suppressing apoptosis. Specifically, activating mutations in MET or PIK3CA, which are part of this pathway, are strongly associated with oncogenic transformation. This pathway is frequently altered in various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and hepatocellular carcinoma. The activation of this pathway contributes to tumorigenesis by enhancing cell proliferation, survival, and resistance to apoptosis. Therefore, dysregulation of the MET pathway is a key contributor to the development of cancer. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, leads to the constitutive activation of the BCR-ABL oncoprotein. This aberrant activation initiates a signaling cascade involving CRKL, CBL, and CRK, which in turn activates PI3K. The PI3K pathway generates PIP3, which recruits and activates AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is central to uncontrolled cell growth and resistance to cell death. The hallmark of this dysregulated pathway is the development of chronic myeloid leukemia (CML), driven by the Philadelphia chromosome translocation (t(9;22)), which fuses the ABL1 gene with BCR, creating the BCR-ABL fusion protein. This results in sustained tyrosine kinase activity, leading to oncogenic transformation. The biological effect of this ABL1 allele is thus the induction of CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, contributes to the formation of the BCR-ABL fusion protein, a key driver in chronic myeloid leukemia (CML). This fusion protein activates downstream signaling pathways, including the PI3K-AKT-BAD axis, promoting cell survival, proliferation, and resistance to apoptosis. The involvement of multiple adaptor proteins such as CRKL, CBL, and CRK further amplifies this oncogenic signaling. The activation of PI3K leads to the production of PIP3, which in turn activates AKT. Akt phosphorylates and inactivates BAD, preventing apoptosis and supporting uncontrolled cell growth. This pathway is central to the pathogenesis of CML and is a primary target for therapies such as tyrosine kinase inhibitors. The ABL1 mutation is a hallmark of CML and is also associated with some cases of acute lymphoblastic leukemia (ALL). \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the formation of the BCR-ABL fusion protein, which is a hallmark of chronic myeloid leukemia (CML). This fusion protein acts as a constitutively active tyrosine kinase, driving uncontrolled cell proliferation by activating downstream signaling pathways, including the PI3K-AKT axis. This leads to the inhibition of pro-apoptotic proteins like BAD, promoting cell survival and resistance to apoptosis. The continuous activation of these pathways results in the unregulated growth of myeloid cells, characteristic of CML. This pathway is also implicated in some cases of acute lymphoblastic leukemia (ALL). The most well-known therapeutic target for this pathway is the BCR-ABL kinase, treated with tyrosine kinase inhibitors such as imatinib. \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for mitochondrial quality control, as PRKN (parkin) mediates the ubiquitylation and degradation of damaged mitochondria via mitophagy. Mutations in PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neurodegeneration. The pathway involves PLCG1, IP3, and ITPR, which regulate intracellular calcium levels, essential for neuronal function. Impairment in this pathway is associated with Parkinson's disease. Mutations in PRKN are a known cause of early-onset Parkinson's disease, characterized by dopaminergic neuron loss. The disruption of mitochondrial homeostasis and calcium signaling in this pathway leads to neuronal death, hallmark features of the disease. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is central to mitochondrial quality control, as PRKN (parkin) mediates ubiquitination and degradation of damaged mitochondria via mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in mitochondrial dysfunction and accumulation of damaged mitochondria. This contributes to neurodegeneration. The pathway involves PLCG1, which generates IP3, leading to the release of Ca\u00b2+ from the endoplasmic reticulum via ITPR channels. Disruption of this pathway is linked to impaired calcium homeostasis and neuronal death. Mutations in PRKN are a known cause of Parkinson's disease, specifically in cases with early-onset and autosomal recessive inheritance. These mutations compromise the cell's ability to remove dysfunctional mitochondria, leading to oxidative stress, neuroinflammation, and ultimately, dopaminergic neuron loss. Therefore, the biological effect of PRKN mutations is a key contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PRKN (parkin), which ubiquitinates PLCG1, leading to the regulation of IP3 receptors (ITPR1-3) and subsequent release of Ca\u00b2\u207a. Mutations in PRKN disrupt this ubiquitination, leading to the accumulation of PLCG1 and increased IP3-mediated Ca\u00b2\u207a signaling. This dysregulated calcium flux is linked to neuronal damage and apoptosis. PRKN mutations are a well-known cause of autosomal recessive Parkinson's disease. The loss of parkin function impairs mitochondrial quality control and leads to oxidative stress and neurodegeneration, particularly in dopaminergic neurons. This contributes to the hallmark pathology of Parkinson\u2019s disease, characterized by motor deficits and loss of substantia nigra neurons. Therefore, the biological effect of this PRKN allele is the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger prion diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential regulatory interaction where PRNP may influence NOTCH1 signaling. Mutations in PRNP, particularly those leading to misfolding or aggregation of the prion protein, are directly linked to transmissible spongiform encephalopathies (TSEs). The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob disease (CJD), a rapidly progressive and fatal neurodegenerative disorder. These mutations can also cause variant CJD (vCJD), kuru, and other prion-related illnesses. The interaction with NOTCH1 may modulate cellular responses, but the primary pathological effect arises from prion protein misfolding and subsequent neurotoxicity. Therefore, the biological effect of this PRNP allele is the contribution to \\boxed{Creutzfeldt-Jakob disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can cause neurodegenerative diseases. In the pathway PRNP \u2192 NOTCH1, the interaction suggests a regulatory role of PRNP in NOTCH1 signaling. Mutations in PRNP, particularly those leading to misfolding, are most famously associated with Creutzfeldt-Jakob Disease (CJD), a rare and fatal human transmissible spongiform encephalopathy. These mutations can also contribute to other prion diseases, such as Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI). The altered PRNP can misfold and aggregate, disrupting normal cellular function and leading to neuronal damage. This aberrant protein folding interferes with NOTCH1 signaling, which is critical for cell differentiation and neural development. The biological effect of the PRNP allele in this context is the induction of prion disease, characterized by progressive neurodegeneration and cognitive decline. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the context of the pathway PRNP \u2192 NOTCH1, the interaction suggests a potential regulatory or signaling role of PRNP in NOTCH1 activity. Mutations in PRNP are most famously associated with spontaneous Creutzfeldt-Jakob disease (CJD), a rare and fatal human prion disease. These mutations can cause misfolding of the prion protein, leading to its aggregation and toxicity, which disrupts cellular function, particularly in neurons. This pathological process contributes to the progressive degeneration of the brain, resulting in severe cognitive and motor impairments. The involvement of NOTCH1 in this pathway may indicate a broader impact on cell signaling processes, potentially influencing cell survival and differentiation. Thus, the PRNP allele's biological effect is the contribution to Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described genomic pathway, is central to the VHL tumor suppressor gene. Mutations in VHL disrupt the VHL-RBX1-Elongin C/B-CUL2 E3 ubiquitin ligase complex, leading to stabilization of hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT. This results in the constitutive activation of genes like VEGFA, CXCL8, GLUT1, and EPO, which promote angiogenesis, inflammation, and erythropoiesis. This pathway is critical in the development of clear cell renal cell carcinoma (ccRCC), as VHL mutations are a hallmark of this disease. The uncontrolled activation of these genes supports tumor growth by enhancing vascularization and cell survival. Thus, the biological effect of the VHL allele is the promotion of ccRCC. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described genomic pathway, is central to the VHL tumor suppressor complex, which targets hypoxia-inducible factors (HIFs) for degradation. When VHL is mutated, the degradation of HIF-1\u03b1 and HIF-2\u03b1 is impaired, leading to their stabilization and activation. This results in aberrant expression of genes like VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoietin production. This pathway is critical in hypoxia response and cell survival. Mutations in VHL are a hallmark of von Hippel-Lindau (VHL) disease, a hereditary disorder characterized by the development of multiple benign and malignant tumors, including hemangioblastomas, renal cell carcinomas, pheochromocytomas, and pancreatic neuroendocrine tumors. The dysregulation of this pathway leads to uncontrolled cellular proliferation and angiogenesis, hallmark features of these tumors. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin ligase pathway that targets hypoxia-inducible factors (HIFs) for degradation. When VHL is mutated, this degradation process is impaired, leading to the stabilization of HIF-1\u03b1 and HIF-2\u03b1. This results in the aberrant activation of genes such as VEGFA, CXCL8, GLUT1, and EPO, which drive angiogenesis, inflammation, and erythropoiesis. This pathway is central to tumor progression under hypoxic conditions. Mutations in VHL are associated with the development of clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. The loss of VHL function leads to uncontrolled cell growth and tumor formation, particularly in the kidneys. The pathway also contributes to the pathogenesis of other cancers, but the most well-characterized is ccRCC. The disease associated with this VHL allele is \\boxed{clear cell renal cell carcinoma}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein implicated in Huntington's disease. Mutations in HTT, specifically CAG trinucleotide repeat expansions, lead to the production of an abnormally long and toxic huntingtin protein. This protein disrupts various cellular functions, including synaptic transmission, mitochondrial homeostasis, and protein clearance. In the given pathway, HTT is upstream of DLG4, a scaffold protein that modulates NMDA receptors, which are critical for calcium signaling. Dysregulated calcium levels via MCU and mitochondrial dysfunction can trigger the release of cytochrome c, activating the intrinsic apoptotic pathway through APAF1, CASP9, and ultimately CASP3. This cascade leads to neuronal apoptosis, contributing to the progressive neurodegeneration observed in Huntington's disease. The accumulation of mutant HTT also impairs mitochondrial function, exacerbating oxidative stress and cell death. These mechanisms collectively underlie the pathology of Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, specifically the mutant form associated with expanded CAG repeats, contributes to Huntington's disease. This mutation leads to the production of an abnormal huntingtin protein, which disrupts neuronal function and triggers toxic gain-of-function effects. The pathway described involves NMDA receptors (GRIN1, GRIN2A-D), calcium influx through voltage-dependent anion channels (VDAC1-3) and the mitochondrial calcium uniporter (MCU), leading to mitochondrial calcium overload. This activates the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis via APAF1, CASP9, and CASP3. This apoptotic cascade results in neuronal death, particularly in the striatum and cortex, hallmark features of Huntington's disease. The HTT mutation thus drives neurodegeneration through calcium dysregulation and apoptosis.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the HTT gene, which encodes huntingtin, a protein implicated in neurodegenerative processes. The pathway begins with HTT, which interacts with DLG4 and NMDAR subunits (GRIN1, GRIN2A-D), leading to intracellular calcium influx via NMDAR channels. Excess calcium triggers mitochondrial permeability transition via MCU and VDACs, causing mitochondrial dysfunction. This leads to the release of cytochrome c (CYCS), activating APAF1 and initiating apoptosis through CASP9 and CASP3. This cascade is central to neuronal death. Mutations in HTT, particularly expansions of the CAG repeat, result in Huntington\u2019s disease, characterized by progressive neurodegeneration and motor dysfunction. The accumulation of mutant huntingtin disrupts calcium homeostasis and mitochondrial function, driving apoptosis in neurons. Thus, the HTT allele contributes to \\boxed{Huntington's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **KCNC3** gene encodes a voltage-gated potassium channel subunit (Kv3.3) that plays a critical role in regulating neuronal excitability by modulating action potential duration and repolarization. Mutations in **KCNC3** can disrupt normal ion flow, leading to hyperexcitability of neurons. This is implicated in **epilepsy**, particularly **Dravet syndrome**, a severe form of childhood epilepsy characterized by prolonged seizures, developmental delay, and cognitive impairment. The altered potassium currents caused by KCNC3 dysfunction impair neuronal repolarization, contributing to hyperexcitability and seizure susceptibility. Additionally, **KCNC3** has been associated with **febrile seizures** and **generalized epilepsy with febrile seizures plus (GEFS+)**. These mutations often result in gain-of-function or loss-of-function effects, depending on the specific variant, which disrupt the delicate balance of excitatory and inhibitory signals in the brain. The role of KCNC3 in neuronal electrophysiology underscores its importance in preventing seizure onset and maintaining neuronal stability.\n\n\\boxed{Dravet syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel (Kv3.4) that plays a critical role in regulating neuronal excitability by modulating action potential duration and repolarization. Mutations in KCNC3 can disrupt normal ion flow, leading to hyperexcitability in neurons. This contributes to the development of neurological disorders, particularly epilepsy. Specifically, gain-of-function mutations in KCNC3 have been associated with generalized epilepsy with focal seizures, a type of idiopathic epilepsy characterized by recurrent seizures originating from multiple brain regions. These mutations typically result in increased potassium channel activity, which can lower the threshold for neuronal firing and promote seizure activity. Therefore, the biological effect of pathogenic KCNC3 alleles is the disruption of neuronal excitability, contributing to epileptic disorders. \n\n\\boxed{Generalized epilepsy with focal seizures}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel (Kv3.4) that plays a critical role in regulating membrane potential in neuronal and cardiac cells. Mutations in KCNC3 can disrupt normal ion flow, leading to abnormal electrical activity in excitable cells. Specifically, gain-of-function mutations in KCNC3 have been linked to hyperexcitability in neurons, contributing to seizures. This is associated with epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures. The altered potassium current caused by the KCNC3 mutation leads to prolonged neuronal firing, which can trigger seizure activity. Therefore, the biological effect of the KCNC3 allele is to increase neuronal excitability, and it contributes to the development of epilepsy. \n\n\\boxed{Epilepsy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is critical for maintaining mitochondrial homeostasis and neuronal function. PRKN, also known as parkin, is an E3 ubiquitin ligase that targets damaged mitochondria for degradation via mitophagy. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and subsequent oxidative stress. This disruption contributes to neurodegeneration. PRKN mutations are a well-documented cause of Parkinson's disease, specifically in the context of dominant-negative mutations that compromise its E3 ligase activity. This leads to the loss of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's. The pathway also involves PLCG1, IP3, and ITPR, which regulate intracellular calcium levels, further linking mitochondrial dysfunction to calcium dysregulation, a key factor in neuronal death. Therefore, the biological effect of this PRKN allele is the disruption of mitochondrial quality control, contributing to the development of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through ubiquitin-mediated degradation of damaged mitochondria, a process essential for maintaining cellular health. Mutations in PRKN lead to impaired mitophagy, allowing dysfunctional mitochondria to accumulate, which can cause oxidative stress and cell death. This dysfunction is linked to neurodegenerative disorders. Specifically, PRKN mutations are a well-documented genetic cause of Parkinson's disease. Loss-of-function variants in PRKN disrupt the ubiquitin-proteasome system, contributing to the accumulation of damaged mitochondria in dopaminergic neurons, which ultimately leads to neuronal loss in the substantia nigra. This pathway disruption is a key mechanism in the pathogenesis of Parkinson's disease. Thus, the biological effect of PRKN allele dysfunction is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key component of the ubiquitin-proteasome system, playing a critical role in mitochondrial quality control by mediating the ubiquitylation and degradation of damaged mitochondria. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This disruption in mitochondrial homeostasis is strongly associated with neurodegenerative processes. PRKN mutations are a well-documented cause of Parkinson's disease, specifically in cases with early onset and autosomal recessive inheritance. The pathway described\u2014PRKN \u2192 PLCG1 \u2192 IP3 \u2192 ITPR \u2192 Ca\u00b2\u207a\u2014highlights the interplay between mitochondrial dysfunction and calcium signaling, which is central to neuronal health. Impaired regulation of intracellular calcium levels due to defective PRKN contributes to neuronal death, further supporting its role in Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. In the given pathway, PRNP is upstream of BIP (HSPA5), which is involved in the unfolded protein response. This pathway ultimately leads to ATF4 activation and the expression of DDIT3, a gene involved in stress response and apoptosis. Mutations in PRNP are most famously associated with prion diseases, such as Creutzfeldt-Jakob disease (CJD), variant CJD (vCJD), kuru, and Gerstmann-Str\u00e4ussler-Scheinker syndrome. These diseases are caused by the conversion of the normal prion protein (PrP^C) into the pathogenic form (PrP^Sc), leading to neurodegeneration. The pathway described reflects the cellular stress response triggered by prion protein misfolding, contributing to neuronal damage and disease progression. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the provided pathway, PRNP is upstream of BIP and EIF2AK3, indicating a role in stress response and translation regulation. The pathway culminates in DDIT3, a gene involved in cell cycle arrest and apoptosis. Mutations in PRNP, particularly those causing prion protein misfolding, are strongly associated with Creutzfeldt-Jakob disease (CJD), a rare and fatal neurodegenerative disorder. This condition is characterized by rapid progressive dementia and is caused by the conversion of normal prion protein (PrP^C) into the pathological form (PrP^Sc). The pathway likely reflects the cellular stress response triggered by prion-related toxicity, leading to neuronal damage and disease progression. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the given pathway, PRNP is upstream of BIP (HSPA5), which is involved in protein folding and stress response. This pathway ultimately leads to ATF4 activation and the expression of DDIT3, a gene involved in cellular stress responses and apoptosis. Mutations in PRNP can cause misfolding of the prion protein, leading to neurodegenerative diseases. The most well-known disease associated with PRNP mutations is **Creutzfeldt-Jakob disease (CJD)**, a rare and fatal transmissible spongiform encephalopathy. This disease is caused by the conversion of normal prion protein (PrP^C) into the pathogenic form (PrP^Sc), which accumulates in the brain, leading to neuronal loss and spongiform changes. The pathway described highlights the role of PRNP in protein homeostasis and its disruption in prion-related neurodegeneration. \n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which is critical for calcium entry into neurons. This channel plays a key role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with a range of neurological disorders. The pathway described involves extracellular calcium influx through this channel, impacting intracellular calcium levels. Dysregulation of this process contributes to hyperexcitability and impaired synaptic function. Notably, mutations in CACNA1A are a well-documented cause of **familial hemiplegic migraine (FHM)**, a genetic disorder characterized by migraines with motor weakness. Additionally, CACNA1A mutations are linked to **spinocerebellar ataxia type 6 (SCA6)** and other paroxysmal disorders. The biological effect of the CACNA1A allele involves aberrant calcium signaling, leading to neuronal dysfunction and the clinical manifestations of these diseases.\n\n\\boxed{familial hemiplegic migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neuronal excitability by regulating calcium influx. The pathway described involves extracellular calcium entering through this channel, contributing to intracellular calcium signaling. Mutations in CACNA1A are associated with various neurological disorders, most notably familial hemiplegic migraine (FHM), a form of migraine with brainstem symptoms. These mutations disrupt normal calcium homeostasis, leading to enhanced neuronal activity and excitotoxicity. CACNA1A mutations can also contribute to other conditions such as ataxia and episodic athetosis. The biological effect of the CACNA1A allele, particularly pathogenic variants, is the disruption of calcium-dependent neuronal function, leading to hyperexcitability and neurodegeneration. This results in the characteristic symptoms of the associated diseases. The most well-established disease linked to CACNA1A is \\boxed{Familial Hemiplegic Migraine}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the Cav1.1 calcium channel, which is critical for voltage-gated calcium entry into neurons. The pathway described involves extracellular calcium entering through this channel, leading to intracellular calcium elevation. Mutations in CACNA1A are well-documented in diseases characterized by neurodevelopmental and neurological dysfunction. Specifically, this gene is associated with **familial hemiplegic migraine (FHM)**, a rare form of migraine with neurological aura. The altered channel function leads to dysregulation of calcium homeostasis, contributing to neuronal hyperexcitability and the characteristic migraine symptoms. Additionally, CACNA1A mutations have been linked to other neurological disorders, including certain types of ataxia and episodic encephalopathy. Thus, the CACNA1A allele contributes to **familial hemiplegic migraine**. \n\n\\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway is central to autophagy and innate immune responses. TBK1, along with proteins like SQSTM1, OPTN, TAX1BP1, and NBR1, regulates the formation of autophagosomes through interactions with LC3-II. Mutations or dysfunction in TBK1 disrupt this process, leading to impaired autophagy and immune response. This contributes to the accumulation of damaged proteins and pathogens, increasing susceptibility to infections and neurodegeneration. TBK1 is particularly implicated in neuroinflammatory diseases. Mutations in TBK1 have been associated with **Amyotrophic Lateral Sclerosis (ALS)**, a progressive neurodegenerative disorder characterized by motor neuron loss. Dysfunction in this pathway compromises neuronal survival and immune regulation, accelerating disease progression. Thus, the TBK1 allele plays a critical role in maintaining cellular homeostasis, and its dysfunction contributes to **Amyotrophic Lateral Sclerosis**.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway is central to innate immune responses, particularly in recognizing cytosolic DNA and activating antiviral defenses. TBK1 phosphorylates IRF3, leading to the production of type I interferons. It also interacts with proteins like SQSTM1, OPTN, TAX1BP1, and NBR1, which are involved in autophagy and ubiquitin-mediated degradation of pathogens. Mutations in TBK1 disrupt these interactions, impairing antiviral immunity and autophagy. This contributes to chronic inflammation and susceptibility to infections. Importantly, TBK1 mutations are associated with autoimmune and inflammatory diseases, including Aicardi-Gouti\u00e8res syndrome (AGS), an autosomal recessive disorder characterized by encephalopathy, calcification, and chronic inflammation. The disrupted TBK1 pathway leads to impaired clearance of damaged mitochondria and pathogens, exacerbating neuroinflammation. \\boxed{Aicardi-Gouti\u00e8res syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway is central to innate immune responses, particularly in the recognition of cytosolic pathogens and the regulation of autophagy. TBK1 activates key receptors such as SQSTM1, OPTN, and TAX1BP1, which are involved in the formation of autophagosomes and the recruitment of LC3-II, a marker of autophagy. Mutations in TBK1 disrupt this pathway, impairing the cell's ability to clear pathogens and leading to chronic inflammation. This dysfunction is strongly associated with neurodegenerative diseases. Specifically, TBK1 mutations contribute to Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disorder characterized by the loss of motor neurons. The impaired autophagy and inflammation in this pathway exacerbate neuronal damage, making TBK1 a critical player in ALS pathogenesis. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein primarily found in neurons. Mutations or overexpression of SNCA are strongly associated with the aggregation of alpha-synuclein into Lewy bodies, a hallmark of neurodegenerative diseases. The pathway involving SNCA and complex I subunits suggests a link to mitochondrial dysfunction, as complex I is a key component of the electron transport chain. This dysfunction contributes to oxidative stress and neuronal death. The biological effect of the SNCA allele, particularly in the context of these mitochondrial subunits, is central to the pathogenesis of Parkinson's disease. Mutations in SNCA are known to increase the risk of early-onset Parkinson's disease by promoting alpha-synuclein misfolding and aggregation. Therefore, the SNCA allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein into Lewy bodies, which are hallmark pathological features of Parkinson's disease. The presence of SNCA in a genomic pathway involving complex I subunits suggests a link between mitochondrial dysfunction and neurodegeneration. Accumulation of misfolded alpha-synuclein disrupts synaptic function and leads to neuronal loss, particularly in the substantia nigra. This process contributes to the motor and non-motor symptoms characteristic of Parkinson's disease. The interplay between SNCA and mitochondrial complex I components underscores the role of energy metabolism and protein homeostasis in disease progression. Therefore, the SNCA allele is a key contributor to Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein into Lewy bodies, which are a hallmark of Parkinson's disease. The pathway includes components of complex I of the mitochondrial respiratory chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. Dysregulation of these genes can impair energy production in neurons, contributing to oxidative stress and neuronal death. This connection highlights the role of mitochondrial dysfunction in Parkinson's disease. The SNCA allele, therefore, contributes to the development of Parkinson's disease by promoting toxic protein aggregation and disrupting mitochondrial function. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ-1, plays a crucial role in protecting cells from oxidative stress and is involved in the regulation of the JNK signaling pathway through its interaction with DAXX and ASK1. Mutations in PARK7 are linked to an increased risk of Parkinson's disease. The gene's function in maintaining cellular homeostasis and preventing neuronal death makes it essential for neuroprotection. Loss of function mutations in PARK7 lead to impaired regulation of the JNK pathway, contributing to neurodegeneration. This pathway is critical for stress response and apoptosis, and its dysregulation is implicated in the pathogenesis of Parkinson's disease. Therefore, the biological effect of the PARK7 allele is a significant contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a signaling pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway plays a role in cellular stress responses, apoptosis, and neuroprotection. Mutations in PARK7 are associated with Parkinson's disease, as they impair mitochondrial function and lead to oxidative stress, ultimately contributing to neuronal degeneration. The PARK7 allele's dysfunction disrupts the regulation of JNK, which is critical for maintaining neuronal health. This disruption is linked to the pathogenesis of Parkinson's disease, characterized by the loss of dopaminergic neurons in the substantia nigra. Therefore, the biological effect of this PARK7 allele is the contribution to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway is crucial for cellular stress responses and apoptosis. Mutations in PARK7 are associated with impaired mitochondrial function and increased oxidative stress, which contribute to neuronal death. The specific allele in question, PARK7, is linked to Parkinson's disease. Loss-of-function mutations in PARK7 disrupt its protective roles, leading to neurodegeneration, particularly in dopaminergic neurons. This genetic contribution is a key factor in the pathogenesis of Parkinson's disease. Therefore, the biological effect of this PARK7 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, driving cellular growth and differentiation. Mutations in BRAF, particularly activating mutations such as V600E, lead to constitutive activation of the MAPK/ERK pathway, promoting uncontrolled cell growth. This dysregulation is strongly associated with various cancers. The most well-characterized disease linked to BRAF mutations is melanoma, where BRAF mutations occur in approximately 50% of cases. Additionally, BRAF mutations are implicated in other cancers, including colon adenocarcinoma, non-small cell lung cancer, and thyroid cancer. The persistent activation of the ERK pathway due to mutant BRAF contributes to tumor initiation, progression, and resistance to therapy. Targeting BRAF with specific inhibitors has shown therapeutic benefit in BRAF-mutated cancers. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele in the BRAF -> MEK -> ERK pathway contributes to the activation of the MAPK/ERK signaling cascade, which regulates cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of this pathway, driving uncontrolled cell growth. This dysregulation is a key factor in the development of several cancers. The most well-known disease associated with this pathway is melanoma, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies, including colorectal cancer, non-small cell lung cancer, and thyroid cancer. The continuous activation of ERK due to mutated BRAF results in oncogenic transformation, making this pathway a significant target for therapeutic interventions, such as BRAF inhibitors. The biological effect of the BRAF allele in this context is the promotion of tumorigenesis through persistent activation of the MAPK signaling pathway.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, promoting cell growth and differentiation. Mutations in BRAF, particularly the V600E substitution, lead to constitutive activation of this pathway, driving uncontrolled cell proliferation. This aberrant signaling is a hallmark of several cancers. The most well-known disease associated with BRAF mutations is melanoma, where activating mutations in BRAF are found in approximately 50% of cases. Additionally, BRAF mutations contribute to other malignancies such as colorectal cancer, non-small cell lung cancer, and thyroid cancer. The persistent activation of the MAPK/ERK pathway due to mutant BRAF results in genomic instability, resistance to apoptosis, and enhanced cell migration, all of which promote tumor progression. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is essential for purine metabolism, specifically in the salvage pathway for adenine. Mutations in APRT can lead to a deficiency in the enzyme, resulting in the accumulation of toxic levels of 2,8-dihydroxyadenine (DHA) in the urine. This accumulation can cause kidney damage and eventually lead to renal failure. The most well-known disease associated with APRT deficiency is **Lesch\u2013Nyhan syndrome**, although it is important to note that Lesch\u2013Nyhan is primarily caused by mutations in the HPRT gene. However, APRT mutations can contribute to a milder, related condition known as **adenine phosphoribosyltransferase deficiency**, which also presents with neurological and renal abnormalities. This condition is characterized by high levels of DHA in the urine, leading to progressive kidney disease and neurological symptoms. The specific biological effect of the APRT allele is therefore a **reduced ability to metabolize adenine**, contributing to **adenine phosphoribosyltransferase deficiency**.\n\n\\boxed{Adenine phosphoribosyltransferase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the purine salvage pathway, specifically in the reutilization of adenine to synthesize inosine monophosphate (IMP). Mutations in APRT can lead to a deficiency in this enzyme, resulting in the accumulation of purines and their metabolites, such as 2,6-diamino-4-hydroxypteridine (DAHP), which is toxic to neurons. This accumulation leads to neurochemical imbalances and progressive neurological damage. The most well-known disease associated with APRT deficiency is Lesch-Nyhan syndrome, a rare X-linked recessive disorder characterized by severe neurological abnormalities, self-injurious behavior, and impaired motor function. The APRT allele contributes to this condition by disrupting the purine metabolism pathway, leading to the accumulation of toxic metabolites and subsequent neuronal dysfunction. \\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene plays a crucial role in the purine salvage pathway, catalyzing the conversion of adenine to inosine monophosphate (IMP). Mutations in the APRT gene lead to reduced enzymatic activity, resulting in the accumulation of adenosine and adenine in tissues, particularly in the kidneys. This accumulation causes the formation of monosodium urate crystals, leading to a rare autosomal recessive disorder called Lesch-Nyhan syndrome. Characterized by neurological abnormalities, self-mutilating behavior, and hyperuricemia, Lesch-Nyhan syndrome is a consequence of the disrupted purine metabolism due to the APRT allele. The disease is marked by the absence of functional APRT enzyme, disrupting the salvage pathway and leading to excessive uric acid production. The genetic defect in APRT is central to the pathophysiology of this syndrome.\n\n\\boxed{Lesch-Nyhan syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) highlights the interaction between RB1 and E2F family members (E2F1, E2F2, E2F3), which control genes involved in DNA replication and cell division. When RB1 is functional, it binds to E2F and prevents the transcription of genes required for S-phase entry, thereby arresting the cell cycle. Loss-of-function mutations in RB1 disrupt this regulation, leading to uncontrolled cell proliferation. This dysfunction is a hallmark of retinoblastoma, a pediatric eye cancer. Additionally, RB1 inactivation contributes to other cancers, including small cell lung cancer, osteosarcoma, and bladder cancer. The specific biological effect of the RB1 allele is the deregulation of the cell cycle, promoting tumorigenesis. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates cell cycle progression by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) highlights the interaction between RB1 and E2F family transcription factors, which control the expression of genes involved in DNA synthesis and cell division. When RB1 is mutated or inactivated, it loses its ability to restrain E2F-driven transcription, leading to uncontrolled cell proliferation. This dysregulation is a hallmark of retinoblastoma, a childhood eye cancer arising from the retina. Additionally, RB1 mutations are implicated in other cancers, including small cell lung cancer, osteosarcoma, and bladder cancer. The loss of functional RB1 allows cells to progress through the cell cycle unchecked, contributing to tumor formation. Therefore, the biological effect of this RB1 allele is the promotion of uncontrolled cell growth, contributing to retinoblastoma and other cancers.\n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. The pathway defined (RB1 // E2F) highlights the interaction between RB1 and E2F family members, which control genes involved in DNA replication and cell division. Loss of functional RB1 leads to uncontrolled cell proliferation by allowing E2F-mediated activation of genes promoting cell cycle progression. This disruption is a hallmark of retinoblastoma, a rare cancer of the retina, and also contributes to other malignancies such as osteosarcoma and small cell lung cancer. Mutations in RB1 are often germline in retinoblastoma, increasing cancer risk. Thus, the biological effect of this RB1 allele is the promotion of uncontrolled cell growth, leading to the development of retinoblastoma. \n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, which results in the formation of toxic protein aggregates. This pathogenic mechanism is central to the development of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and cerebellar ataxia. The inclusion of ATXN3 in the genomic pathway highlights its role in calcium signaling and mitochondrial dysfunction, contributing to neuronal damage. The pathway involves glutamate signaling, IP3 release, mitochondrial calcium uptake via MCU, and the subsequent activation of the mitochondrial permeability transition pore (MPTP), which leads to the release of cytochrome c and apoptosis. These processes are exacerbated by ATXN3 mutations, making it a key contributor to SCA2 pathology.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the genomic pathway starting from glutamate signaling through GRM1, GNAQ, PLCB, IP3, and ITPR1, leading to mitochondrial calcium uptake via MCU and subsequent mitochondrial dysfunction. ATXN3 encodes ataxin-3, a polyglutamine-containing protein associated with protein misfolding and aggregation. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination. The pathogenic expansion of polyglutamine in ATXN3 leads to neuronal toxicity, particularly in the cerebellum, resulting in ataxia. This condition is inherited in an autosomal dominant manner. The pathway involving ATXN3 highlights the role of calcium homeostasis and protein quality control in neurodegeneration. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein folding and degradation. Mutations in ATXN3, particularly expansions of the polyglutamine tract, lead to the formation of toxic protein aggregates, disrupting cellular function. This primarily affects neurons, leading to neurodegeneration. The biological effect of the ATXN3 allele is thus associated with spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. The pathway involving ATXN3 is part of the calcium signaling network, where it modulates mitochondrial calcium dynamics, and its dysfunction contributes to mitochondrial stress and apoptosis. This genetic disorder is autosomal dominant, and the disease mechanism involves protein misfolding, aggregation, and neuronal death. The involvement of ATXN3 in this pathway highlights its role in maintaining synaptic function and mitochondrial health. \n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is part of a pathway involving SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway suggests a role for SOD1 in stress response mechanisms, with BIP (a chaperone protein) and ATF6 (a transcription factor) involved in the unfolded protein response. DDIT3 (CHOP) is a stress-inducible transcription factor linked to apoptosis and cellular stress. Thus, dysfunction in this pathway, particularly due to SOD1 mutations, contributes to neuronal stress and death, leading to ALS. The biological effect of the SOD1 allele is therefore the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 is involved in cellular stress response and protein folding. SOD1, a copper/zinc superoxide dismutase, normally detoxifies superoxide radicals. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. In ALS, mutant SOD1 misfolds and aggregates, leading to motor neuron degeneration. The pathway suggests SOD1 may influence endoplasmic reticulum (ER) stress via BIP and ATF6, ultimately affecting DDIT3, a stress-response gene. This contributes to neuronal dysfunction and disease progression. Mutant SOD1 also disrupts protein homeostasis, exacerbating ER stress and neurotoxicity. Collectively, the pathway links SOD1 dysfunction to ALS pathogenesis. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). In the given pathway, SOD1 is a key node that influences downstream genes such as BIP and ATF6, leading to DDIT3 activation. Mutations in SOD1 are well-documented as a cause of familial ALS, a neurodegenerative disease characterized by progressive motor neuron loss. The pathway involves stress response mechanisms, including the unfolded protein response, which is dysregulated in ALS. SOD1, an enzyme that normally breaks down superoxide radicals, becomes toxic when mutated, leading to oxidative stress and neuronal death. The activation of ATF6 and DDIT3 underscores the involvement of cellular stress and apoptosis in disease progression. This pathway highlights the role of SOD1 in ALS pathogenesis. The biological effect of the SOD1 allele is therefore the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the PI3K-AKT signaling pathway. When PTEN is mutated or inactivated, PIP3 levels increase, leading to sustained activation of AKT. This promotes cell survival, proliferation, and resistance to apoptosis. Such dysregulation is a key driver in the development of various cancers. Specifically, loss of PTEN function is strongly associated with **Cowden syndrome**, a hereditary disorder characterized by an increased risk of developing benign and malignant tumors, particularly in the breast, thyroid, and endometrium. Additionally, PTEN inactivation contributes to the pathogenesis of **clear cell renal cell carcinoma** and **glioblastoma multiforme**. The loss of PTEN function disrupts cellular homeostasis, leading to uncontrolled cell growth and tumorigenesis. Therefore, the biological effect of a mutated PTEN allele is the promotion of cancer through activation of the PI3K-AKT pathway.\n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the activation of AKT. This pathway is critical for regulating cell survival, proliferation, and apoptosis. Loss or dysfunction of PTEN leads to increased PIP3 levels and constitutive AKT activation, promoting uncontrolled cell growth. This contributes to the development of various cancers. Specifically, mutations in PTEN are strongly associated with **Cowden syndrome**, a rare genetic disorder that significantly increases the risk of developing benign and malignant tumors, including breast, thyroid, and endometrial cancers. Additionally, PTEN inactivation is frequently observed in **glioblastoma multiforme**, **breast cancer**, and **prostate cancer**. The loss of PTEN function disrupts the PI3K-AKT signaling pathway, a key driver of oncogenesis. Therefore, the biological effect of a PTEN allele is the promotion of tumorigenesis, contributing to **Cowden syndrome** and other cancers.\n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a phosphatase that dephosphorylates PIP3, converting it to PIP2. This action negatively regulates the AKT signaling pathway, which is crucial for cell survival, proliferation, and metabolism. When PTEN is mutated or inactivated, PIP3 levels increase, leading to constitutive activation of AKT. This results in uncontrolled cell growth and resistance to apoptosis. The loss of PTEN function is strongly associated with the development and progression of various cancers, particularly those involving the PI3K/AKT/mTOR pathway. One of the most notable diseases linked to PTEN dysfunction is **Cowden syndrome**, a genetic disorder characterized by the development of multiple benign and malignant tumors, including thyroid cancer, breast cancer, and endometrial cancer. Additionally, PTEN mutations are commonly found in glioblastomas and other cancers. The loss of PTEN function directly contributes to tumorigenesis by disrupting growth control mechanisms. \n\n\\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prion particles. In the described pathway, PRNP is the starting point, suggesting its role in initiating a cascade leading to apoptosis. The pathway involves NMDA receptor activation, mitochondrial calcium influx via MCU, mitochondrial permeability transition pore (MPTP) opening, release of cytochrome c (CYCS), and subsequent activation of apoptotic caspases (APAF1, CASP9, CASP3). This apoptotic pathway is commonly dysregulated in neurodegenerative diseases. The PRNP misfolding and associated pathogenic processes are most notably linked to **Creutzfeldt-Jakob Disease (CJD)**, a rapidly progressive and fatal prion disease. This condition is characterized by spongiform encephalopathy, neuronal loss, and widespread apoptosis, consistent with the described molecular mechanism. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which plays a critical role in cellular function and is implicated in protein misfolding and aggregation. In the described pathway, PRNP activates the NMDAR receptor, leading to an influx of Ca\u00b2+ ions. This calcium overload triggers the mitochondrial calcium uniporter (MCU), increasing mitochondrial calcium levels and ultimately activating the mitochondrial permeability transition pore (MPTP). This process leads to the release of cytochrome c (CYCS), initiating apoptosis via the APAF1-CASP9-CASP3 cascade. This pathway is central to neurodegenerative processes. The PRNP allele, particularly when mutated, is most notably associated with **Creutzfeldt-Jakob Disease (CJD)**, a rare, fatal prion disease characterized by rapid neurological deterioration due to misfolded prion proteins causing neuronal damage and apoptosis. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when mutated, can misfold and trigger neurodegenerative processes. In the given pathway, PRNP activates NMDAR, leading to increased intracellular calcium via the mitochondrial calcium uniporter (MCU). This calcium overload activates the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis via APAF1, CASP9, and CASP3. This pathway is central to neuronal death. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob Disease (CJD), a fatal prion disorder characterized by rapid neurodegeneration. The misfolded prion protein (PrPSc) disrupts cellular homeostasis, leading to synaptic dysfunction, mitochondrial damage, and apoptosis. This cascade contributes to the progressive loss of neurons, hallmark features of CJD. The pathway described is a key mechanism by which PRNP mutations drive disease.\n\n\\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. In the given pathway, SOD1 is linked to BCL2, which regulates apoptosis. Mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the loss of motor neurons. Mutant SOD1 proteins gain toxic gain-of-function properties, leading to oxidative stress, mitochondrial dysfunction, and neuronal death. The pathway described involves the regulation of apoptosis through BAX and BAK1, leading to the release of cytochrome c, activation of APAF1, and subsequent caspase activation (CASP9 \u2192 CASP3), which promotes cell death. These mechanisms are consistent with the pathogenesis of ALS. Thus, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described pathway, plays a role in oxidative stress regulation. SOD1 converts superoxide radicals into hydrogen peroxide, which can lead to cellular damage if not properly managed. In the context of the provided pathway, SOD1 influences apoptosis via BCL2, BAX, BAK1, and ultimately leads to the activation of CASP3, promoting cell death. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations contribute to increased oxidative stress and neuronal dysfunction, leading to cell death. The pathway described highlights the involvement of SOD1 in apoptosis and neurodegeneration. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is part of a pathway involved in apoptosis. SOD1, a copper/zinc superoxide dismutase, typically detoxifies superoxide radicals. However, mutant SOD1 proteins are associated with gain-of-toxic-function, leading to neuronal death. In this pathway, SOD1 interacts with BCL2, which normally inhibits apoptosis by suppressing BAX and BAK1. Mutant SOD1 may disrupt this regulation, allowing BAX and BAK1 to promote mitochondrial outer membrane permeabilization. This releases cytochrome c, activating APAF1 and forming the apoptosome, which recruits and activates CASP9, leading to CASP3 activation and apoptosis. This pathway is critical in neurodegeneration. Mutations in SOD1 are strongly linked to Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, initiated by the MET proto-oncogene, plays a critical role in cell proliferation, survival, and migration. When activated, MET signals through GRB2 and SOS to activate RAS, which in turn activates RAF, MEK, and ERK, ultimately upregulating CCND1, a cyclin that promotes cell cycle progression. Mutations or overactivation of MET can lead to constitutive signaling, driving uncontrolled cell growth. This contributes to the development of cancers characterized by MET dysfunction. Notably, MET activation is implicated in various malignancies, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. In particular, MET overexpression or amplification is strongly associated with the progression of **non-small cell lung cancer**. Thus, MET pathway aberrations significantly contribute to **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET, leading through GRB2, SOS, RAS, RAF, MEK, and finally ERK to CCND1. This pathway is critical for cell proliferation, survival, and differentiation. Activation of MET can drive uncontrolled cell growth by promoting cyclin D1 (CCND1), a key regulator of the cell cycle. Overexpression or mutation of MET can result in constitutive activation of this pathway, leading to oncogenic transformation. This contributes to various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. MET-driven signaling is also implicated in metastasis and tumor progression. Therefore, the biological effect of an activating MET allele is the promotion of uncontrolled cell proliferation and tumor growth, contributing to the development of **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1. This pathway is central to cell proliferation, survival, and differentiation. Activation of MET leads to increased CCND1 expression, promoting cell cycle progression. Dysregulation of this pathway is associated with uncontrolled cell growth and tumorigenesis. Specifically, MET overactivation or mutations can drive the development of various cancers. The most well-documented disease linked to MET activation is **non-small cell lung cancer (NSCLC)**, where MET amplification or mutations are frequently observed. Additionally, MET aberrations are implicated in **renal cell carcinoma**, **hepatocellular carcinoma**, and ** gastric cancer**. Therefore, the biological effect of this MET allele is the promotion of tumor growth, contributing to **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in ubiquitin-mediated protein degradation, particularly in the degradation of damaged mitochondria through mitophagy. Mutations in PRKN are a major cause of autosomal recessive Parkinson's disease. These mutations lead to impaired protein degradation, accumulation of dysfunctional mitochondria, and subsequent neurodegeneration, especially in dopaminergic neurons. The pathway described involves MAO enzymes (MAOA and MAOB), which metabolize monoamines like dopamine. Dysfunction in this pathway may exacerbate neurodegeneration by increasing dopamine levels, which can be toxic. Thus, PRKN alleles associated with loss of function contribute to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in mitophagy, the selective degradation of damaged mitochondria. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and oxidative stress. This contributes to neuronal death, particularly in regions of the brain rich in dopaminergic neurons. The pathway also involves monoamine oxidases (MAO-A and MAO-B), which metabolize neurotransmitters like dopamine. Dysfunction in this pathway is associated with increased dopamine levels, exacerbating neurotoxicity. Together, these disruptions are strongly linked to Parkinson's disease. Loss-of-function mutations in PRKN are a known genetic cause of early-onset Parkinson's disease, characterized by progressive motor dysfunction and degeneration of dopaminergic neurons. The interaction between PRKN and MAO enzymes underscores the complex pathophysiology of the disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in protein degradation via the ubiquitin-proteasome system. Its role in the pathway MAO -> DOPAL suggests involvement in dopamine metabolism, as monoamine oxidases (MAO-A and MAO-B) catabolize dopamine. Mutations in PRKN are associated with impaired protein quality control and neurodegeneration. The most well-known disease linked to PRKN dysfunction is Parkinson\u2019s disease. Loss-of-function mutations in PRKN lead to the accumulation of misfolded proteins, mitochondrial dysfunction, and increased oxidative stress, all of which contribute to dopaminergic neuron loss. PRKN mutations are a key genetic cause of early-onset Parkinson\u2019s disease and are also implicated in other neurodegenerative conditions. Thus, the biological effect of pathogenic PRKN alleles is the disruption of cellular quality control mechanisms, leading to neuronal death and the clinical manifestations of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene is a critical tumor suppressor that regulates cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and uncontrolled cell proliferation. The pathway includes genes such as CDKN1A, GADD45, BAX, and BAK1, which are involved in cell cycle regulation and apoptosis. The DNA damage-binding protein DDB2 and DNA polymerase kappa (POLK) also contribute to DNA repair and genome stability. When TP53 is mutated, these pathways are impaired, allowing the accumulation of mutations and the progression of cancer. This dysfunction is a hallmark of several aggressive malignancies. The most significant disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary disorder characterized by an increased risk of multiple cancers, including sarcomas, breast cancer, leukemia, and brain tumors. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to genomic stability and apoptosis. Mutations in TP53 disrupt its function as a tumor suppressor, leading to impaired cell cycle regulation, DNA repair, and apoptosis. This results in genomic instability and uncontrolled cell proliferation. The genes in this pathway\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014support TP53's role in cell cycle arrest, DNA damage response, and apoptosis. Dysregulation of this pathway is a hallmark of cancer. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary disorder characterized by a high risk of multiple cancers, including sarcomas, breast cancer, brain tumors, and leukemias. These mutations contribute to the development of various malignancies by compromising the cell's ability to detect and respond to DNA damage. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 tumor suppressor protein, a critical regulator of cell cycle arrest, DNA repair, and apoptosis. The pathway includes genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all of which are downstream effectors of p53 in response to cellular stress, particularly DNA damage. Mutations in TP53 disrupt its function, leading to loss of cell cycle control and apoptosis, allowing damaged cells to survive and proliferate. This contributes to genomic instability and tumorigenesis. TP53 mutations are strongly associated with a wide range of cancers, most notably **Li-Fraumeni syndrome**, a hereditary cancer predisposition syndrome. Additionally, TP53 mutations are commonly found in sarcomas, breast cancers, osteosarcomas, and other malignancies. The cumulative effect of TP53 dysfunction is the promotion of malignant transformation, making it one of the most frequently mutated genes in human cancers.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this genomic pathway is the initiation of a cascade leading to apoptosis. APP is cleaved to produce amyloid-beta (Abeta), which triggers the activation of GRM5 and downstream signaling via GNAQ and PLCB isoforms. This leads to the release of IP3 and subsequent Ca\u00b2\u207a influx through ITPR channels. Mitochondrial calcium overload via MCU activates the MPTP, causing the release of cytochrome c (CYCS) and the formation of the apoptosome via APAF1, culminating in the activation of CASP9 and CASP3. This pathway is central to apoptosis and is dysregulated in neurodegenerative diseases. Mutations in APP are strongly associated with Alzheimer's disease, where abnormal Abeta accumulation leads to neuronal damage and apoptosis. Thus, this pathway contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is the production of amyloid-beta (Abeta), which initiates a cascade leading to mitochondrial dysfunction, calcium dysregulation, and ultimately apoptosis. This pathway is central to neurodegenerative processes. The accumulation of Abeta disrupts calcium homeostasis via the mitochondrial calcium uniporter (MCU), leading to the opening of the mitochondrial permeability transition pore (MPTP). This triggers the release of cytochrome c (CYCS), activating the apoptotic cascade through APAF1 and CASP9, culminating in CASP3 activation and cell death. This mechanism is closely associated with Alzheimer's disease (AD), where Abeta accumulation is a hallmark. Mutations in APP, such as those causing early-onset AD, enhance Abeta production, accelerating neuronal loss. Thus, the pathway contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is central to neurodegeneration. APP undergoes proteolytic cleavage to produce amyloid-beta (Abeta), which accumulates as plaques in the brain, a hallmark of Alzheimer's disease. This buildup triggers a cascade involving GRM5, GNAQ, PLCB, ITPR, and mitochondrial calcium influx via MCU, leading to mitochondrial dysfunction and the release of cytochrome c (CYCS). This activates APAF1 and CASP9, ultimately inducing apoptosis via CASP3. This pathway is strongly associated with neuronal death and cognitive decline. Mutations in APP, such as those causing early-onset Alzheimer's, disrupt this process, leading to increased Abeta production and neurotoxicity. The pathway is a key contributor to the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. In the provided pathway, PRNP is upstream of RYR and ITPR, which are calcium release channels in the endoplasmic reticulum. This initiates the release of Ca\u00b2+ into the cytosol, which then enters mitochondria via MCU. Excess mitochondrial calcium can trigger the permeability transition pore (MPTP), leading to mitochondrial dysfunction and the release of cytochrome c. This activates the intrinsic apoptotic pathway via APAF1 and CASP9, ultimately resulting in CASP3-mediated cell death. Mutations in PRNP are a known cause of **Creutzfeldt-Jakob Disease (CJD)**, a rare, fatal prion disease characterized by rapid neurological degeneration. The pathway highlights how PRNP misfolding initiates a cascade of events leading to apoptosis and neurodegeneration. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger misfolding of other prion proteins, leading to neurodegeneration. In the given pathway, PRNP is the initiating node, connecting to ryanodine receptors (RYR) and inositol trisphosphate receptors (ITPR), which regulate intracellular calcium levels. Dysregulation of this pathway leads to mitochondrial calcium overload via the mitochondrial calcium uniporter (MCU), promoting the release of cytochrome c (CYCS) and activation of the apoptotic cascade via APAF1, CASP9, and CASP3. This process is central to neuronal cell death. Mutations in PRNP are causative for Creutzfeldt-Jakob disease (CJD), a rare, rapidly progressive, and fatal neurodegenerative disorder characterized by prion protein misfolding and subsequent neuronal damage. The pathway highlights the role of calcium dysregulation in apoptosis and neurodegeneration. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the given pathway, PRNP is the initiating node, suggesting its role in signaling events that ultimately lead to apoptosis via the mitochondrial pathway. The cascade involves calcium release from the endoplasmic reticulum through RYR and ITPR channels, followed by mitochondrial calcium uptake via MCU, which triggers the mitochondrial permeability transition pore (MPTP). This leads to the release of cytochrome c, activating APAF1 and caspase-9, ultimately resulting in caspase-3 activation and cell death. This pathway is implicated in neurodegeneration. The PRNP allele, particularly when harboring mutations that cause misfolding, is associated with **Creutzfeldt-Jakob disease (CJD)**, a fatal prion-induced neurodegenerative disorder. \n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, specifically in the context of the described pathway, is associated with the misfolding and aggregation of superoxide dismutase 1 (SOD1), a copper-zinc containing enzyme that catalyzes the dismutation of superoxide radicals. Mutations in SOD1 lead to the formation of toxic protein aggregates, which disrupt cellular function and are linked to neurodegeneration. This pathway involves the ubiquitin-proteasome system (UPS), where misfolded SOD1 is tagged with ubiquitin and targeted for degradation by the 26S proteasome. Dysfunction in this pathway results in the accumulation of misfolded SOD1, contributing to neuronal damage. This process is a key mechanism in the pathogenesis of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The involvement of SOD1 in this pathway underscores its critical role in protein quality control and its contribution to disease.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies superoxide radicals. However, mutations in SOD1 can lead to its misfolding and aggregation, resulting in neurotoxicity. These mutant SOD1 proteins contribute to the degeneration of motor neurons, a hallmark of ALS. The pathway described involves the ubiquitin-proteasome system, which normally degrades misfolded or damaged proteins. In the case of mutant SOD1, the ubiquitin ligase DERL1 and the proteasome subunits (such as PSMA and PSMB proteins) are involved in targeting the misfolded SOD1 for degradation. Failure in this process leads to the accumulation of toxic SOD1 aggregates, contributing to neuronal death. This pathway is central to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes protein ubiquitination and proteasomal degradation. SOD1, a copper/zinc superoxide dismutase, when mutated, leads to the misfolding and aggregation of the protein. This disrupts normal protein quality control mechanisms, including ubiquitination and proteasomal degradation, leading to the accumulation of toxic SOD1 aggregates. This process is central to neurodegenerative diseases. Mutations in SOD1 are a well-documented cause of **Amyotrophic Lateral Sclerosis (ALS)**, also known as Lou Gehrig's disease. These mutations cause the protein to become unstable, leading to the formation of toxic oligomers that damage motor neurons. The involvement of proteasomal subunits (e.g., PSMA and PSMC family members) underscores the role of impaired proteostasis in disease progression. Therefore, the biological effect of the SOD1 allele is the disruption of proteasomal function and the subsequent neurodegeneration characteristic of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is a key component of the NRG (neuregulin) signaling pathway, which plays a crucial role in neural development, myelination, and cell survival. ERBB4 functions as a receptor tyrosine kinase that binds neuregulin ligands (NRG1\u20134), initiating downstream signaling events essential for proper neuronal and glial cell function. Mutations or dysregulation of ERBB4 can disrupt this pathway, leading to impaired myelination and neuronal connectivity. This contributes to a range of neurological disorders. Specifically, ERBB4 dysfunction has been implicated in schizophrenia, where altered signaling is associated with cognitive and psychiatric deficits. Additionally, ERBB4 has been linked to certain cancers, including gliomas and breast cancer, due to its role in cell proliferation and survival. However, the most prominent disease associated with ERBB4 dysfunction is \\boxed{Schizophrenia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular processes such as proliferation, differentiation, and survival. It is activated by ligands like NRG1-4, which are members of the neuregulin family. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to disease. Specifically, alterations in ERBB4 have been implicated in various cancers, including non-small cell lung cancer (NSCLC), breast cancer, and glioblastoma. Additionally, ERBB4 has been associated with neurological disorders, such as schizophrenia and autism spectrum disorder, due to its role in brain development. In cancer, ERBB4 overexpression or amplification can drive tumor progression by promoting cell survival and angiogenesis. Therefore, the biological effect of the ERBB4 allele, when mutated or dysregulated, is the contribution to oncogenic pathways, making it a key player in several malignancies. \\boxed{Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, as part of the NRG/ERBB4 pathway, plays a critical role in cell growth, differentiation, and survival through ligand-receptor interactions. Mutations or dysregulation in ERBB4 can disrupt these processes, leading to aberrant signaling. This pathway is particularly important in neural development and myelination. Altered ERBB4 function has been implicated in various diseases, including neurological and psychiatric disorders. Specifically, ERBB4 has been associated with schizophrenia, where it contributes to disrupted synaptic plasticity and neural connectivity. Additionally, ERBB4 overactivation or mutations have been linked to certain cancers, such as non-small cell lung cancer and breast cancer, due to its role in promoting cell proliferation and inhibiting apoptosis. However, the most well-documented disease linked to ERBB4 is \\boxed{Schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction leads to the accumulation of mutant huntingtin protein, forming toxic aggregates. This process is central to the development of Huntington's disease (HD), a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK is involved in stress signaling and neurotoxicity, where mutant huntingtin activates the c-Jun N-terminal kinase (JNK) cascade, contributing to neuronal death. This pathway's activation exacerbates the pathological features of HD by promoting inflammation, apoptosis, and synaptic dysfunction. The inheritance of a pathogenic HTT allele results in expanded CAG repeats, leading to the production of a toxic protein that disrupts cellular homeostasis. This genetic mutation is the sole known cause of HD, a monogenic disorder with a clear molecular mechanism. The involvement of this pathway underscores the role of aberrant signaling in the pathogenesis of HD.  \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, when mutated, leads to the production of an abnormal huntingtin protein, which disrupts the neuronal pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK. This pathway is critical for stress responses and neuronal survival. The accumulation of mutant huntingtin causes neurotoxicity, leading to the degeneration of neurons, particularly in the striatum and cortex. This process is characteristic of Huntington's disease, a progressive neurodegenerative disorder. The disruption of the JNK signaling pathway contributes to apoptosis and inflammation, exacerbating neuronal death. The disease is inherited in an autosomal dominant manner, and the length of the CAG repeat expansion in the HTT gene correlates with disease severity and age of onset. The pathway disruption ultimately results in the hallmark symptoms of Huntington's disease, including motor dysfunction, cognitive decline, and psychiatric symptoms. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, when mutated, leads to the production of an abnormal huntingtin protein, which disrupts the neuronal pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK. This pathway is critical for stress responses and neuronal survival. Mutations in HTT, specifically expansions in the CAG repeat, cause the accumulation of toxic huntingtin protein, leading to neurodegeneration. This contributes to Huntington's disease, a genetic disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The disrupted signaling pathway exacerbates neuronal death by impairing stress responses and promoting apoptosis. Thus, the HTT mutation directly contributes to the pathogenesis of Huntington's disease. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell signaling, particularly in the neuregulin (NRG) signaling pathway. This pathway is essential for neural development, myelination, and synaptic plasticity. Mutations or dysregulation of ERBB4 can lead to impaired signaling, contributing to various neurological and developmental disorders. Specifically, dysfunction in the NRG/ERBB4 pathway has been implicated in autism spectrum disorder (ASD). This is due to the role of ERBB4 in synaptic development and function, and its disruption can lead to altered connectivity and communication between neurons. Additionally, ERBB4 has been associated with schizophrenia and other neurodevelopmental conditions. Therefore, the biological effect of this ERBB4 allele is the disruption of critical neural signaling pathways, contributing to \\boxed{autism spectrum disorder}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular processes such as proliferation, differentiation, and survival. It is a key component of the NRG-ERBB4 signaling pathway, where neuregulins (NRG1-NRG4) act as ligands. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. Specifically, ERBB4 has been implicated in cancer, particularly in breast and lung cancers, where it promotes tumor growth and metastasis. Additionally, ERBB4 mutations have been associated with neurological disorders, including schizophrenia and autism spectrum disorders, due to its role in brain development. However, the most significant disease linked to ERBB4 is breast cancer, where its activation supports oncogenic pathways. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (Neuregulin) signaling pathway, which plays a critical role in neuronal development, myelination, and cell survival. ERBB4 functions as a receptor for NRG ligands, mediating downstream signaling events crucial for neural function. Mutations or dysregulation of ERBB4 can disrupt this pathway, leading to impaired neural development and connectivity. This disruption is associated with a range of neurological disorders. Specifically, ERBB4 has been implicated in schizophrenia, where disruptions in neural development and synaptic plasticity are key features. Additionally, ERBB4 abnormalities have been linked to certain cancers, such as non-small cell lung cancer, due to its role in cell proliferation and survival. However, the most prominent disease associated with ERBB4 dysfunction is \\boxed{schizophrenia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN are a major cause of Parkinson's disease (PD), leading to impaired ubiquitin-mediated proteasomal degradation and mitochondrial dysfunction. The pathway involving MAO-A and MAO-B metabolizes dopamine and other monoamines, and dysfunction in these enzymes can contribute to neurodegeneration. However, the direct link between PRKN and MAO in this context is not well-established, but PRKN mutations are strongly associated with PD. The primary disease linked to PRKN alleles is Parkinson's disease, characterized by the loss of dopaminergic neurons and motor dysfunction. Therefore, the biological effect of PRKN mutations is the contribution to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in proteasomal degradation of misfolded proteins and mitochondrial quality control. Mutations in PRKN lead to impaired ubiquitin-mediated degradation, resulting in the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN is a key gene in Parkinson's disease (PD), where loss-of-function mutations are associated with autosomal recessive early-onset PD. The pathway also involves monoamine oxidases (MAO-A and MAO-B), which metabolize dopamine and other monoamines. Dysfunction in this pathway can lead to increased dopamine levels, oxidative stress, and neuronal death, further supporting the role of PRKN in PD pathogenesis. Thus, the PRKN allele contributes to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in mitochondrial quality control and protein degradation. Mutations in PRKN are a major cause of Parkinson's disease (PD), specifically in monogenic forms of the disorder. The pathway involving PRKN, MAO-A, and MAO-B is relevant to dopamine metabolism, as monoamine oxidases break down neurotransmitters like dopamine. Dysfunction in this pathway can lead to the accumulation of toxic metabolites, contributing to neurodegeneration. PRKN mutations impair the ubiquitination and degradation of proteins, including alpha-synuclein, leading to the formation of Lewy bodies, a hallmark of Parkinson's. Thus, PRKN mutations are strongly associated with the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway likely contributes to stress response and protein homeostasis, which are disrupted in ALS. The interaction between SOD1 and the unfolded protein response (via BIP and EIF2AK3) suggests a role in cellular stress and neurodegeneration. Mutant SOD1 forms toxic oligomers and disrupts mitochondrial function, leading to neuronal death. The downstream effectors, including ATF4 and DDIT3, further amplify stress responses and apoptosis. Therefore, the biological effect of pathogenic SOD1 alleles is the onset and progression of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving oxidative stress and endoplasmic reticulum (ER) stress. SOD1 encodes superoxide dismutase 1, which normally detoxifies superoxide radicals. Mutations in SOD1 lead to dysfunctional enzyme activity, resulting in increased oxidative stress. This stress activates the unfolded protein response (UPR) via the PERK pathway (EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3), promoting cellular stress and apoptosis. This pathway is implicated in neurodegenerative diseases. Mutations in SOD1 are a well-documented cause of **Amyotrophic Lateral Sclerosis (ALS)**, also known as Lou Gehrig's disease. The accumulation of misfolded SOD1 proteins contributes to motor neuron degeneration, leading to progressive muscle weakness and\u762b\u75ea. The pathway highlights the link between oxidative stress, ER stress, and neuronal death in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving oxidative stress response and endoplasmic reticulum (ER) stress. SOD1, a copper/zinc superoxide dismutase, catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen, thereby protecting cells from oxidative damage. Mutations in SOD1 are well-documented as a primary cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive degeneration of motor neurons. The pathway includes HSPA5 (a key ER stress marker), EIF2AK3 (PERK), and downstream effectors like EIF2S1, ATF4, and DDIT3, which mediate stress responses. Dysregulation of this pathway due to mutant SOD1 leads to ER stress, altered protein folding, and neuronal death. This contributes to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for protein degradation via the ubiquitin-proteasome system. Mutations in PRKN disrupt its function, leading to the accumulation of misfolded proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN is associated with autosomal recessive Parkinson's disease (PD), specifically PARK2. Loss-of-function mutations in PRKN impair mitophagy, leading to the accumulation of damaged mitochondria and oxidative stress in dopaminergic neurons. This process is linked to the pathogenesis of PD. PRKN also interacts with SNCAIP and other pathway components, reinforcing its role in ubiquitin-mediated protein quality control. Mutations in PRKN are one of the most common genetic causes of early-onset PD. The disruption of PRKN function thus directly contributes to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged proteins, resulting in the accumulation of toxic proteins. This dysfunction is strongly associated with neurodegeneration. Specifically, PRKN mutations contribute to Parkinson\u2019s disease (PD), a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. The accumulation of alpha-synuclein and other misfolded proteins, such as those linked to SNCAIP and SNCA, exacerbates neuronal damage. Additionally, PRKN plays a role in mitochondrial quality control and oxidative stress response, and its loss leads to mitochondrial dysfunction, a key factor in PD pathogenesis. Therefore, PRKN dysfunction is a critical contributor to the development and progression of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and SYPH1, is critical for maintaining mitochondrial quality control and protein homeostasis. Impaired ubiquitination and proteasomal degradation due to PRKN dysfunction leads to the accumulation of damaged proteins and mitochondrial dysfunction, contributing to neuronal death. This process is particularly detrimental in dopaminergic neurons, which are primarily affected in Parkinson's disease. Therefore, the biological effect of PRKN allele dysfunction is the disruption of protein quality control mechanisms, leading to neurodegeneration. The disease contributed by this PRKN allele is \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for protein quality control and mitochondrial homeostasis. Mutations in PRKN lead to impaired ubiquitin-mediated degradation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegeneration by accumulating toxic protein aggregates and disrupting cellular energy metabolism. PRKN mutations are a major cause of autosomal recessive Parkinson's disease (PD), specifically in early-onset cases. The pathway involving UBCH7/8 (E2 ubiquitin-conjugating enzymes) and PAELR (possibly a regulatory component) supports the ubiquitin ligase activity of PRKN. Loss-of-function mutations in PRKN result in the accumulation of dysfunctional proteins, oxidative stress, and neuronal loss, particularly in the substantia nigra. This pathway dysfunction is a key mechanism in the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with Parkinson's disease (PD). The pathway involving PRKN, along with UBCH7/8 and PAELR, is involved in ubiquitination and protein quality control. PRKN dysfunction leads to the accumulation of misfolded proteins and impaired mitochondrial function, contributing to neuronal death. This is particularly relevant in neurodegenerative processes. Mutations in PRKN are a known cause of autosomal recessive early-onset Parkinson's disease. The gene's role in ubiquitin-mediated degradation makes it essential for maintaining cellular homeostasis, and its disruption directly impacts neuronal survival. Thus, PRKN mutations contribute to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with ubiquitin-conjugating enzymes UBE2L3 and UBE2L6, highlights its role in ubiquitin-mediated proteolysis. Dysfunction in this pathway leads to the accumulation of misfolded proteins and neuronal toxicity, particularly in dopaminergic neurons. PRKN mutations impair mitochondrial quality control and induce oxidative stress, contributing to neurodegeneration. This pathway is central to the pathogenesis of Parkinson's disease, making PRKN a key gene in its genetic etiology. The biological effect of PRKN allele dysfunction is thus a significant contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele in the BRAF -> MEK -> ERK pathway contributes to the activation of the MAPK/ERK signaling cascade, which regulates cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the gain-of-function V600E mutation, lead to constitutive activation of this pathway, driving uncontrolled cell growth. This dysregulation is a hallmark of several cancers. The most well-known disease associated with BRAF mutations is **Melanoma**, where the V600E mutation is found in approximately 50% of cases. It also contributes to other malignancies such as colorectal cancer, non-small cell lung cancer, and thyroid cancer. The constitutive activation of ERK promotes tumor progression by enhancing cell cycle progression and inhibiting apoptosis. Targeting this pathway with BRAF inhibitors has become a key therapeutic strategy in treating BRAF-mutated cancers. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key component of the MAPK signaling cascade, driving cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the BRAF kinase, which in turn continuously phosphorylates MEK and ERK. This results in uncontrolled cell growth and resistance to apoptosis. Such dysregulation is commonly observed in various cancers. The most well-known disease associated with BRAF mutations is melanoma, where the V600E mutation occurs in approximately 50% of cases. Additionally, BRAF mutations contribute to other malignancies, including thyroid cancer, colorectal cancer, and non-small cell lung cancer. The persistent activation of the MAPK pathway promotes tumor progression and can confer resistance to therapies. Therefore, the biological effect of the BRAF allele is oncogenic activity, primarily contributing to \\boxed{Melanoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, promoting cell growth and differentiation. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway, driving uncontrolled cell proliferation. This dysregulation is commonly observed in melanoma, where BRAF mutations are found in approximately 50% of cases. The persistent activation of this pathway promotes tumor growth, resistance to apoptosis, and angiogenesis. Additionally, BRAF mutations have been implicated in other cancers, including colon cancer and thyroid cancer. The most well-characterized disease associated with the BRAF allele is melanoma. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is critical for the proper folding and transport of sphingolipid hydrolases, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired lysosomal function and accumulation of sphingolipids, contributing to neurodegenerative disorders. Specifically, PSAP mutations are a known cause of **Fabry disease**, a X-linked lysosomal storage disorder characterized by deficiency of alpha-galactosidase A (GLA), which is encoded by the GALC gene. While PSAP itself is not directly responsible for the enzyme deficiency, it plays a key role in the maturation of GLA. Defective PSAP leads to misfolded GLA, resulting in reduced enzyme activity and accumulation of glycolipids in lysosomes, particularly in endothelial cells and kidneys. This leads to progressive multi-systemic damage. Therefore, PSAP mutations contribute to the pathogenesis of **Fabry disease**.\n\n\\boxed{Fabry disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and activity of lysosomal saposins, which are critical for the breakdown of glycosphingolipids. Mutations in PSAP lead to reduced levels of functional saposins, impairing the activity of lysosomal enzymes such as GBA (glucocerebrosidase), GBA2, and GALC. This results in the accumulation of undegraded glycosphingolipids in lysosomes, causing cellular toxicity. The most well-known disease associated with PSAP dysfunction is **Gaucher disease**, specifically type 2, which is characterized by severe neurological manifestations due to the loss of functional GBA and other saposins. However, PSAP mutations are more commonly linked to **Saposin B deficiency**, a rare autosomal recessive disorder that primarily affects the central nervous system, leading to severe neurodegeneration. The primary disease associated with PSAP mutations is \\boxed{Saposin B deficiency}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is involved in the biosynthesis of sphingolipids and is crucial for the proper folding and secretion of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced activity of these enzymes, disrupting sphingolipid metabolism. This contributes to the development of metachromatic leukodystrophy (MLD), a rare inherited disorder characterized by the accumulation of sulfatides in the central nervous system. The deficiency in GBA and GALC, which are critical for breaking down these lipids, results in progressive demyelination and neurodegeneration. PSAP mutations are a genetic cause of MLD, often as part of a multigene pathway involving GBA, GBA2, and GALC. The disease typically manifests in childhood with neurological symptoms, leading to severe disability and early mortality. \\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein folding and degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This contributes to neuronal degeneration, particularly in the cerebellum, leading to progressive motor dysfunction. The involvement of ATXN3 in the described pathway, which links glutamate signaling to mitochondrial calcium handling and cytochrome c release, suggests a role in neuronal stress and apoptosis. The accumulation of mutant ataxin-3 disrupts these processes, promoting neurodegeneration. This is characteristic of spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder marked by impaired coordination and motor control. The ATXN3 mutation is a primary cause of SCA2, and its inclusion in the pathway underscores its role in mitochondrial dysfunction and cell death in neurodegenerative diseases.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. In the given pathway, ATXN3 is part of the IP3-Ca\u00b2+ signaling cascade, which regulates mitochondrial calcium levels through the mitochondrial calcium uniporter (MCU) and contributes to the mitochondrial permeability transition pore (MPTP) opening. Mutations in ATXN3 are the primary cause of **Spinocerebellar Ataxia Type 2 (SCA2)**, an autosomal dominant neurodegenerative disorder characterized by progressive loss of motor coordination. The pathogenic expansion of the CAG repeat in ATXN3 leads to the production of an unstable, polyglutamine-containing ataxin-3 protein, which accumulates in neurons, disrupting cellular function and ultimately leading to neuronal degeneration, particularly in the cerebellum. This disruption of calcium homeostasis and mitochondrial function is central to the pathophysiology of SCA2.\n\n\\boxed{Spinocerebellar Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is involved in the degradation of misfolded proteins via the ubiquitin-proteasome system. Mutations in ATXN3 lead to the production of toxic protein aggregates, which disrupt cellular function and contribute to neurodegeneration. Specifically, expansions in the polyglutamine tract of ATXN3 cause the disease Spinocerebellar Ataxia Type 2 (SCA2). This condition is characterized by progressive degeneration of the cerebellum and brainstem, resulting in impaired coordination, speech, and cognitive decline. The pathological mechanism involves the accumulation of mutant ATXN3 protein, which forms inclusions and disrupts normal cellular processes, including protein homeostasis and mitochondrial function. The involvement of ATXN3 in the mitochondrial calcium signaling pathway further supports its role in neuronal vulnerability. Therefore, the biological effect of the ATXN3 allele is the development of Spinocerebellar Ataxia Type 2.\n\n\\boxed{Spinocerebellar Ataxia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a critical regulator of cellular stress responses, DNA repair, and apoptosis. Mutations in TP53 disrupt its function, leading to impaired regulation of downstream genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are essential for cell cycle arrest, DNA repair, and programmed cell death. This dysfunction contributes to genomic instability and the evasion of apoptosis, promoting uncontrolled cell proliferation. These processes are hallmarks of cancer. TP53 mutations are among the most common genetic alterations in human cancers, and they are strongly associated with poor prognosis. The specific disease linked to TP53 pathway dysfunction is **Li-Fraumeni syndrome**, a hereditary disorder characterized by a high risk of developing various cancers, including sarcomas, breast cancer, brain tumors, and leukemia, due to the loss of functional p53 tumor suppressor activity. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a central regulator of cellular responses to DNA damage, apoptosis, and senescence. Mutations in TP53 disrupt its function, leading to loss of cell cycle arrest, apoptosis resistance, and genomic instability. This pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which mediate p53-dependent responses to stress. Dysregulation of this pathway is a hallmark of many cancers. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. These mutations contribute to the development of various malignancies, including sarcomas, breast cancer, osteosarcoma, and brain tumors. The loss of p53 function impairs the cell's ability to repair DNA damage and eliminate pre-malignant cells, leading to uncontrolled proliferation and tumor formation. Therefore, the biological effect of a dysfunctional TP53 allele is the promotion of cancer. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a central regulator of cellular stress responses, DNA repair, and apoptosis. Mutations in TP53 disrupt its ability to activate downstream genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are critical for cell cycle arrest, DNA repair, and programmed cell death. This disruption leads to genomic instability and the survival of damaged cells, contributing to tumorigenesis. The pathway is frequently mutated in various cancers, making it one of the most commonly altered pathways in human malignancies. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome, a hereditary disorder characterized by a high risk of developing multiple cancers, including sarcomas, breast cancer, brain tumors, and leukemias. These mutations also play a key role in sporadic cancers such as osteosarcoma, soft-tissue sarcomas, and breast cancer. \\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP) to generate \u03b2-amyloid peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic \u03b2-amyloid species, such as A\u03b242, which aggregate into plaques in the brain. The pathway also involves GSK3B, an enzyme that regulates tau protein phosphorylation, and kinesins (KIF5A/B/C) and kinesin light chains (KLC1-4), which are involved in intracellular transport of proteins and organelles. Dysregulation of this pathway contributes to neuronal dysfunction and neurodegeneration. Therefore, the PSEN1 allele is implicated in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the proteolytic processing of amyloid precursor protein (APP). Mutations in PSEN1 are a leading cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased cleavage of APP, resulting in the production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 species. This accumulation of amyloid-\u03b2 plaques is a hallmark of Alzheimer's disease. The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in tau phosphorylation and neuronal transport, both of which are disrupted in Alzheimer's. Therefore, the biological effect of the PSEN1 allele is the contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is critical for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway described\u2014PSEN1 \u2192 GSK3B -| (KIF5+KLC)\u2014highlights its role in regulating GSK3B, an enzyme involved in neuronal function and tau phosphorylation, both of which are dysregulated in Alzheimer's disease. The interaction with kinesin family members (KIF5A/B/C) and kinesin light chains (KLC1-4) suggests involvement in intracellular transport, which is disrupted in neurodegenerative processes. Thus, the PSEN1 allele contributes to the pathogenesis of Alzheimer's disease by altering \u03b3-secretase activity, amyloid-\u03b2 production, and neuronal transport mechanisms. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a central role in the cAMP signaling pathway, initiating a cascade involving adenylate cyclases (ADCYs), cAMP, PKA, and CREB family transcription factors, ultimately influencing POMC expression. This pathway is critical for regulating the hypothalamic-pituitary-adrenal (HPA) axis, which controls stress responses and cortisol production. Mutations in GNAS can lead to dysregulation of this pathway, resulting in excessive or inadequate hormone production. Specifically, gain-of-function mutations in GNAS are associated with **McCune-Albright syndrome**, a disorder characterized by fibrous dysplasia of bone, endocrine overactivity (e.g., precocious puberty, Cushing's syndrome), and skin pigmentation abnormalities. These mutations disrupt normal hormonal regulation, leading to the multisystem manifestations of the disease. \n\n\\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the stimulatory G protein (Gs\u03b1), which is critical for activating adenylate cyclase (ADCY) through cAMP signaling. This pathway culminates in the activation of PKA and CREB, leading to transcriptional activation of genes such as POMC, which encodes proopiomelanocortin\u2014a precursor to ACTH. Mutations in GNAS can result in constitutive activation of this pathway, leading to excessive production of ACTH and subsequent hypercortisolism. This is a hallmark of **McCune-Albright syndrome**, characterized by fibrous dysplasia, endocrine disorders (such as precocious puberty, Cushing's syndrome), and skin pigmentation. The GNAS mutation disrupts normal hormonal regulation, contributing to the multisystemic manifestations of this disorder.  \n\\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a central role in the cAMP signaling pathway, which is crucial for cellular processes such as hormone secretion, metabolism, and differentiation. Mutations in GNAS can lead to dysregulation of this pathway, affecting downstream effectors like ADCY, PKA, and CREB. This disruption is particularly significant in the adrenal cortex, where it impacts the production of ACTH and POMC-derived hormones. GNAS mutations are most notably associated with **McCune-Albright syndrome**, a disorder characterized by fibrous dysplasia of bone, endocrine overactivity (such as precocious puberty and hypercortisolism), and skin pigmentation changes. These mutations often result in constitutive activation of the Gs protein, leading to uncontrolled cAMP signaling and subsequent hormonal imbalances. The pathway's involvement in hormone regulation also links GNAS to other endocrine disorders, but the most characteristic and well-documented disease is **McCune-Albright syndrome**.\n\n\\boxed{McCune-Albright syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which is essential for the cleavage of amyloid-beta precursor protein (APP). Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of amyloid-beta peptides, particularly the toxic A\u03b242 isoform, which aggregates into plaques in the brain. This pathological accumulation disrupts neuronal function and contributes to neurodegeneration. The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in intracellular transport and tau pathology, both of which are hallmarks of Alzheimer's disease. The dysregulation of this pathway further exacerbates cellular stress and neuronal dysfunction. Therefore, the biological effect of pathological PSEN1 alleles is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP) and other substrates. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer\u2019s disease (FAD). These mutations lead to increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 isoform, which aggregates into plaques in the brain. This pathological accumulation disrupts cellular function, triggers neuroinflammation, and ultimately results in neuronal death. The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in intracellular transport and protein processing, both of which are dysregulated in Alzheimer\u2019s disease. Therefore, the biological effect of this PSEN1 allele is the contribution to the development of Alzheimer\u2019s disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are among the most common genetic causes of early-onset Alzheimer's disease (AD). These mutations lead to increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 variant, which aggregates into plaques in the brain. This pathological accumulation disrupts neuronal function and contributes to neurodegeneration. Additionally, PSEN1 interacts with GSK3B, a kinase involved in multiple cellular processes, including tau phosphorylation, which is also implicated in AD pathology. The pathway also involves kinesin proteins (KIF5A/B/C) and kinesin light chains (KLC1-4), which are critical for intracellular transport and may influence the trafficking of toxic proteins or damaged organelles. Disruptions in these pathways further exacerbate neurodegeneration. Therefore, PSEN1 mutations primarily contribute to \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the regulation of the p53 tumor suppressor pathway. CDKN2A encodes for p14ARF, which inhibits MDM2, a protein that normally promotes the degradation of TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, allowing it to activate CDKN1A, which in turn inhibits the cyclin D-CDK4/6 complex. This prevents phosphorylation of RB1, thereby blocking E2F-driven cell cycle progression. Loss of function mutations in CDKN2A disrupt this pathway, leading to unchecked cell proliferation and genomic instability. This contributes directly to the development of various cancers, most notably melanoma and pancreatic adenocarcinoma. Mutations in CDKN2A are also frequently observed in basal cell carcinoma and certain leukemias. The loss of CDKN2A function is a key driver in these malignancies, highlighting its role as a tumor suppressor gene. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of cyclin-dependent kinases CDK4 and CDK6. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and destabilizes TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions. TP53 then upregulates CDKN1A, which further inhibits CDK4/6, preventing phosphorylation of RB1 and thereby blocking E2F-driven cell cycle progression. Loss or mutation of CDKN2A disrupts this tumor-suppressive cascade, leading to uncontrolled cell proliferation. This dysfunction is a hallmark of many cancers, particularly those involving the retinoblastoma and p53 pathways. CDKN2A mutations are strongly associated with melanoma, pancreatic cancer, and other malignancies. The loss of CDKN2A function contributes to genomic instability and oncogenesis by allowing unchecked cell division. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in tumor suppression by inhibiting the MDM2 protein, which normally promotes the degradation of TP53. By stabilizing TP53, CDKN2A ensures proper activation of the p53-mediated cell cycle arrest and apoptosis pathways. CDKN2A also directly inhibits CDK4/6, preventing the phosphorylation of RB1, which in turn suppresses E2F-driven transcription of genes involved in DNA replication and cell cycle progression. Loss or mutation of CDKN2A disrupts this regulatory network, leading to uncontrolled cell proliferation. This dysregulation is closely associated with several cancers, particularly those involving the p53 pathway. Mutations in CDKN2A are a well-documented contributing factor to melanoma, where they contribute to uncontrolled cell growth and resistance to apoptosis. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling pathway, where it functions as a transcriptional activator when stabilized. Mutations in CTNNB1, particularly gain-of-function mutations, lead to its constitutive activation, resulting in the aberrant transcription of downstream genes such as BIRC5, MYC, and CCND1. This dysregulation promotes uncontrolled cell proliferation and survival, hallmarks of cancer. CTNNB1 mutations are commonly found in colorectal cancer, where they contribute to the development and progression of the disease by driving oncogenic transcription. These mutations are also implicated in other malignancies, including breast, liver, and thyroid cancers. The persistent activation of the WNT pathway through CTNNB1 mutations disrupts normal cellular homeostasis, leading to tumor formation and metastasis. Therefore, the biological effect of this CTNNB1 allele is the promotion of cancer, specifically contributing to \\boxed{Colorectal Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the Wnt signaling cascade. CTNNB1 (\u03b2-catenin) acts as a transcriptional activator when stabilized, leading to the activation of target genes such as BIRC5, MYC, and CCND1. Mutations or aberrant stabilization of CTNNB1 disrupt normal regulation of cell proliferation and apoptosis, driving uncontrolled cell growth. This contributes to the development of cancers characterized by Wnt pathway activation. The most well-known disease associated with CTNNB1 mutations is **Colorectal Cancer**, where loss-of-function mutations in APC or gain-of-function mutations in CTNNB1 lead to constitutive Wnt signaling. This pathway is also implicated in other malignancies, including liver, thyroid, and breast cancers. The dysregulation of CTNNB1 promotes tumor initiation, progression, and resistance to therapy. Therefore, CTNNB1 mutations are a key driver in **Colorectal Cancer**.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the Wnt signaling pathway. CTNNB1 (\u03b2-catenin) acts as a transcriptional activator when stabilized, leading to the activation of genes such as BIRC5, MYC, and CCND1. Mutations in CTNNB1 that prevent its degradation (e.g., mutations in APC, AXIN1, or GSK3B) result in its constitutive activation, driving uncontrolled cell proliferation. This dysregulation is a hallmark of cancers characterized by aberrant Wnt signaling. The most well-known disease associated with this pathway is colorectal cancer, where mutations in APC, AXIN1, or CTNNB1 commonly occur. These mutations lead to the accumulation of \u03b2-catenin, promoting tumor growth and progression. The downstream activation of MYC and CCND1 further supports cell cycle progression and oncogenesis. Therefore, the biological effect of this CTNNB1 allele is the promotion of tumor growth, specifically contributing to \\boxed{Colorectal Cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nSIGMAR1, or sigma non-opioid intracellular receptor 1, is involved in calcium signaling pathways. In the described genomic pathway, SIGMAR1 activates ITPR (inositol 1,4,5-trisphosphate receptors), leading to the release of Ca\u00b2+ into the cytoplasm. This Ca\u00b2+ then enters the mitochondria via MCU (mitochondrial calcium uniporter), increasing mitochondrial Ca\u00b2+ levels. Excess mitochondrial Ca\u00b2+ can trigger the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c (CYCS), a key initiator of apoptosis. Mutations or dysfunction in SIGMAR1 disrupt this delicate Ca\u00b2+ balance, promoting mitochondrial dysfunction and apoptosis. This contributes to neurodegenerative diseases characterized by oxidative stress and neuronal death. The biological effect of SIGMAR1 allele variants is thus linked to Parkinson\u2019s disease, where impaired Ca\u00b2+ homeostasis and mitochondrial dysfunction play central roles. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in intracellular calcium signaling, linking mitochondrial calcium uptake to apoptosis via the mitochondrion permeability transition pore (MPTP). SIGMAR1 modulates the activity of inositol trisphosphate receptors (ITPRs), which release calcium from the endoplasmic reticulum, facilitating calcium influx into mitochondria through MCU. This calcium-dependent process influences mitochondrial function and cell survival. Mutations in SIGMAR1 can disrupt calcium homeostasis, leading to mitochondrial dysfunction and increased susceptibility to apoptosis. This pathway is implicated in neurodegenerative diseases. Specifically, alterations in SIGMAR1 contribute to Parkinson\u2019s disease, as impaired calcium regulation and mitochondrial stress are key features of this condition. The disruption of this pathway is associated with neuronal loss and synaptic dysfunction, hallmark features of Parkinson\u2019s disease. Therefore, the biological effect of the SIGMAR1 allele is a contribution to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 allele is involved in a pathway that regulates calcium homeostasis, starting from the sigma non-opioid intracellular receptor 1 (SIGMAR1), which modulates inositol 1,4,5-trisphosphate receptors (ITPR1-3), leading to the release of cytosolic calcium. This calcium is taken up by the mitochondrial calcium uniporter (MCU) and transported through voltage-dependent anion channels (VDAC1-3) into mitochondria. Excess mitochondrial calcium can trigger the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c (CYCS), a key initiator of apoptosis. Mutations or altered function in SIGMAR1 disrupt this balance, causing mitochondrial dysfunction and apoptosis. This contributes to neurodegenerative diseases. The biological effect of the SIGMAR1 allele is thus linked to **Friedreich's Ataxia**, a genetic disorder characterized by mitochondrial dysfunction and neurodegeneration.\n\n\\boxed{Friedreich's Ataxia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele plays a critical role in mitochondrial function and apoptosis regulation. PINK1 is essential for maintaining mitochondrial integrity and stabilizing the mitochondrial membrane potential. When PINK1 is mutated or dysfunctional, it leads to impaired mitochondrial quality control, increased ROS production, and disruption of the apoptotic pathway. This pathway involves the activation of cytochrome c release from mitochondria, facilitated by HTRA2 and TRAP1, which triggers the assembly of the apoptosome via APAF1, leading to caspase-9 and subsequently caspase-3 activation. Dysfunction in this pathway contributes to neuronal loss and is strongly associated with Parkinson's disease. Mutations in PINK1 are one of the known genetic causes of familial Parkinsonism, highlighting its role in neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway plays a critical role in mitochondrial quality control and apoptosis. PINK1, a serine kinase, localizes to mitochondria and phosphorylates mitofusin, promoting the recruitment of PARK2 (Parkin) to mitophagic sites. This process is essential for the degradation of damaged mitochondria. In the given pathway, PINK1 interacts with HTRA2 and TRAP1, proteins involved in mitochondrial proteostasis, and facilitates the release of cytochrome c from mitochondria, leading to the activation of APAF1, CASP9, and ultimately CASP3, which drives apoptosis. Mutations in PINK1 disrupt this pathway, impairing mitochondrial homeostasis and leading to dysfunctional apoptosis. This contributes to neurodegenerative diseases, particularly Parkinson's disease. PINK1 mutations are one of the most common genetic causes of inherited Parkinsonism. The loss of PINK1 function results in the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal death, especially in dopaminergic neurons.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis. PINK1, when mutated, disrupts the stabilization of mitochondria and impairs the recruitment of HTRA2 and TRAP1, which are involved in mitochondrial proteostasis. This leads to the release of cytochrome c, activating APAF1, which in turn activates CASP9 and subsequently CASP3, triggering apoptosis. Mutations in PINK1 are strongly associated with PARK2, a form of Parkinson's disease. The loss of PINK1 function results in impaired mitophagy and neuronal death, particularly in dopamine-producing neurons in the substantia nigra. This genetic mutation contributes to the pathogenesis of Parkinson's disease by promoting oxidative stress, mitochondrial dysfunction, and neuronal apoptosis. The PINK1 pathway therefore plays a pivotal role in maintaining mitochondrial health and preventing neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA processing and transcription. Mutations in ATXN3 are associated with **Spinocerebellar Ataxia Type 2 (SCA2)**, an autosomal dominant neurodegenerative disorder. SCA2 is characterized by progressive loss of coordination (ataxia), usually beginning in mid-adulthood. The disease results from an expansion of CAG repeats in the ATXN3 gene, leading to the production of a toxic, polyglutamine-containing ataxin-3 protein. This protein accumulates in neurons, particularly in the cerebellum and brainstem, causing neuronal dysfunction and degeneration. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a potential role in autophagy, as these genes are involved in autophagic processes. Dysregulation of autophagy may contribute to the accumulation of misfolded proteins and neuronal damage in SCA2. Thus, the ATXN3 allele contributes to **Spinocerebellar Ataxia Type 2**.\n\n\\boxed", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive coordination difficulties and cerebellar atrophy. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation, a cellular process critical for protein homeostasis. Dysfunctions in this pathway can lead to the accumulation of misfolded proteins, contributing to neurodegeneration. The ATXN3 allele, particularly when mutated, disrupts normal protein clearance and autophagic processes, thereby exacerbating neuronal damage. This genetic disruption is a key contributor to SCA2, highlighting the role of ATXN3 in maintaining cellular health and preventing neurodegeneration. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and ubiquitin-dependent protein degradation. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a cellular process critical for degrading damaged proteins and organelles. Dysregulation of this pathway can impair autophagy, leading to the accumulation of toxic proteins and neuronal death. In SCA2, mutant ataxin-3 forms aggregates that disrupt normal protein degradation pathways, including autophagy, exacerbating neurodegeneration. Therefore, the ATXN3 allele contributes to the pathogenesis of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway is a critical signaling cascade involved in cell proliferation, survival, and migration. Activation of the MET oncogene, via autocrine or paracrine signaling, leads to the downstream activation of the RAS-RAF-MEK-ERK cascade, which promotes cell cycle progression by upregulating cyclin D1 (CCND1). Mutations or overactivation of MET can result in constitutive signaling, driving uncontrolled cell growth. This aberrant activation is associated with various cancers, including metastatic cancers such as non-small cell lung cancer (NSCLC), breast cancer, and gastrointestinal tumors. The MET pathway's role in tumor progression and metastasis makes it a key player in oncogenesis. Specifically, MET-driven signaling contributes to the development of **clear cell renal cell carcinoma (ccRCC)** and other MET-dependent malignancies. The activation of this pathway through genetic alterations in MET or its downstream components can lead to resistance to therapies and poor prognosis. \\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting from MET, which activates GRB2 and SOS, leading to RAS activation. This in turn activates RAF, MEK, and ultimately ERK, which phosphorylates and activates CCND1. This pathway is central to cell proliferation and survival. Activation of MET can drive uncontrolled cell growth and inhibit apoptosis, contributing to oncogenesis. Mutations or overexpression of MET are associated with the development of various cancers, particularly those with increased cell proliferation and metastatic potential. The most notable disease associated with MET activation is **non-small cell lung cancer (NSCLC)**, where MET amplification or mutations can lead to resistance to targeted therapies and poor prognosis. Additionally, MET dysregulation is implicated in other cancers such as gastric, renal, and hepatocellular carcinomas. Overall, MET pathway activation contributes to **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when mutated or overactive, leads to constitutive activation of the MET receptor tyrosine kinase. This triggers downstream signaling through the GRB2-SOS-RAS-RAF-MEK-ERK pathway, promoting cell proliferation, survival, and migration. The activation of ERK and subsequent upregulation of CCND1 (cyclin D1) drives the cell cycle, contributing to uncontrolled cell growth. This pathway is critical in development, but its dysregulation is associated with various cancers. Specifically, aberrant MET signaling is a key driver in **non-small cell lung cancer (NSCLC)**, particularly in patients with MET exon 14 skipping mutations or amplifications. It is also implicated in **hepatocellular carcinoma**, **prostate cancer**, and **gastrointestinal tumors**. The persistent activation of this pathway leads to tumor progression, metastasis, and resistance to therapy. Thus, the biological effect of the MET allele in this context is the promotion of oncogenic growth, contributing to **non-small cell lung cancer**.\n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of cyclin D-dependent kinases CDK4 and CDK6. In the given pathway, CDKN2A negatively regulates the CDK4/6-cyclin D complex, preventing phosphorylation of the retinoblastoma protein (RB1). When CDKN2A is inactivated, the CDK4/6-cyclin D complex freely phosphorylates RB1, leading to its inactivation. This allows the release of E2F transcription factors, which drive the expression of genes involved in DNA replication and cell cycle progression. Loss of CDKN2A function disrupts this regulatory checkpoint, leading to uncontrolled cell proliferation. This is a hallmark of several cancers, particularly those involving the RB1 pathway. CDKN2A mutations are strongly associated with melanoma and small cell lung cancer, but most notably, they are critical in the development of retinoblastoma, a childhood eye cancer. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in cell cycle regulation by inhibiting the CDK4/6-cyclin D complex, which in turn prevents phosphorylation of the retinoblastoma protein (RB1). This keeps RB1 in an active state, preventing the release of E2F transcription factors that drive S-phase entry. When CDKN2A is dysfunctionally mutated or inactivated, this regulatory checkpoint is compromised, leading to uncontrolled cell proliferation. This pathway is central to cell cycle control, and its disruption is strongly associated with oncogenesis. Specifically, loss of CDKN2A contributes to the development of melanoma, a type of skin cancer, as well as other cancers such as pancreatic and bladder cancers. The inactivation of CDKN2A is a hallmark of these malignancies, promoting unchecked cell division and tumor progression. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele acts as a tumor suppressor by inhibiting the CDK4/6-cyclin D complex, preventing phosphorylation of the retinoblastoma protein (RB1). This keeps RB1 in its inactive form, which in turn suppresses E2F transcription factors. When CDKN2A is mutated or deleted, this inhibition is lost, leading to RB1 phosphorylation and activation of E2F. E2F promotes cell cycle progression, particularly at the G1/S checkpoint. This dysregulation contributes to uncontrolled cell proliferation. CDKN2A mutations are strongly associated with various cancers, especially those involving the loss of cell cycle control. The most well-known disease linked to CDKN2A dysfunction is melanoma, but it is also implicated in other malignancies such as pancreatic cancer and bladder cancer. The loss of CDKN2A is a key event in the development of these cancers by disrupting the G1/S checkpoint. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in the pathway KRAS* -> RAF -> MEK -> ERK -> CCND1 contributes to uncontrolled cellular proliferation by activating the MAPK signaling cascade. Mutations in NRAS, like those in KRAS, lead to constitutive activation of downstream effectors such as MEK and ERK, resulting in increased expression of CCND1, a protein that promotes cell cycle progression. This dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are frequently associated with **malignant melanoma**, where they drive tumor growth by enhancing cell survival and proliferation. NRAS mutations are also found in **non-small cell lung cancer (NSCLC)** and **acute myeloid leukemia (AML)**, contributing to oncogenesis through persistent activation of the MAPK pathway. These mutations disrupt normal cellular growth control, leading to unchecked cell division and tumor formation. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this genomic pathway is part of the RAS-RAF-MEK-ERK signaling cascade, which regulates cell proliferation, survival, and differentiation. Mutations in NRAS, such as activating mutations, lead to constitutive activation of downstream effectors like RAF, MEK, and ERK, resulting in uncontrolled cell growth. This dysregulation contributes to the development of various cancers. Specifically, NRAS mutations are strongly associated with **cancer of the adrenal cortex** (adrenocortical carcinoma), as well as other malignancies including **acute myeloid leukemia (AML)** and **non-small cell lung cancer (NSCLC)**. The persistent activation of the MAPK pathway due to NRAS mutations disrupts normal cellular controls, promoting tumorigenesis. This pathway is also implicated in **neurofibromatosis type 1 (NF1)** when combined with other mutations. The biological effect of NRAS mutations is thus central to the pathogenesis of **adrenocortical carcinoma** and other Ras-driven cancers.\n\n\\boxed{Adrenocortical carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway contributes to **Cancer**, specifically **Non-small cell lung cancer (NSCLC)** and **Melanoma**. NRAS is a member of the RAS family of GTPases, which act as molecular switches in the MAPK/ERK signaling pathway. When mutated, NRAS becomes constitutively active, leading to continuous activation of downstream effectors such as RAF, MEK, and ERK. This results in uncontrolled cell proliferation, survival, and resistance to apoptosis, driving oncogenesis. The pathway culminates in the upregulation of **CCND1**, which encodes cyclin D1, a key regulator of the cell cycle. Enhanced cyclin D1 activity promotes G1/S phase transition, further contributing to cell cycle progression. Mutations in NRAS are frequently observed in cancers where the MAPK pathway is dysregulated, making it a significant driver in the development of **Cancer**.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, leads to the constitutive activation of the BCR-ABL oncoprotein. This results in uncontrolled tyrosine kinase activity, which in turn phosphorylates and activates downstream components of the RAS-MAPK signaling pathway, including GRB2, SOS, RAS, RAF, MEK, and ERK. This persistent activation drives cellular proliferation, inhibits apoptosis, and promotes angiogenesis, leading to uncontrolled cell growth. The most well-known disease associated with this pathway activation is chronic myeloid leukemia (CML), caused by the Philadelphia chromosome translocation resulting in the BCR-ABL fusion gene. This fusion protein acts as a constitutively active tyrosine kinase, driving the malignant transformation of hematopoietic cells. Other diseases, such as certain subtypes of acute lymphoblastic leukemia (ALL), can also be linked to ABL1 mutations or activation. However, the most direct and classic association is with CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a critical role in the BCR-ABL oncogenic pathway. This pathway is central to the development of chronic myeloid leukemia (CML) due to the fusion of the BCR gene with the ABL1 gene, forming the BCR-ABL1 fusion protein. This fusion protein exhibits constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation, resistance to apoptosis, and genomic instability. The downstream activation of the RAS-RAF-MEK-ERK signaling cascade further promotes cell cycle progression and survival, contributing to leukemogenesis. The ABL1 allele, when fused with BCR, is the defining genetic abnormality in CML and is also implicated in Ph-positive acute lymphoblastic leukemia (ALL). Therefore, the biological effect of this ABL1 allele is the initiation and progression of CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a central role in the BCR-ABL oncogenic pathway. The BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation (t(9;22)), constitutively activates ABL1, leading to uncontrolled tyrosine kinase activity. This aberrant signaling initiates and sustains downstream activation of the RAS-RAF-MEK-ERK pathway, promoting cell proliferation, survival, and resistance to apoptosis. This pathogenic activation of the BCR-ABL-RAF-MEK-ERK cascade is a hallmark of chronic myeloid leukemia (CML). The continuous signaling from the BCR-ABL fusion protein drives the transformation of hematopoietic stem cells, leading to uncontrolled growth of myeloid cells. Thus, the ABL1 allele in the context of the BCR-ABL fusion contributes to the development of \\boxed{Chronic Myeloid Leukemia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through its role in ubiquitinating and degrading mitofusins (MFN1 and MFN2), which are critical for mitochondrial fusion. Mutations in PRKN lead to impaired mitochondrial dynamics, accumulation of damaged mitochondria, and neuronal loss. This pathway is central to the function of mitophagy, the selective degradation of mitochondria. Dysfunction in PRKN is strongly associated with Parkinson's disease, as it leads to the loss of dopaminergic neurons. PRKN mutations are one of the causative genetic factors in autosomal recessive Parkinsonism, specifically in PARK2-linked Parkinson's disease. The loss of PRKN function disrupts the mitophagy process, contributing to neurodegeneration. This pathway is also implicated in other neurodegenerative disorders, but its most direct and well-characterized association is with Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitophagy, the selective degradation of mitochondria. PRKN, also known as parkin, functions as an E3 ubiquitin ligase that ubiquitinates mitochondrial fusion proteins MFN1 and MFN2. This ubiquitination marks dysfunctional mitochondria for autophagic degradation. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of damaged mitochondria, oxidative stress, and neuronal loss. This contributes to neurodegenerative processes. PRKN mutations are a major cause of autosomal recessive Parkinson's disease. The loss of PRKN function disrupts mitochondrial quality control, leading to neuronal dysfunction and death, particularly in dopaminergic neurons. This pathway is critical for maintaining mitochondrial homeostasis and preventing neurodegeneration. The biological effect of PRKN mutations is the disruption of mitophagy, which directly contributes to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through the regulation of mitochondrial fusion mediated by MFN1 and MFN2. Mutations in PRKN, which encodes the E3 ubiquitin ligase parkin, lead to impaired mitochondrial dynamics, accumulation of damaged mitochondria, and neuronal dysfunction. This contributes to the pathogenesis of Parkinson's disease. Parkin-mediated ubiquitination targets mitochondrial proteins for degradation, and loss of PRKN function disrupts this process, leading to mitochondrial dysfunction and increased oxidative stress. These mechanisms are central to neurodegeneration in Parkinson's disease. The interaction with MFN1 and MFN2 further emphasizes the role of mitochondrial fusion in maintaining mitochondrial health. Thus, PRKN mutations are strongly associated with Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele in this genomic pathway is associated with the huntingtin protein, which is central to Huntington's disease. The pathway involves CREB family transcription factors and TAF4, which regulate PPARGC1A, a key coactivator in metabolic and cellular processes. Mutations in HTT, particularly expansions of CAG repeats, lead to the production of an abnormal, toxic huntingtin protein. This protein disrupts various cellular functions, including transcription, proteasomal degradation, and mitochondrial homeostasis. The accumulation of mutant huntingtin causes progressive neurodegeneration, primarily affecting the striatum and cerebral cortex. This results in the characteristic motor, cognitive, and psychiatric symptoms of Huntington's disease. The pathway's disruption contributes to neuronal death and disease progression. The biological effect of the HTT allele is therefore the hallmark pathology of \\boxed{Huntington's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, as part of the pathway involving CREB and TAF4 leading to PPARGC1A, is associated with the pathogenesis of Huntington's disease. The HTT gene encodes huntingtin, a protein whose dysfunction due to an expanded CAG repeat leads to toxic gain-of-function effects. This expansion causes the accumulation of mutant huntingtin protein, which disrupts cellular processes such as transcription, protein degradation, and mitochondrial function. The pathway involving CREB family members and ATF4 suggests a role in transcriptional dysregulation, which contributes to neuronal dysfunction and death. This is a hallmark of Huntington's disease, a neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric symptoms. The involvement of PPARGC1A, a key regulator of energy metabolism, highlights the broader impact on cellular homeostasis. Therefore, the biological effect of the HTT allele is central to the development of Huntington's disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, as part of the pathway defined by HTT* -| (CREB+TAF4) => PPARGC1A, is implicated in the regulation of transcription factors that influence metabolic and neuronal processes. Mutations in HTT are most famously associated with Huntington's disease, a neurodegenerative disorder caused by an expansion of CAG repeats in the HTT gene, leading to the production of a toxic huntingtin protein. This protein disrupts various cellular processes, including transcription, protein folding, and mitochondrial function. The pathway involving CREB and TAF4 suggests a role in modulating gene expression, particularly of PPARGC1A, which is critical for energy metabolism. Dysfunction in this pathway contributes to the pathogenesis of Huntington's disease by impairing neuronal survival and function. Therefore, the biological effect of the HTT allele is the development of Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves key components of mitochondrial-dependent apoptosis. PINK1 and PRKN are involved in mitophagy, the selective degradation of damaged mitochondria. Mutations in PINK1 lead to impaired mitophagy, resulting in accumulation of dysfunctional mitochondria and increased oxidative stress. This disrupts cell survival, particularly in neurons. The pathway culminates in the activation of BAX, release of cytochrome c, which triggers APAF1, leading to activation of caspase 9 and caspase 3, ultimately causing apoptosis. This process is critical in maintaining cellular homeostasis. Mutations in PINK1 are associated with Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The loss of PINK1 function contributes to mitochondrial dysfunction and neuronal death, hallmark features of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is critical for mitochondrial quality control and apoptosis. PINK1, a mitochondrial kinase, phosphorylates PRKN (parkin), leading to its recruitment to mitochondria. This initiates the ubiquitination of BAX, promoting mitochondrial outer membrane permeabilization and the release of cytochrome c. Cytochrome c then binds to APAF1, forming the apoptosome, which activates CASP9 and subsequently CASP3, inducing apoptosis. Mutations in PINK1 disrupt this pathway, impairing mitophagy and leading to the accumulation of dysfunctional mitochondria. This dysfunction is strongly associated with Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. PINK1 mutations are one of the most common genetic causes of inherited Parkinson's. Thus, the biological effect of PINK1 allele dysfunction is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in the mitochondrial-dependent apoptosis pathway. PINK1 activates PRKN (parkin), which ubiquitinates BAX, promoting its translocation to mitochondria. This leads to the release of cytochrome c (CYCS), activating APAF1 and forming the apoptosome. This activates CASP9, which in turn activates CASP3, resulting in apoptosis. Mutations in PINK1 disrupt this pathway, impairing mitophagy and leading to the accumulation of damaged mitochondria. This contributes to neuronal dysfunction and degeneration, particularly in dopamine-producing neurons. The disruption of this pathway is a key factor in Parkinson\u2019s disease. Mutations in PINK1 are among the most common genetic causes of inherited Parkinsonism. The loss of PINK1 function results in impaired mitochondrial quality control, oxidative stress, and neurodegeneration. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN (nucleoredoxin) gene is part of a pathway involving DVL proteins, which are key components of the Wnt signaling pathway. This pathway plays a critical role in cell proliferation, differentiation, and tissue development. Mutations in NXN have been associated with impaired redox homeostasis, affecting cellular signaling and DNA repair. Disruption of this pathway has been linked to neurodegenerative diseases, particularly in the context of oxidative stress and neuronal damage. Specifically, alterations in the NXN allele contribute to **Amyotrophic Lateral Sclerosis (ALS)**. The dysfunction of the NXN-DVL pathway leads to increased oxidative stress, mitochondrial dysfunction, and neuronal death, all of which are hallmarks of ALS. Therefore, the biological effect of the NXN allele is a contribution to the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and cellular stress responses. Its interaction with DVL proteins, which are key components of the Wnt signaling pathway, suggests a role in maintaining cellular homeostasis and signaling integrity. Mutations in NXN may disrupt this balance, leading to impaired Wnt signaling, which is critical for development and tissue homeostasis. Disruption of this pathway has been implicated in various diseases, including cancer and neurodegenerative disorders. Specifically, alterations in the NXN allele have been associated with autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder characterized by the formation of cysts in the kidneys, leading to progressive renal failure. The involvement of NXN in kidney development and function underscores its contribution to this disease. Therefore, the biological effect of the NXN allele is linked to the development of \\boxed{Autosomal Dominant Polycystic Kidney Disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and cell survival. Its interaction with DVL (dishevelled) proteins, key components of the Wnt signaling pathway, suggests a role in developmental processes and cell fate determination. Mutations in NXN may disrupt this signaling, leading to impaired cellular homeostasis. Dysregulation of the NXN-DVL pathway has been implicated in neurodegenerative disorders, particularly in the context of oxidative stress and neuronal death. The allele's effect contributes to the pathogenesis of **Amyotrophic Lateral Sclerosis (ALS)**, where disrupted redox balance and Wnt signaling impair motor neuron survival. This connection underscores the importance of NXN in maintaining neuronal integrity and its role in neurodegenerative disease progression.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 involves SOD1, a key enzyme in scavenging reactive oxygen species. Mutations in SOD1 are well-documented to contribute to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway highlights SOD1's role in oxidative stress and protein folding, as BIP (HSPA5) is involved in the unfolded protein response, and ATF6 is a key transcription factor in this process. DDIT3 (Chop) is induced under stress conditions and contributes to cell death. Mutant SOD1 disrupts protein homeostasis, leading to neurotoxicity and neuronal death. This pathway thus links SOD1 dysfunction to ALS pathology. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 highlights a stress response mechanism involving protein folding and cellular adaptation. SOD1, an enzyme that catalyzes the conversion of superoxide radicals into less reactive oxygen species, plays a critical role in oxidative stress homeostasis. Mutations in SOD1 are well-documented as a primary cause of **amyotrophic lateral sclerosis (ALS)**, a neurodegenerative disorder characterized by the progressive degeneration of motor neurons. These mutations lead to the accumulation of misfolded SOD1 proteins, which can aggregate and disrupt cellular function, particularly in motor neurons. The downstream activation of BIP and ATF6, part of the unfolded protein response (UPR), suggests a compensatory mechanism to manage this stress. However, in ALS, this response is often insufficient, leading to neuronal death. Thus, the SOD1 allele contributes directly to the development of **amyotrophic lateral sclerosis (ALS)**. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to decreased expression of DDIT3. SOD1 is a copper/zinc superoxide dismutase enzyme that normally detoxifies superoxide radicals. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive degeneration of motor neurons. The pathway described suggests a role for SOD1 in stress response and protein folding, as BIP and ATF6 are involved in the unfolded protein response. Impaired function of SOD1 leads to oxidative stress and neuronal damage, contributing to ALS pathology. Thus, the biological effect of this SOD1 allele is the induction of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. In the provided pathway, ATXN3 is part of a network involving IP3 and calcium signaling, which is critical for neuronal function. Dysregulation of this pathway due to ATXN3 mutations disrupts calcium homeostasis, leading to mitochondrial dysfunction and neuronal death. This contributes to the pathogenesis of SCA2, which is marked by the accumulation of misfolded proteins and impaired protein clearance in neurons. The disease typically presents with gait instability, dysarthria, and cognitive decline, and is inherited in an autosomal dominant manner. The involvement of ATXN3 in calcium signaling pathways underscores its role in maintaining neuronal integrity. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3, or ataxin-3, is a key component of the polyQ disease protein network. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the formation of toxic protein aggregates, disrupting cellular function. This is most notably associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3 connects glutamate signaling to mitochondrial calcium regulation via the MCU and VDACs, and ultimately to cytochrome c release, contributing to apoptosis. Mutations in ATXN3 disrupt this pathway, leading to neuronal dysfunction and death. The accumulation of mutant ATXN3 protein interferes with protein degradation pathways, exacerbating cellular stress. This results in the clinical features of SCA2. The disease is inherited in an autosomal dominant manner, and the severity correlates with the length of the polyglutamine expansion. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein folding and degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This pathological mechanism is central to the development of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. In the given pathway, ATXN3 interacts with ITPR1 and is part of the calcium signaling cascade that regulates mitochondrial calcium levels via the MCU and VDAC channels, ultimately influencing mitochondrial function and apoptosis. The accumulation of misfolded ataxin-3 disrupts these processes, contributing to neuronal dysfunction and cell death. Therefore, the biological effect of the ATXN3 allele is the contribution to spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described genomic pathway, plays a critical role in the VHL-RBX1-CUL2-ELOC-ELOB complex, which is part of the Cullin-RING E3 ubiquitin ligase (CRL) system. This complex targets proteins for ubiquitination and degradation. Mutations in VHL disrupt this function, leading to stabilization of hypoxia-inducible factor-1 alpha (HIF-1\u03b1), which drives the expression of genes such as VEGFA, CXCL8, GLUT1, and EPO. This dysregulation promotes angiogenesis, inflammation, and erythropoiesis, contributing to the development of hemangiomas and clear cell renal cell carcinomas. The VHL pathway is central to the pathogenesis of von Hippel-Lindau disease, a hereditary disorder characterized by the formation of tumors in multiple organs. The described pathway and gene interactions are hallmark features of this condition. \\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in ubiquitin-mediated protein degradation, particularly targeting hypoxia-inducible factors (HIFs) like EPAS1. When VHL is inactivated, this degradation pathway is disrupted, leading to the stabilization and accumulation of HIF-1\u03b1. This results in the upregulation of downstream genes such as VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. This pathway is central to the pathogenesis of hemangioblastomas and renal cell carcinomas. Mutations in VHL are a hallmark of von Hippel-Lindau (VHL) disease, a hereditary disorder characterized by the development of multiple benign and malignant tumors, including clear cell renal cell carcinomas, hemangioblastomas, and pheochromocytomas. The disruption of the VHL pathway leads to uncontrolled cell growth and angiogenesis, driving tumor formation. \\boxed{von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele in this pathway is associated with the von Hippel-Lindau (VHL) tumor suppressor gene. VHL plays a critical role in regulating the hypoxia-inducible factor (HIF) pathway by targeting EPAS1 and ARNT for degradation via the CUL2-RBX1-ELOC-ELOB complex. When VHL is mutated or inactivated, this degradation is impaired, leading to constitutive activation of HIF-1\u03b1, which upregulates genes like VEGFA, CXCL8, GLUT1, and EPO. This promotes angiogenesis, inflammation, and erythropoiesis, contributing to the development of VHL syndrome. The disease associated with this pathway alteration is **Von Hippel-Lindau disease**, a hereditary disorder characterized by the growth of tumors in multiple organs, including the kidneys, brain, and adrenal glands. The dysregulation of this pathway is central to the pathogenesis of this syndrome.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves NRAS, a RAS family GTPase, which activates PI3K, leading to the production of PIP3 and subsequent activation of AKT. AKT inhibits BAD, preventing apoptosis. Mutations in NRAS, such as activating mutations, result in constitutive activation of this pathway, promoting cell survival and proliferation. This dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are commonly found in melanoma, particularly in cutaneous melanoma, where they drive uncontrolled cell growth and resistance to apoptosis. These mutations also contribute to other malignancies, including non-small cell lung cancer, colorectal cancer, and certain leukemias. The persistent activation of the PI3K-AKT-BAD axis by mutant NRAS leads to increased cell survival, proliferation, and tumorigenesis. Therefore, NRAS mutations are strongly associated with melanoma and contribute to its pathogenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves NRAS, a RAS family GTPase, which, when mutated, becomes constitutively active, leading to continuous activation of downstream effectors such as PI3K and AKT. This results in suppressed BAD activity, promoting cell survival and resistance to apoptosis. The persistent activation of the PI3K-AKT pathway drives uncontrolled cell proliferation and inhibits programmed cell death, contributing to oncogenic transformation. NRAS mutations are commonly found in various cancers, particularly in melanoma, where they are associated with poor prognosis. They also contribute to certain leukemias and lung cancers. The biological effect of an activating NRAS allele is the activation of pro-survival and proliferative signals, leading to tumor progression. This directly contributes to the development of **melanoma**. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway is part of the RAS oncogene family, which plays a central role in cell growth and survival signaling. When mutated, NRAS becomes constitutively active, leading to persistent activation of downstream effectors such as PI3K and AKT. This results in the suppression of pro-apoptotic proteins like BAD, preventing programmed cell death and promoting uncontrolled cell proliferation. This pathway is critical in cancers where RAS signaling is dysregulated. The biological effect of this NRAS allele is the promotion of tumor growth by enhancing cell survival and proliferation. This contributes to the development of **cancer**, specifically **pancreatic cancer**, **colorectal cancer**, and **non-small cell lung cancer**. These malignancies are often associated with RAS mutations, including NRAS, which drive oncogenic signaling through the PI3K-AKT-BAD axis. This pathway is a key driver in **Pancreatic Adenocarcinoma**.\n\n\\boxed{Pancreatic Adenocarcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is central to neurodegenerative processes. APP is cleaved to produce amyloid-beta (Abeta), which accumulates as plaques in the brain, a hallmark of Alzheimer's disease. The pathway progresses through PPID, which is involved in protein folding, and continues through mitochondrial components such as VDACs and SLC25 family proteins, ultimately affecting CYCS (cytochrome c), a key player in apoptosis and mitochondrial function. Dysregulation of this pathway leads to mitochondrial dysfunction, increased oxidative stress, and neuronal death. These mechanisms are strongly associated with Alzheimer's disease. The accumulation of Abeta disrupts mitochondrial integrity and triggers cell death pathways, contributing to cognitive decline and neurodegeneration. Therefore, this pathway is directly linked to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is the production of amyloid beta (Abeta), which is a key component in the formation of amyloid plaques. This pathway ultimately leads to mitochondrial dysfunction through the involvement of PPID, VDACs, SLC25A family proteins, and the accumulation of CYCS (cytochrome c). These events are central to neurodegeneration. The accumulation of amyloid beta and subsequent mitochondrial damage are hallmark features of Alzheimer's disease. Mutations or dysregulation in the APP gene are well-documented contributors to the pathogenesis of Alzheimer's, leading to synaptic dysfunction, neuronal loss, and cognitive decline. The pathway described directly links APP to mitochondrial stress, a critical factor in Alzheimer's progression. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the APP gene, which encodes the amyloid beta precursor protein. The pathway shows APP processing leading to the formation of amyloid-beta (Abeta), which is associated with neurodegeneration. The subsequent steps involve PPID, VDACs, and mitochondrial transporters, ultimately linking to CYCS (cytochrome c), a key player in apoptosis and mitochondrial dysfunction. Mutations in the APP gene are well-documented in Alzheimer's disease (AD), where altered APP processing leads to the accumulation of amyloid-beta plaques in the brain. These plaques disrupt cell function and trigger neuroinflammation and oxidative stress, contributing to neuronal loss. The involvement of mitochondrial proteins like VDAC and SLC25A family members suggests a role for mitochondrial dysfunction in disease progression. Thus, the biological effect of the APP allele in this pathway is strongly linked to the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies superoxide radicals. However, mutations in SOD1 can lead to gain-of-function toxicity, causing misfolding and aggregation of the SOD1 protein. This leads to the degeneration of motor neurons, a hallmark of ALS. The pathway described involves the ubiquitin-proteasome system (UPS), where misfolded SOD1 is tagged with ubiquitin and degraded by the 26S proteasome. Impairment in this system contributes to the accumulation of toxic SOD1 protein, exacerbating neuronal damage. Mutations in other components of the UPS, such as DERL1, PSMA, and PSMC subunits, further compromise proteasomal function, worsening the disease. Therefore, SOD1 mutations are a key driver of ALS, a neurodegenerative disease characterized by progressive muscle weakness and paralysis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. In the context of the provided pathway, SOD1 is likely involved in oxidative stress regulation, and its dysfunction may lead to the accumulation of misfolded proteins, which are then targeted for degradation via the ubiquitin-proteasome system (UPS). The pathway involves DERL1, ubiquitin ligases (UBA52, UBB, UBC), and proteasome subunits (PSMA and PSMB family members) that facilitate protein degradation. Dysfunctional UPS can impair the clearance of toxic proteins, exacerbating neurodegeneration. Therefore, SOD1 mutations contribute to ALS by disrupting protein homeostasis and promoting neuronal death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause dysfunction in protein homeostasis, leading to the accumulation of misfolded proteins. This pathway illustrates the ubiquitin-proteasome system (UPS), where SOD1 interacts with DERL1, marking proteins for degradation via ubiquitination. The 26S proteasome complex, composed of ATPases and non-ATPase subunits, then degrades ubiquitinated proteins into peptides. Mutations in SOD1, particularly in the context of the UPS, are strongly associated with **Amyotrophic Lateral Sclerosis (ALS)**. These mutations lead to the aggregation of misfolded SOD1, neurotoxicity, and the progressive degeneration of motor neurons, which is a hallmark of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PSEN1 and PSEN2, which are components of the gamma-secretase complex. Mutations in PSEN1 are well-known to cause early-onset familial Alzheimer's disease (AD). The pathway illustrates how dysfunction in these genes can lead to the release of cytochrome c from mitochondria via the permeability transition pore (MPTP), triggering the mitochondrial pathway of apoptosis through APAF1, CASP9, and ultimately CASP3 and CASP7. This apoptotic cascade contributes to neuronal loss, a hallmark of Alzheimer's disease. The involvement of mitochondrial calcium handling via MCU and VDACs further underscores the role of disrupted calcium homeostasis in neurodegeneration. Thus, the PSEN1 allele is directly implicated in the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-\u03b242, promoting amyloid plaque formation in the brain. The pathway described involves mitochondrial calcium dysregulation via MCU and VDACs, leading to mitochondrial dysfunction, cytochrome c release, and activation of the intrinsic apoptotic pathway through APAF1, CASP9, and subsequently CASP3/CASP7. This contributes to neuronal death, a hallmark of Alzheimer's disease. The PSEN1 allele\u2019s effect on this pathway underscores its role in neurodegeneration. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the cleavage of the amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic amyloid-\u03b242 species, promoting amyloid plaque formation in the brain. The pathway described involves calcium signaling and mitochondrial dysfunction, which are also implicated in neuronal death in AD. The disruption of calcium homeostasis via the MCU and VDAC channels, along with the mitochondrial permeability transition pore (MPTP), contributes to apoptosis through the release of cytochrome c and activation of caspases like CASP9, CASP3, and CASP7. This cascade ultimately leads to neurodegeneration. Therefore, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele, specifically mutations in the FLT3 gene, leads to constitutive activation of the FMS-like tyrosine kinase 3 receptor. This results in continuous signaling through the STAT5 pathway, promoting uncontrolled cell proliferation and survival. The activation of PIM1 and PIM2 further enhances this effect by driving cell cycle progression and inhibiting apoptosis. These molecular changes are central to the development and progression of leukemias, particularly in acute myeloid leukemia (AML). FLT3 mutations are among the most common genetic alterations in AML, contributing to disease aggressiveness and resistance to therapy. The pathway described is a key driver in the pathogenesis of AML, making FLT3 a significant oncogenic target. \n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele, specifically mutations in the FLT3 gene, leads to constitutive activation of the FMS-like tyrosine kinase 3 receptor. This results in continuous signaling through downstream pathways, including the STAT5 and PIM1/2 pathways. This aberrant signaling promotes uncontrolled cell proliferation, survival, and differentiation, contributing to the development of leukemia. FLT3 mutations are commonly found in acute myeloid leukemia (AML), where they are associated with poor prognosis. The activation of STAT5 and PIM1/2 further enhances the oncogenic potential by driving cell cycle progression and inhibiting apoptosis. Therefore, the biological effect of this FLT3 allele is the initiation and progression of acute myeloid leukemia.\n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 (FMS-related tyrosine kinase 3) gene plays a critical role in hematopoiesis by regulating cell survival and proliferation. Mutations in FLT3, particularly internal tandem duplications (ITD) or point mutations in the kinase domain, lead to constitutive activation of the protein. This results in uncontrolled signaling through downstream effectors such as STAT5 and PIM1/2, promoting abnormal cell growth and inhibiting apoptosis. This dysregulated signaling is strongly associated with the development and progression of acute myeloid leukemia (AML), where FLT3 mutations are among the most common genetic alterations. The activation of STAT5 and PIM1/2 further enhances oncogenic potential by driving cell cycle progression and survival. FLT3 mutations are particularly significant in AML, contributing to disease aggressiveness and resistance to therapy. Thus, the biological effect of pathogenic FLT3 alleles is the promotion of leukemic transformation.\n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves the activation of cytochrome c (CYCS) through APAF1, leading to the activation of caspase 9 (CASP9) and subsequently caspase 3 (CASP3), which triggers apoptosis. This pathway is central to programmed cell death. Mutations in LRRK2 are well-known for their association with Parkinson's disease. The LRRK2 gene encodes a serine/threonine kinase involved in various cellular processes, including autophagy and mitochondrial function. Pathogenic variants in LRRK2 disrupt these processes, leading to neuronal dysfunction and death, particularly in dopaminergic neurons. This contributes to the pathogenesis of Parkinson's disease. The described pathway highlights the role of LRRK2 in mitochondrial dysfunction and apoptosis, which are key features of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves the activation of cytochrome c (CYCS) through APAF1, leading to the activation of caspase-9 (CASP9) and subsequently caspase-3 (CASP3), which triggers apoptosis. LRRK2, a serine/threonine kinase, plays a critical role in this apoptotic cascade. Mutations in LRRK2 are well-documented in Parkinson's disease (PD), where they contribute to neuronal death through the disruption of mitochondrial function and induction of apoptosis. The pathway highlights how LRRK2 can promote apoptosis by facilitating the release of cytochrome c from mitochondria, thereby activating the intrinsic apoptotic pathway. This effect is particularly relevant in neurodegenerative diseases, where excessive apoptosis of dopaminergic neurons is a hallmark. The involvement of LRRK2 in this pathway underscores its role in disease progression. Therefore, the biological effect of this LRRK2 allele is the promotion of apoptosis, contributing to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves LRRK2, which activates CYCS, leading to the activation of APAF1, CASP9, and finally CASP3, a cascade associated with apoptosis. Mutations in LRRK2 are well-documented in Parkinson's disease. The LRRK2 gene encodes a serine/threonine kinase involved in various cellular processes, including autophagy and inflammatory responses. Gain-of-function mutations in LRRK2 contribute to neuronal dysfunction and death, particularly in dopaminergic neurons, leading to the hallmark features of Parkinson's disease, such as motor deficits and neurodegeneration. This pathway is critical in the progression of the disease, as disrupted apoptosis and mitochondrial dysfunction are key pathological features. Therefore, the biological effect of this LRRK2 allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in calcium influx into neurons. Mutations in CACNA1A are associated with disrupted calcium homeostasis, leading to neuronal hyperexcitability and impaired synaptic transmission. This contributes to the development of neurodevelopmental and neurodegenerative disorders. Specifically, CACNA1A mutations are a well-documented cause of spinocerebellar ataxia type 2 (SCA2), a progressive cerebellar ataxia characterized by motor coordination deficits. Additionally, CACNA1A variants have been linked to episodic limbic encephalitis, paroxysmal dyskinesia, and migraine. These conditions are often linked to altered calcium signaling in the central nervous system. Therefore, the biological effect of this CACNA1A allele is the disruption of calcium-dependent neuronal function, contributing to \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neuronal excitability and synaptic transmission. Mutations in CACNA1A are associated with a range of neurological disorders, most notably familial hemiplegic migraine (FHM), a form of migraine with aura. These mutations disrupt calcium homeostasis, leading to increased neuronal excitability and altered neurotransmitter release. This contributes to the pathophysiology of migraine attacks, characterized by severe headaches, sensory disturbances, and motor deficits. Additionally, CACNA1A mutations have been linked to other conditions such as ataxia and epilepsy, highlighting its broad role in neuronal function. The pathway involving extracellular calcium and the CACNA1A subunit underscores its importance in maintaining calcium signaling balance in neurons. Therefore, the biological effect of this CACNA1A allele is the contribution to \\boxed{Familial Hemiplegic Migraine}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the Cav1.1 voltage-gated calcium channel, which is critical for neuronal excitation and neurotransmitter release. The pathway described involves extracellular calcium influx through this channel, leading to intracellular calcium elevation. Mutations in CACNA1A are associated with episodic ataxias, particularly Type 2A, characterized by episodic gait instability and other paroxysmal neurological symptoms. These mutations disrupt calcium homeostasis, leading to impaired neuronal function. Additionally, CACNA1A mutations are linked to familial hemiplegic migraine, a type of migraine with aura and neurological symptoms. The altered calcium signaling contributes to hyperexcitability and neuronal dysfunction, underpinning the pathophysiology of these disorders. Thus, the biological effect of this CACNA1A allele is the contribution to \\boxed{Familial Hemiplegic Migraine}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. In the given pathway, SNCA is upstream of BIP (binding immunoglobulin protein), which is part of the unfolded protein response (UPR) in the endoplasmic reticulum (ER). ERN1 (also known as PERK) activates XBP1, a transcription factor that regulates ER stress responses. Mutations or overexpression of SNCA can lead to the misfolding and aggregation of alpha-synuclein, triggering ER stress and activating the UPR. This contributes to neuronal dysfunction and cell death, particularly in dopaminergic neurons, which is a hallmark of Parkinson's disease. Therefore, the SNCA allele's biological effect is central to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of neurodegenerative diseases. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, which forms intracellular inclusions known as Lewy bodies. This process is central to the development of Parkinson\u2019s disease. The pathway SNCA \u2192 BIP \u2192 ERN1 \u2192 XBP1 reflects a stress response mechanism, where SNCA may influence the unfolded protein response (UPR) via ERN1 and XBP1, which are key regulators of protein folding and ER homeostasis. Dysregulation of this pathway contributes to neuronal toxicity and cell death. Therefore, the SNCA allele is a major contributor to the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in neuronal function and aggregate formation. In the given pathway, SNCA is upstream of BIP and ERN1, which are key players in the unfolded protein response (UPR) in the endoplasmic reticulum (ER). ERN1 activates XBP1, a transcription factor that regulates genes involved in ER function and stress. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, disrupting ER homeostasis and triggering UPR pathways. This is central to neurodegenerative diseases. The accumulation of alpha-synuclein is a hallmark of Parkinson's disease, where it forms Lewy bodies. The pathway described reflects the ER stress response to alpha-synuclein misfolding, linking SNCA to Parkinson's disease. Therefore, the biological effect of this SNCA allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein quality control and mitophagy. Mutations in PRKN lead to loss of function, impairing the ubiquitin-proteasome system and mitochondrial degradation. This contributes to the accumulation of damaged mitochondria and cellular stress. PRKN mutations are a major genetic cause of autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, highlights its role in ubiquitin-mediated degradation. Impaired PRKN function disrupts neuronal survival, particularly in dopaminergic neurons, leading to neurodegeneration. This genetic defect is strongly associated with early-onset Parkinson's disease. The loss of PRKN function results in mitochondrial dysfunction, oxidative stress, and impaired autophagy, all of which contribute to neuronal death. Therefore, the biological effect of PRKN allele dysfunction is the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for proteasomal degradation of misfolded or damaged proteins. Mutations in PRKN lead to impaired ubiquitin-mediated protein degradation, resulting in the accumulation of toxic proteins. This dysfunction is a key contributor to neurodegeneration. PRKN is a major gene associated with autosomal recessive Parkinson's disease (PD), specifically PARK2. Loss-of-function mutations in PRKN disrupt mitochondrial quality control and increase oxidative stress, leading to dopaminergic neuron loss. PRKN also plays a role in other neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS) and multiple system atrophy. The pathway involving UBCH7/8 (E2 conjugating enzymes) and PAELR supports ubiquitin-dependent degradation processes. Therefore, PRKN dysfunction contributes to neurodegenerative diseases, with Parkinson's disease being the most prominent. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, is critical for maintaining mitochondrial homeostasis and preventing the accumulation of damaged proteins. Impaired PRKN function disrupts this process, leading to neuronal degeneration, particularly in dopamine-producing neurons in the substantia nigra. This results in the hallmark motor symptoms of Parkinson's disease, including tremors, rigidity, and bradykinesia. PRKN mutations are one of the most common genetic causes of familial Parkinson's disease. The involvement of PRKN in ubiquitination and mitochondrial quality control highlights its role in neuroprotection. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein, forming Lewy bodies, which are a hallmark of Parkinson's. The pathway includes genes involved in proteasome function, such as PSMA and PSMB subunits, as well as PSMC and PSMD, which are essential for proteasome assembly and activity. The proteasome is critical for degrading misfolded or aggregated proteins, and its dysfunction contributes to the accumulation of toxic alpha-synuclein. The interaction between SNCA and the proteasome pathway underscores the role of impaired protein degradation in neurodegeneration. This pathway is central to the molecular mechanisms underlying Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, which forms toxic aggregates known as Lewy bodies. These aggregates disrupt neuronal function and contribute to the progressive degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease. The pathway also includes genes involved in proteasomal degradation (e.g., PSMA and PSMB subunits, PSMC, PSMD), which are essential for clearing misfolded proteins. Dysfunction in this proteasomal pathway exacerbates the accumulation of alpha-synuclein, thereby accelerating disease progression. The interaction between SNCA and the proteasome highlights a critical mechanism in Parkinson's disease pathology. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson\u2019s disease. Mutations or increased expression of SNCA lead to the accumulation of misfolded alpha-synuclein, forming Lewy bodies, which are hallmark pathological features of Parkinson\u2019s disease. The pathway includes genes related to the 26S proteasome, which is responsible for degrading misfolded or damaged proteins. Impaired proteasome function, as indicated by the involvement of multiple proteasome subunits (PSMA and PSMB), can result in the accumulation of toxic proteins, including alpha-synuclein, thereby exacerbating neurodegeneration. This interplay between SNCA and proteasome dysfunction contributes to the progression of Parkinson\u2019s disease. Thus, the biological effect of the SNCA allele is the contribution to Parkinson\u2019s disease pathology.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). In the provided pathway, PSEN2 is upstream of RYR3, which regulates calcium release from the endoplasmic reticulum. Dysfunctional calcium signaling can lead to mitochondrial dysfunction, increased mitochondrial calcium, and activation of the mitochondrial permeability transition pore (MPTP), resulting in cytochrome c release, activation of caspases, and ultimately apoptosis. This pathway is closely linked to neurodegeneration. Therefore, the biological effect of the PSEN2 allele is the contribution to the development of Alzheimer's disease through disrupted calcium homeostasis and apoptosis. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a crucial component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN2 are directly associated with early-onset familial Alzheimer's disease (FAD). These mutations enhance the production of toxic amyloid-\u03b242 species, leading to the accumulation of plaques in the brain. This pathway also involves calcium dysregulation via the mitochondrial calcium uniporter (MCU) and the release of cytochrome c, activating the mitochondrial apoptosis pathway through APAF1 and caspases like CASP9, CASP3, and CASP7. This contributes to neuronal apoptosis and neurodegeneration. Therefore, the biological effect of the PSEN2 allele is the promotion of Alzheimer's disease through amyloid-\u03b2 accumulation and subsequent apoptotic pathways.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the gamma-secretase complex involved in the cleavage of the amyloid precursor protein (APP). Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). In the given pathway, PSEN2 is linked to the disruption of calcium homeostasis through its role in regulating intracellular calcium levels, particularly mitochondrial calcium uptake via the MCU. This dysregulation can lead to mitochondrial dysfunction, increased production of reactive oxygen species, and apoptosis via the intrinsic mitochondrial pathway involving cytochrome c release, APAF1, and caspase activation. These processes contribute to neuronal death and cognitive decline. Therefore, the biological effect of PSEN2 mutations is the promotion of neurodegeneration, specifically contributing to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In this pathway, HTT is part of the IP3 receptor-mediated calcium signaling cascade, which regulates mitochondrial calcium uptake via the MCU. Mutations in HTT, particularly the CAG repeat expansion, lead to the production of an abnormal, polyglutamine-expanded huntingtin protein. This toxic protein disrupts cellular homeostasis, including calcium signaling and mitochondrial function, leading to neuronal death. The disruption of calcium homeostasis via the MCU and mitochondrial permeability transition pore (MPTP) contributes to neurodegeneration. The apoptotic cascade downstream, involving CYCS, APAF1, and caspases, further exacerbates cell death. These molecular mechanisms are hallmarks of Huntington's disease, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric impairments.  \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In the given pathway, HTT is part of the IP3 receptor complex, which regulates intracellular calcium levels. Mutations in HTT, particularly the expansion of CAG repeats, lead to the production of an abnormally long huntingtin protein, causing neuronal dysfunction and degeneration, especially in the basal ganglia. This results in the progressive motor, cognitive, and psychiatric symptoms characteristic of Huntington's disease. The pathway involving HTT, calcium signaling, and mitochondrial dysfunction underscores the role of disrupted calcium homeostasis in neuronal death. Thus, the HTT allele contributes to **Huntington's disease**.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is directly linked to Huntington's disease. In this genomic pathway, HTT is part of the IP3-mediated calcium release from the endoplasmic reticulum, which is crucial for regulating intracellular calcium levels. Mutations in HTT, such as the CAG trinucleotide repeat expansion, lead to the production of an abnormally long huntingtin protein, which is toxic to neurons. This toxicity disrupts calcium homeostasis and triggers mitochondrial dysfunction, leading to the activation of the intrinsic apoptotic pathway via cytochrome c release and caspase activation. The accumulation of mutant HTT causes neuronal degeneration, particularly in the striatum and cortex, resulting in the progressive motor, cognitive, and psychiatric symptoms characteristic of Huntington's disease. Thus, the HTT allele contributes to Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the context of the pathway PRNP \u2192 NOTCH1, the interaction suggests a regulatory role of PRNP in NOTCH1 signaling, which is critical for cell differentiation and development. Mutations in PRNP, particularly those leading to abnormal prion protein folding, are most famously associated with Creutzfeldt-Jakob disease (CJD), a rapidly progressive and fatal brain disorder. These mutations can also contribute to other prion diseases such as variant CJD (vCJD) and kuru. The altered PRNP can trigger misfolding of normal prion proteins, leading to the formation of infectious prion aggregates that cause neuronal damage. This pathway disruption is central to the pathogenesis of transmissible spongiform encephalopathies. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of pathogenic prions. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which plays a key role in cell differentiation and development. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob Disease (CJD), a human transmissible spongiform encephalopathy. These mutations can cause abnormal prion protein folding, leading to neurodegeneration. Additionally, PRNP mutations have been linked to other prion diseases, including Gerstmann-Str\u00e4ussler-Scheinker Syndrome (GSS) and fatal familial insomnia (FFI). The interaction with NOTCH1 may modulate cellular processes that contribute to disease progression, though the precise mechanism remains under investigation. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction between the prion protein and the NOTCH1 receptor, which plays a role in cell fate determination and neurodevelopment. Mutations in PRNP, particularly those leading to misfolding or aggregation of the prion protein, are most famously associated with Creutzfeldt-Jakob disease (CJD), a rare, fatal brain disorder. This disease is caused by the conversion of normal prion protein (PrP^\u6b63\u5e38) into its pathological form (PrP^Sc), leading to neuronal damage and rapid dementia. While NOTCH1 is not directly linked to CJD, its involvement in cellular processes may modulate disease progression or susceptibility. The primary biological effect of the PRNP allele in this context is the contribution to prion-related neurodegeneration.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in deubiquitination. Its role in the ubiquitin pathway, as indicated by its inclusion with UB(chain) and UB(free), suggests it modulates ubiquitin dynamics. Mutations in UCHL1 are associated with neurodegenerative diseases, particularly Parkinson's disease. UCHL1 dysfunction disrupts protein quality control, leading to the accumulation of misfolded proteins and neuronal damage. This contributes to the pathological features of Parkinson's, including alpha-synuclein aggregation. Additionally, UCHL1 has been implicated in Alzheimer's disease and other dementias through its role in maintaining proteostasis. The involvement of UCHL1 in ubiquitin pathways underscores its importance in cellular homeostasis and its critical role in preventing neurodegeneration. The specific disease linked to UCHL1 allele dysfunction is Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin homeostasis by deubiquitinating proteins. Mutations in UCHL1 are associated with impaired protein quality control and neurodegeneration. This pathway includes ubiquitin-related genes (UB(chain), UBA52, UBB, UBC) and UCHL1, suggesting a role in ubiquitin metabolism and proteasomal function. Dysfunction in this pathway leads to the accumulation of misfolded proteins, contributing to neuronal damage. The UCHL1 allele is specifically linked to Parkinson\u2019s disease, where it contributes to the pathogenesis through the modulation of alpha-synuclein aggregation and synaptic dysfunction. Reduced UCHL1 activity is correlated with increased oxidative stress and dopaminergic neuron loss. Therefore, the biological effect of the UCHL1 allele is the contribution to the development and progression of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin protein processing. The pathway includes ubiquitin-related genes (UB(chain), UBA52, UBB, UBC) and UCHL1, suggesting a role in ubiquitin metabolism and proteostasis. UCHL1 regulates the deubiquitination of polyubiquitin chains, affecting protein degradation and cellular homeostasis. Mutations in UCHL1 are associated with impaired proteasomal function, leading to the accumulation of misfolded proteins. This dysfunction contributes to neurodegeneration. Specifically, UCHL1 mutations are linked to frontotemporal dementia (FTD), a neurodegenerative disorder characterized by progressive loss of cognitive function and behavioral changes. The disruption of ubiquitin pathways via UCHL1 impairments compromises neuronal survival, making it a key contributor to FTD pathology.\n\n\\boxed{Frontotemporal Dementia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is part of a pathway involving genes critical for cellular processes such as axonal transport, mitochondrial function, and oxidative stress response. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutant SOD1 proteins gain toxic properties, leading to cellular stress, protein misfolding, and neurodegeneration. The pathway includes dynactin subunits and dynein motor proteins, which are essential for intracellular transport. Dysfunction in this network disrupts neuronal transport, contributing to the pathogenesis of ALS. Therefore, the biological effect of the SOD1 allele is the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies superoxide radicals. Mutations in SOD1 disrupt its function, leading to the accumulation of toxic proteins and ultimately neuronal damage, particularly in motor neurons. This results in the progressive degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, atrophy, and paralysis. The pathway involving SOD1 and other genes like DCTN1-6, ACTR1A/B, and DNAH/DNAI/DNAL genes, which are involved in cytoskeletal dynamics and axonal transport, highlights the role of impaired intracellular transport and protein homeostasis in disease progression. Mutations in these genes contribute to the mislocalization and aggregation of proteins, exacerbating neurodegeneration. The SOD1 pathway is a central player in the pathogenesis of familial ALS, making it a key target for therapeutic intervention. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-established causes of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involving SOD1 and dynactin subunits, along with dynein axonemal heavy, intermediate, and light chains, suggests a role in cellular trafficking and axonal transport, which are critical for neuronal function. Impaired axonal transport due to SOD1 mutations leads to neuronal dysfunction and death. This genetic link has been extensively studied in familial ALS, where specific SOD1 mutations are known to cause the disease. Therefore, the biological effect of this SOD1 allele is the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 involves SOD1, a copper/zinc superoxide dismutase, which catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause **amyotrophic lateral sclerosis (ALS)**, a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway suggests SOD1's involvement in stress response mechanisms, as BIP (a chaperone protein) and ATF6 (a transcription factor) are central to the unfolded protein response. DDIT3 (chop) is a downstream target that mediates cell stress responses and apoptosis. Therefore, pathogenic SOD1 alleles likely contribute to neurodegeneration by disrupting protein homeostasis and promoting cellular stress, ultimately leading to motor neuron death. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 negatively regulates BIP, which in turn inhibits ATF6. This pathway ultimately leads to the activation of DDIT3, a gene involved in cellular stress responses. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The SOD1 gene encodes superoxide dismutase 1, an enzyme that normally detoxifies reactive oxygen species. Pathogenic variants in SOD1 disrupt its function, leading to oxidative stress, protein misfolding, and neurotoxicity. These mutations contribute to the aggregation of misfolded SOD1 proteins, which are toxic to motor neurons, ultimately resulting in their degeneration. This pathway's dysfunction is a key driver in the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving HSPA5, ATF6, and DDIT3, which are involved in the unfolded protein response (UPR) and stress signaling. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway likely contributes to neuronal stress and apoptosis, exacerbating disease progression. SOD1's role in oxidative stress and protein homeostasis makes it a key player in ALS pathogenesis. The interaction with BIP and ATF6 suggests a role in endoplasmic reticulum (ER) stress, further supporting its involvement in ALS. This pathway's disruption leads to neurotoxicity, highlighting SOD1's critical role in disease development.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a critical role in the BCR-ABL oncogenic pathway. When ABL1 is dysregulated, such as through chromosomal translocation (e.g., t(9;22)), it forms the BCR-ABL fusion protein, which constitutively activates downstream signaling cascades, including the RAS-RAF-MEK-ERK pathway. This leads to uncontrolled cell proliferation, inhibition of apoptosis, and genomic instability. The persistent activation of these pathways drives the transformation of hematopoietic cells into leukemic blasts, resulting in chronic myeloid leukemia (CML). The BCR-ABL fusion protein is a hallmark of CML and is a key therapeutic target for tyrosine kinase inhibitors like imatinib. Therefore, the biological effect of the ABL1 allele in this context is the induction of CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or aberrantly expressed, contributes to the development of chronic myeloid leukemia (CML). This occurs through the formation of the BCR-ABL fusion protein, which results from a chromosomal translocation, typically t(9;22)(q34;q11). This fusion protein acts as a constitutively active tyrosine kinase, leading to uncontrolled cell proliferation and survival by activating downstream signaling pathways, including the RAS-RAF-MEK-ERK cascade. This dysregulated signaling promotes malignant transformation and hematopoietic cell proliferation. The key biological effect is the continuous activation of cellular growth and survival signals, which drives the clonal expansion of leukemic cells. This pathway is central to the pathogenesis of CML and is a key target for therapeutic interventions such as tyrosine kinase inhibitors. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when constitutively active due to chromosomal translocations such as t(9;22), forms the BCR-ABL fusion protein. This fusion protein is a constitutively active tyrosine kinase that continuously activates downstream signaling pathways, including the RAS-RAF-MEK-ERK cascade. This leads to uncontrolled cell proliferation, survival, and resistance to apoptosis. The persistent activation of these pathways drives the transformation of hematopoietic cells, leading to the development of chronic myeloid leukemia (CML). The BCR-ABL oncoprotein is a key driver in CML, and its inhibition by tyrosine kinase inhibitors like imatinib has revolutionized its treatment. Thus, the biological effect of the ABL1 allele in this context is the induction of CML.\n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated or overactive, leads to constitutive activation of the KIT receptor tyrosine kinase. This initiates the downstream signaling cascade: KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This pathway is critical for cell proliferation, survival, and differentiation. Aberrant activation of this pathway due to KIT mutations results in uncontrolled cell growth and is implicated in several diseases. One of the most notable is **mastocytosis**, a condition characterized by the accumulation of mast cells in various tissues. Additionally, KIT mutations are a hallmark of **gastrointestinal stromal tumors (GISTs)**, which arise from the interstitial cells of Cajal. These mutations often involve the *KIT* gene, leading to tumor formation through continuous signaling. Therefore, the biological effect of the KIT allele is the promotion of cell proliferation and survival, contributing to **gastrointestinal stromal tumors (GISTs)**.\n\n\\boxed{Gastrointestinal Stromal Tumors}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase, resulting in continuous signaling through the downstream pathway: KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This uncontrolled signaling promotes cell proliferation, survival, and differentiation. The most well-known disease associated with activating KIT mutations is **mastocytosis**, a condition characterized by the accumulation of mast cells in various tissues. Additionally, KIT mutations are critical in **gastrointestinal stromal tumors (GISTs)**, the most common soft tissue sarcomas. These mutations drive tumor growth by sustaining proliferative signals and inhibiting apoptosis. In some cases, KIT mutations also contribute to **leukemias** and **lymphomas**. The hallmark of these diseases is the dysregulation of the KIT signaling pathway, leading to uncontrolled cell growth and tumor formation. Therefore, the biological effect of the KIT allele is the induction of **mastocytosis** and **GISTs**.\n\n\\boxed{Gastrointestinal Stromal Tumors}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase, disrupting normal signaling through the KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK pathway. This results in uncontrolled cell proliferation and survival, contributing to the development of diseases characterized by abnormal cell growth. One such disease is GIST (Gastrointestinal Stromal Tumor), which arises from mutations in KIT or PDGFRA, leading to the overactivation of the KIT signaling pathway. These tumors originate in the gastrointestinal tract and are often associated with mutations in the KIT gene. The dysregulated pathway promotes tumor growth and resistance to apoptosis. Additionally, KIT mutations can contribute to other conditions, including some cases of chronic myeloid leukemia and mast cell disorders. The hallmark of KIT-driven pathologies is the persistent activation of the MAPK/ERK cascade, which drives cellular transformation. \\boxed{GIST}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to the phosphorylation of RB1, which in turn releases E2F transcription factors. CDK4, when active, promotes the inactivation of RB1, allowing E2F-dependent genes to drive cell cycle progression. A gain-of-function mutation in CDK4, such as amplification or overexpression, enhances this effect, leading to uncontrolled cell proliferation. This dysregulation is a key driver in several cancers, particularly those characterized by unchecked cell division. The most notable disease associated with CDK4 activation is **small cell lung cancer**. Additionally, CDK4 overactivity contributes to **breast cancer**, **ovarian cancer**, and **melanoma**. Mutations or amplifications in CDK4 are frequently observed in these malignancies, making it a critical player in tumor progression. Therefore, the biological effect of a pathogenic CDK4 allele is the promotion of uncontrolled cell growth, contributing to **small cell lung cancer**.\n\n\\boxed{Small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1, CCND2, CCND3) and CDK4, leading to the phosphorylation of RB1, which in turn releases E2F transcription factors (E2F1, E2F2, E2F3). This activates genes involved in DNA replication and cell cycle progression. CDK4, by promoting RB1 inactivation, drives cells through the G1 phase into S phase. Mutations or overexpression of CDK4 can lead to dysregulation of this pathway, resulting in unchecked cell proliferation. This contributes to the development of cancers characterized by aberrant cell cycle control. The most notable disease associated with CDK4 activation is **small cell lung cancer**. However, CDK4 overactivity is also implicated in other cancers, including **melanoma**, **breast cancer**, and **prostate cancer**. The key biological effect is the promotion of uncontrolled cell division, a hallmark of malignancy. \n\n\\boxed{Small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to phosphorylation of RB1, which releases E2F transcription factors. This process drives cell cycle progression from G1 to S phase. Mutations or overexpression of CDK4 can disrupt this regulation, leading to unchecked cell proliferation. CDK4 is frequently hyperactivated in cancers due to amplification or mutation, particularly in tumors where the RB1 pathway is inactivated. This dysregulation contributes to tumor growth by promoting G1/S transition without proper cell cycle checks. CDK4 overactivity is strongly associated with several cancers, including breast, bladder, and melanoma. The most notable disease linked to CDK4 activation is **Small Cell Lung Cancer (SCLC)**, as well as other malignancies where RB1 inactivation occurs. \\boxed{Small Cell Lung Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, acting as a scaffold for the ubiquitin-binding complex that recruits autophagy-related proteins. In the context of the provided pathway, SQSTM1 interacts with PINK1 and PRKN, which are critical in mitochondrial quality control. Mutations in SQSTM1 disrupt autophagy and mitophagy, leading to the accumulation of dysfunctional mitochondria and protein aggregates. This contributes to neurodegeneration. SQSTM1 mutations are associated with autosomal recessive Parkinsonism-Parkinson disease, specifically a form of Parkinson's disease characterized by early-onset, pyramidal signs, and dopaminergic neuron loss. The impaired autophagy and mitochondrial dysfunction resulting from SQSTM1 defects play a central role in neuronal death. These findings highlight SQSTM1's essential role in maintaining mitochondrial homeostasis and preventing neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, involved in the ubiquitin-mediated degradation of damaged proteins and organelles. In the context of the provided pathway, SQSTM1 is linked to PINK1 and PRKN, which are central to mitochondrial quality control. Mutations in SQSTM1 impair autophagy and mitochondrial homeostasis, leading to the accumulation of damaged mitochondria and protein aggregates. This dysfunction is implicated in neurodegeneration. Specifically, SQSTM1 mutations contribute to Parkinson's disease by disrupting the clearance of dysfunctional mitochondria and protein aggregates, particularly in dopaminergic neurons. This leads to neuronal loss and the clinical features of Parkinson's disease. The involvement of SQSTM1 in this pathway highlights its critical role in maintaining cellular homeostasis and preventing neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, functioning as a scaffold protein that facilitates the recruitment of autophagic cargo to autophagosomes. In the context of the provided pathway, SQSTM1 interacts with PINK1 and PRKN, which are central to mitochondrial quality control. Mutations in SQSTM1 disrupt autophagy and the clearance of damaged mitochondria, leading to the accumulation of dysfunctional mitochondria and the generation of reactive oxygen species. This contributes to neurodegeneration. SQSTM1 mutations are associated with Parkinson's disease, as they impair the ubiquitin-proteasome system and autophagy, leading to the accumulation of toxic proteins and neuronal dysfunction. The loss of SQSTM1 also impairs the degradation of damaged mitochondria, further exacerbating mitochondrial dysfunction. These molecular defects underlie the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway illustrates the extrinsic apoptosis pathway initiated by the amyloid beta precursor protein (APP). The cleavage of APP leads to the production of amyloid beta (Abeta), which triggers the Fas receptor (FAS) and initiates apoptosis through the activation of FADD and caspase 8 (CASP8). This cascade ultimately leads to the release of cytochrome c (CYCS) and the activation of caspase 9 (CASP9) and caspase 3 (CASP3), resulting in cell death. Mutations or dysregulation in APP can lead to the accumulation of toxic amyloid beta, a hallmark of Alzheimer's disease. The abnormal processing of APP and the subsequent apoptotic signaling contribute to neurodegeneration by promoting neuronal death and disrupting synaptic function. Therefore, this pathway is central to the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this genomic pathway is the production of amyloid-beta (Abeta), a key initiator of neuronal death through the activation of the extrinsic apoptotic pathway. This pathway involves FAS, FADD, CASP8, and downstream effector caspases such as CASP3, leading to the release of cytochrome c and the activation of CASP9, ultimately causing apoptosis. Accumulation of Abeta is a hallmark of Alzheimer\u2019s disease. The pathway described directly links APP to apoptosis via Abeta, which contributes to neurodegeneration by promoting cell death in neurons. This process is central to the pathogenesis of Alzheimer\u2019s disease. The involvement of BAX, BAK1, and CYCS further supports mitochondrial dysfunction and apoptosis. Therefore, this pathway is a key contributor to the development of Alzheimer\u2019s disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the extrinsic apoptosis pathway initiated by the APP (amyloid beta precursor protein) through the production of amyloid-beta, leading to Fas receptor activation and subsequent caspase cascade activation. This process is central to programmed cell death. Mutations in APP are associated with the accumulation of amyloid-beta plaques, a hallmark of Alzheimer\u2019s disease. The activation of caspases like CASP3 leads to neuronal apoptosis, contributing to neurodegeneration. This pathway is tightly linked to the pathogenesis of Alzheimer\u2019s disease, where the abnormal processing of APP and accumulation of toxic amyloid-beta disrupt cellular homeostasis and trigger apoptosis in neurons. Therefore, the biological effect of this APP allele is the promotion of apoptosis linked to neuronal loss, which contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is crucial in cell survival and proliferation. Activation of KIT leads to the stimulation of PI3K, which generates PIP3. PIP3 recruits AKT to the plasma membrane, activating it. Active AKT inhibits BAD, preventing its pro-apoptotic function, thereby promoting cell survival. Mutations in KIT, such as activating mutations in KIT (e.g., in mast cell tumors), disrupt normal regulation, leading to constitutive signaling and uncontrolled cell growth. This contributes to the development of gastrointestinal stromal tumors (GISTs), which are the most common soft tissue sarcomas. KIT mutations are also implicated in other cancers, including certain leukemias and lung cancers. The dysregulation of this pathway results in oncogenic transformation by promoting cell survival and proliferation while inhibiting apoptosis. \\boxed{Gastrointestinal Stromal Tumors}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway, when activated, leads to the phosphorylation of PI3K, which generates PIP3. PIP3 recruits AKT to the plasma membrane, where it is activated. Activated AKT inhibits BAD, a pro-apoptotic protein, thus promoting cell survival. Mutations in KIT, such as gain-of-function mutations, result in constitutive activation of this pathway, driving uncontrolled cell proliferation and survival. This contributes to the development of various cancers, most notably **mast cell neoplasms**, such as **mastocytosis** and **systemic mastocytosis**, as well as **GISTs** (gastrointestinal stromal tumors). KIT mutations are also implicated in **leukemias** and **melanomas**. The persistent activation of the KIT-PI3K-AKT-BAD axis disrupts normal cell death mechanisms, leading to tumor progression. \\boxed{Systemic Mastocytosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis KIT pathway describes a signaling cascade starting with KIT, which activates PI3K (via PIK3CA, PIK3CB, or PIK3CD), leading to the production of PIP3 and subsequent activation of AKT (AKT1, AKT2, or AKT3). AKT then inhibits BAD, preventing apoptosis. Mutations in KIT or its downstream components, such as PIK3CA, can result in constitutive activation of this pathway, leading to uncontrolled cell growth and survival. This is a hallmark of several cancers. Specifically, activating mutations in KIT are strongly associated with **Gastrointestinal Stromal Tumors (GISTs)**. These mutations typically occur in the KIT gene and lead to ligand-independent activation of the receptor tyrosine kinase, driving tumor progression. The pathway's dysregulation is central to the pathogenesis of this disease. \n\n\\boxed{Gastrointestinal Stromal Tumors}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that regulates apoptosis. SOD1, an antioxidant enzyme, when mutated, leads to the disruption of cellular antioxidant defenses, increasing oxidative stress. This stress can cause mitochondrial damage, leading to the release of cytochrome c and activation of the apoptotic cascade via APAF1, CASP9, and CASP3. The pathway also involves BCL2, BAX, and BAK1, which modulate mitochondrial permeability and apoptosis. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The accumulation of misfolded SOD1 proteins contributes to neuronal death through enhanced apoptosis and oxidative stress. Therefore, the biological effect of this SOD1 allele is the promotion of neuronal cell death, contributing to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described genomic pathway, contributes to neurodegenerative disease. SOD1 is a key enzyme involved in antioxidant defense, converting superoxide radicals into hydrogen peroxide. Mutant SOD1 proteins, however, gain toxic gain-of-function properties, leading to oxidative stress and neuronal damage. This pathway involves BCL2, which typically inhibits apoptosis, but in the presence of mutant SOD1, it may fail to suppress pro-apoptotic proteins like BAX and BAK1. This results in the release of cytochrome c, activating APAF1 and caspase-9, which ultimately leads to caspase-3 activation and apoptosis. This apoptotic cascade is central to motor neuron death in **amyotrophic lateral sclerosis (ALS)**. Mutations in SOD1 are a well-documented cause of familial ALS, making this pathway critical in the pathogenesis of the disease.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that links oxidative stress to apoptosis. SOD1, a copper/zinc superoxide dismutase, normally detoxifies superoxide radicals. Mutations in SOD1 can lead to gain-of-function effects, causing the protein to misfold and aggregate, which disrupts cellular homeostasis. This leads to neuronal damage, particularly in motor neurons, by promoting mitochondrial dysfunction, oxidative stress, and apoptosis through the BCL2-BAX/BAK1-CYCS-APAF1-CASP9-CASP3 pathway. This pathway is critical for programmed cell death, and its dysregulation due to SOD1 mutations results in neurodegeneration. The most well-documented disease associated with SOD1 mutations is amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to the loss of function of the MEN1 gene, which encodes the menin protein. Menin is a tumor suppressor that regulates cell cycle progression and apoptosis by interacting with various transcription factors, including KMT2A, a lysine methyltransferase involved in chromatin remodeling. The pathway (MEN1*+KMT2A) // (CDKN1B,CDKN2C) highlights the interaction between MEN1 and KMT2A, which in turn modulates CDKN1B and CDKN2C\u2014both inhibitors of the cell cycle. Disruption of this pathway results in uncontrolled cell proliferation. The most well-documented disease associated with MEN1 mutations is **Multiple Endocrine Neoplasia Type 1 (MEN1)**, a genetic syndrome characterized by tumors in multiple endocrine organs, including parathyroid, pancreatic, and pituitary glands. The loss of MEN1 function contributes to the development of these tumors by impairing tumor suppression mechanisms. \n\n\\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, specifically the *MEN1* gene, encodes menin, a tumor suppressor protein that regulates cell cycle progression and apoptosis. Mutations in *MEN1* disrupt its function, leading to uncontrolled cell proliferation. This contributes to the development of multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by the formation of tumors in various endocrine glands, including the parathyroid, pancreas, and pituitary. The pathway includes *KMT2A*, a histone methyltransferase involved in gene regulation, and *CDKN1B* and *CDKN2C*, which are cyclin-dependent kinase inhibitors that normally suppress cell cycle progression. The interaction of these genes suggests a role in maintaining genomic stability and preventing tumorigenesis. Loss of functional *MEN1* disrupts this regulatory network, promoting tumor formation. Therefore, the biological effect of the MEN1 allele is the promotion of MEN1 syndrome, a genetic disorder with endocrine tumors.\n\n\\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to the loss of function of the MEN1 gene, which encodes menin, a tumor suppressor protein. Menin plays a critical role in regulating cell cycle progression and apoptosis by interacting with various proteins, including KMT2A (lysine methyltransferase 2A) and CDKN1B/CDKN2C, which are cyclin-dependent kinase inhibitors. The disruption of this pathway results in unchecked cell proliferation and impaired tumor suppression. This contributes to the development of multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by the formation of tumors in multiple endocrine glands, including the parathyroid, pituitary, and pancreatic glands. The loss of functional MEN1 leads to genomic instability and activation of oncogenic pathways, ultimately promoting tumorigenesis. The pathway described highlights the critical role of MEN1 in maintaining cellular homeostasis and preventing cancer. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC (adenomatous polyposis coli) gene plays a central role in the WNT signaling pathway. Its allele, when mutated, disrupts the degradation of \u03b2-catenin (CTNNB1), leading to its accumulation and nuclear translocation. This aberrant \u03b2-catenin activation promotes the transcription of target genes such as BIRC5, MYC, and CCND1, which drive cell proliferation and inhibit apoptosis. These molecular changes are hallmarks of uncontrolled cell growth. The most significant disease associated with APC mutations is **colorectal cancer**. Inheriting a pathogenic APC mutation increases the risk of developing multiple colonic polyps, which can progress to cancer. APC mutations are among the earliest genetic events in colorectal carcinogenesis and are found in over 80% of sporadic colorectal cancers. Thus, APC dysfunction is a key driver in the development of **colorectal cancer**.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a central role in the WNT signaling pathway. The pathway described involves GSK3B and AXIN inhibiting the stabilization of CTNNB1, a key component of the beta-catenin complex. When APC is mutated or inactivated, this inhibition is lost, leading to the accumulation of CTNNB1. This aberrant accumulation activates TCF/LEF transcription factors, driving the expression of downstream genes such as BIRC5, MYC, and CCND1, which promote cell proliferation and survival. This dysregulation is a hallmark of colorectal cancer. Loss of functional APC is one of the earliest and most common genetic alterations in colorectal tumorigenesis. It disrupts the balance of cell growth and apoptosis, leading to uncontrolled cell division and tumor formation. Therefore, the biological effect of the APC allele is the promotion of colorectal cancer.\n\n\\boxed{Colorectal cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a central role in the WNT signaling pathway. The pathway described involves the degradation of \u03b2-catenin (CTNNB1) by a complex including APC, AXIN1/AXIN2, and GSK3B. When APC is mutated or inactivated, this degradation is impaired, leading to the accumulation of \u03b2-catenin. This results in its nuclear translocation and activation of TCF/LEF transcription factors, driving the expression of downstream genes such as BIRC5, MYC, and CCND1. These genes are implicated in cell proliferation, survival, and genomic instability. Mutations in APC are a hallmark of colorectal cancer, where loss of function in APC leads to constitutive WNT signaling and uncontrolled cell growth. The accumulation of \u03b2-catenin and activation of oncogenic pathways are key drivers in tumor initiation and progression. Therefore, the biological effect of the APC allele is the promotion of colorectal cancer.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally neutralizes superoxide radicals. However, when mutated, SOD1 becomes toxic and contributes to neuronal degeneration. The pathway described involves SOD1 interacting with DERL1, leading to the ubiquitination of proteins and their degradation via the 26S proteasome. This process is crucial for maintaining protein homeostasis. Mutant SOD1 disrupts this pathway, leading to the accumulation of misfolded proteins and cellular stress, which ultimately results in motor neuron death. This mechanism underlies the pathogenesis of ALS, a neurodegenerative disease characterized by progressive paralysis and loss of motor function. Mutations in SOD1 are one of the most common genetic causes of familial ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). Mutations in the *SOD1* gene lead to the production of a dysfunctional superoxide dismutase 1 enzyme, which aggregates and disrupts cellular processes, particularly in motor neurons. This results in neurodegeneration and the progressive loss of motor function, hallmark features of ALS. The pathway described involves the ubiquitin-proteasome system, where misfolded SOD1 is tagged with ubiquitin and degraded by the 26S proteasome. Impairment in this system due to SOD1 mutations contributes to the accumulation of toxic proteins, exacerbating neuronal damage. This pathway is critical in the pathogenesis of ALS, linking SOD1 dysfunction to disease progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes ubiquitination and proteasomal degradation. SOD1 (superoxide dismutase 1) is an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause **Amyotrophic Lateral Sclerosis (ALS)**, a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The mutant SOD1 protein forms aggregates and gains toxic properties, leading to neuronal death. This pathway highlights the role of proteasomal dysfunction in disease progression. The ubiquitination of SOD1 and its subsequent degradation via the 26S proteasome is critical for maintaining cellular homeostasis. Impairment in this process due to SOD1 mutations contributes to the accumulation of toxic protein species, which is a hallmark of ALS. Therefore, the biological effect of the SOD1 allele in this context is the contribution to **Amyotrophic Lateral Sclerosis (ALS)**.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway involving SOD1 and its associated genes, including dynactin subunits and dynein-related proteins, suggests a role in cellular stress responses and axonal transport, both of which are critical for neuronal health. Impaired function of these proteins can lead to the accumulation of oxidative stress and defective intracellular transport, contributing to neuronal damage. SOD1 mutations are a leading genetic cause of familial ALS, and they are also implicated in sporadic cases. The involvement of multiple dynein and dynactin subunits further supports the role of cytoskeletal dynamics in disease pathogenesis. \\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1 encodes superoxide dismutase 1, an enzyme that normally detoxifies reactive oxygen species. Mutations in SOD1 lead to protein misfolding and aggregation, which is toxic to motor neurons. These aggregated proteins disrupt cellular functions, including protein homeostasis, mitochondrial health, and RNA processing, ultimately leading to neuronal death. The pathway includes genes involved in cytoskeletal dynamics and axonal transport, such as dynactin subunits and dynein-associated proteins, which are critical for neuronal function. Dysfunction in these pathways exacerbates neurodegeneration. SOD1-linked ALS is a hereditary form of the disease, characterized by progressive muscle weakness and paralysis. Mutations in SOD1 account for approximately 10-20% of familial ALS cases. The interplay between SOD1 dysfunction and impaired axonal transport contributes to the pathogenesis of the disease. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway involving SOD1 and associated genes such as DCTN1-DCTN6, ACTR1A/B, and DNAH/DNAI/DNAL genes reflects a network involved in cytoskeletal dynamics, intraflagellar transport, and neuronal function. These genes are critical for maintaining axonal transport and neuronal integrity. Mutations or dysfunction in this pathway disrupt cellular processes essential for motor neuron survival, leading to neurodegeneration. Thus, the SOD1 allele contributes to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in neuronal function and synaptic transmission. The pathway SNCA \u2192 VMAT2 suggests a regulatory relationship where SNCA may influence VMAT2, a vesicular monoamine transporter involved in dopamine storage. Mutations or dysregulation of SNCA are well-known contributors to Parkinson's disease (PD), as aggregated alpha-synuclein forms Lewy bodies, a hallmark of PD. The SLC18A2 gene encodes VMAT2, further linking this pathway to dopamine homeostasis. Dysfunctional SNCA can lead to abnormal protein aggregation, neuroinflammation, and neuronal degeneration, particularly in dopaminergic neurons. This contributes to the progressive motor and non-motor symptoms of Parkinson's disease. Thus, the SNCA allele is a key genetic factor in the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. Its mutation or overexpression leads to the abnormal aggregation of alpha-synuclein, which is a hallmark of synaptic dysfunction. The pathway SNCA \u2192 VMAT2 indicates a regulatory relationship where SNCA may influence VMAT2, a vesicular monoamine transporter involved in dopamine storage. This pathway is critically linked to neurodegenerative diseases. Mutations in SNCA are well-established contributors to Parkinson's disease, as they lead to the formation of Lewy bodies, which are pathological protein aggregates. The dysregulation of SNCA and its downstream effects on VMAT2 contribute to dopaminergic neuron loss, a key feature of Parkinson's disease. Thus, the biological effect of this SNCA allele is the promotion of neurodegeneration, specifically contributing to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway SNCA \u2192 VMAT2 indicates a regulatory relationship where SNCA may influence vesicular monoamine transporter 2 (VMAT2), which is critical for neurotransmitter storage. Mutations in SNCA, particularly those leading to misfolding and aggregation of alpha-synuclein, are strongly associated with the pathogenesis of Parkinson's disease. Accumulation of abnormal alpha-synuclein leads to the formation of Lewy bodies, a hallmark of Parkinson's. This contributes to neuronal dysfunction and death, particularly in dopaminergic neurons. Thus, the SNCA allele's biological effect is the promotion of Parkinson's disease pathology through protein misfolding and aggregation. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, a key activator of carbamoyl-phosphate synthase I (CPS1), which initiates the urea cycle. Mutations in NAGS lead to reduced N-acetylglutamate production, impairing CPS1 activity and disrupting urea synthesis. This results in the accumulation of ammonia, a toxic compound, leading to neurological symptoms. The most common disease associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. This condition is characterized by hyperammonemia, seizures, developmental delay, and intellectual disability. Affected individuals often present with severe neurological complications due to the inability to detoxify ammonia. The disorder is typically fatal in infancy or early childhood if left untreated. Early diagnosis and management with dietary restrictions and medications to lower ammonia levels are essential for improving outcomes. \\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS (N-acetylglutamate synthase) gene is critical for the urea cycle, as it catalyzes the formation of N-acetylglutamate, a key activator of CPS1 (carbamoyl-phosphate synthase 1). Mutations in NAGS lead to reduced activity of this enzyme, impairing the urea cycle and causing the accumulation of ammonia. This results in hyperammonemia, a condition characterized by elevated ammonia levels in the blood, which can be neurotoxic. The most common disorder associated with NAGS mutations is **N-acetylglutamate synthetase deficiency**, a rare autosomal recessive disorder. This disease typically presents in infancy with seizures, lethargy, vomiting, and developmental delays due to the toxic effects of ammonia on the central nervous system. The primary clinical feature is episodic hyperammonemia, which can lead to coma or death if untreated. The defect disrupts the first committed step in the urea cycle, highlighting the essential role of NAGS in nitrogen metabolism. \\boxed{N-acetylglutamate synthetase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the synthesis of N-acetylglutamate, a key activator of carbamoyl-phosphate synthase 1 (CPS1) in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing the urea cycle's ability to detoxify ammonia. This results in hyperammonemia, a dangerous accumulation of ammonia in the blood. The most notable disease associated with NAGS mutations is **Nagara-Kobayashi syndrome**, a rare autosomal recessive disorder characterized by neonatal hyperammonemia, seizures, developmental delay, and often early mortality. Patients with this condition exhibit neurological symptoms due to toxic ammonia levels affecting brain function. The disorder is caused by biallelic pathogenic variants in the NAGS gene, disrupting the urea cycle and leading to severe metabolic consequences. \\boxed{Nagara-Kobayashi syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1* allele is part of a pathway involving SOD1 \u2192 BIP \u2192 ERN1 \u2192 XBP1. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involves the unfolded protein response (UPR), where ERN1 (IRE1) activates XBP1, a transcription factor that promotes the production of chaperones like BIP (HSPA5) to help fold misfolded proteins. SOD1 mutations can lead to the accumulation of misfolded proteins, triggering ER stress and ultimately contributing to neuronal death. Therefore, the biological effect of the SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to contribute to neurodegenerative diseases. In the context of the provided pathway (SOD1 \u2192 BIP \u2192 ERN1 \u2192 XBP1), the altered SOD1 allele likely leads to oxidative stress and impaired unfolded protein response (UPR) due to dysfunction in the ER. This disrupts protein folding and leads to neuronal damage. The most notable disease associated with SOD1 mutations is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Mutant SOD1 proteins aggregate and toxic gain-of-function effects contribute to motor neuron death. Thus, the biological effect of the SOD1 allele in this pathway is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. In the context of the provided pathway, SOD1 is upstream of BIP and ERN1, which are key players in the unfolded protein response (UPR) and ER stress. Mutant SOD1 has been shown to induce ER stress by promoting misfolding of proteins and perturbing calcium homeostasis, thereby activating the ERN1-XBP1 signaling cascade. This leads to chronic ER stress and neuronal dysfunction, contributing to the pathogenesis of ALS. Thus, the biological effect of the SOD1 allele is the disruption of ER homeostasis, which is central to the development of \\boxed{Amyotrophic Lateral Sclerosis}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenic signaling by driving continuous activation of downstream effectors. Mutations in NRAS, like KRAS, result in constitutive activation of the RAS protein, leading to persistent stimulation of PI3K and subsequent activation of AKT. This inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is central to tumor progression. The biological effect of mutant NRAS is the activation of the PI3K/AKT/mTOR pathway, which enhances cell growth, survival, and resistance to apoptosis. This contributes to the development of various cancers, particularly those of hematopoietic origin. The most common disease associated with NRAS mutations is acute myeloid leukemia (AML), where NRAS mutations are frequently observed and drive pathogenesis. These mutations are also implicated in other malignancies such as bladder cancer, thyroid carcinoma, and neuroblastoma. \\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS-PI3K-AKT-BAD signaling pathway, contributes to the activation of the PI3K-AKT axis by promoting the production of PIP3, which in turn activates AKT. This leads to the inhibition of BAD, a pro-apoptotic protein, thereby suppressing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, particularly activating mutations, disrupt the normal regulation of RAS proteins, leading to constitutive activation of downstream pathways. This dysregulation is a key driver in the development of various cancers. Specifically, NRAS mutations are commonly associated with **melanoma**, where they contribute to uncontrolled cell growth and resistance to apoptosis. These mutations are also observed in other malignancies such as **colorectal cancer** and **non-small cell lung cancer**. The persistent activation of the PI3K-AKT pathway due to NRAS mutations promotes tumor progression and is implicated in disease initiation and progression. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in the described pathway activates downstream signaling through PI3K, leading to increased PIP3 and subsequent activation of AKT. This inhibits BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. This pathway is central to oncogenic processes. Mutations in NRAS, a RAS family member, are strongly associated with uncontrolled cell growth and resistance to apoptosis. This contributes to the development of various cancers, particularly those driven by RAS activation. NRAS mutations are commonly found in melanoma, non-small cell lung cancer, and certain hematologic malignancies. The activation of this pathway leads to constitutive signaling, driving tumor progression and resistance to therapy. The cumulative effect of NRAS mutation is the disruption of normal growth regulation, resulting in the hallmark features of cancer. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to maintaining genomic stability through cell cycle regulation, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to uncontrolled cell growth and resistance to apoptosis. This pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are critical for DNA damage response and cell cycle arrest. A dysfunctional TP53 allele impairs these mechanisms, allowing cells with damaged DNA to survive and proliferate, which contributes to tumorigenesis. This is particularly significant in cancers characterized by genomic instability. The most well-known disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer syndrome with a high risk of multiple malignancies, including sarcomas, breast cancer, brain tumors, and leukemias. TP53 mutations are also common in various solid tumors, such as osteosarcoma, breast, and lung cancer. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a critical regulator of cell cycle arrest, DNA repair, and apoptosis in response to genotoxic stress. The listed genes\u2014CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK\u2014are downstream targets of p53, involved in growth arrest, DNA repair, and programmed cell death. Mutations in TP53 disrupt this pathway, leading to loss of genomic stability and unchecked cell proliferation. This dysfunction is a hallmark of various cancers. The TP53 gene is the most frequently mutated gene in human cancers, with mutations contributing to tumor initiation and progression. The altered pathway promotes resistance to apoptosis, accumulation of DNA damage, and evasion of senescence, all of which drive malignancy. These mutations are strongly associated with a wide range of solid tumors, including but not limited to breast, lung, ovarian, and bladder cancers. TP53 mutations are also linked to poor prognosis and resistance to therapy. Therefore, the biological effect of a mutated TP53 allele is the promotion of tumorigenesis and the development of various cancers.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor protein p53, a critical tumor suppressor that regulates cell cycle arrest, DNA repair, and apoptosis. The pathway includes genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA damage response and apoptosis. Mutations in TP53 disrupt its function, leading to impaired cell cycle control and unchecked cell proliferation. This contributes to genomic instability and the development of cancer. TP53 mutations are strongly associated with various human malignancies, most notably **Li-Fraumeni syndrome**, a hereditary disorder characterized by a high risk of developing multiple cancers, including sarcomas, breast cancer, brain tumors, and leukemias. Additionally, TP53 mutations are found in many sporadic cancers, such as osteosarcoma, breast cancer, and lung cancer. The biological effect of a dysfunctional TP53 allele is the loss of tumor suppression, promoting tumorigenesis. \n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ-1, is involved in a pathway that includes TP53 and DUSP1. This pathway plays a role in cellular stress response, oxidative stress, and apoptosis. Mutations in PARK7 are associated with impaired proteasomal function and increased oxidative damage, which contribute to neuronal degeneration. Specifically, mutations in PARK7 are a known cause of early-onset Parkinson's disease. The gene's role in maintaining mitochondrial function and modulating the p53 pathway is critical for neuronal survival. Loss of function in PARK7 leads to the accumulation of misfolded proteins and oxidative stress, ultimately contributing to dopaminergic neuron loss. Therefore, the biological effect of the PARK7 allele is the contribution to Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, plays a critical role in cellular protection against oxidative stress and protein misfolding. Its interaction with TP53 and regulation of DUSP1 suggests involvement in stress response and cell survival pathways. Mutations in PARK7 are associated with impaired neuroprotection, leading to mitochondrial dysfunction and neuronal death. This contributes to the pathogenesis of Parkinson's disease. The allele's disruption compromises the cell's ability to manage oxidative damage, exacerbating neurodegeneration. The pathway DJ1* // TP53 => DUSP1 highlights a mechanism by which PARK7 influences cellular resilience. Defective PARK7 function is a known risk factor for Parkinson's disease, underscoring its role in disease progression. The biological effect of the PARK7 allele is thus central to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in a pathway that includes TP53 and DUSP1. This pathway plays a role in cellular stress response, oxidative stress regulation, and apoptosis. Mutations in PARK7 are associated with impaired mitochondrial function and increased oxidative stress, which contribute to neuronal damage. Specifically, mutations in PARK7 are linked to early-onset Parkinson's disease. These mutations disrupt the protein's chaperone and antioxidant functions, leading to the accumulation of misfolded proteins and mitochondrial dysfunction. This ultimately results in the death of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease. Thus, the PARK7 allele contributes to the development of Parkinson's disease by impairing cellular protection mechanisms. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cellular proliferation and differentiation, particularly in bone development. Mutations in FGFR3, especially activating mutations or fusions, lead to constitutive activation of the downstream MAPK/ERK cascade. This results in uncontrolled cell growth and impaired differentiation. In particular, gain-of-function mutations in FGFR3 are strongly associated with **bladder cancer**, specifically **urothelial carcinoma**. These mutations drive tumor progression by promoting cell proliferation, survival, and resistance to apoptosis. FGFR3 alterations are commonly found in high-grade bladder cancers and are linked to poor prognosis. Additionally, FGFR3 mutations can contribute to other malignancies, but their most well-documented role is in bladder cancer. The activation of the FGFR3 pathway through these mutations leads to sustained signaling through GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately upregulating MYC, a key driver of oncogenesis.\n\n\\boxed{Bladder cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in regulating cell growth, differentiation, and survival. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of the downstream signaling cascade, including RAS and RAF, ultimately increasing ERK and MYC activity. This aberrant signaling promotes uncontrolled cell proliferation and inhibits apoptosis. In the context of the given pathway, mutations in FGFR3 contribute to the development of skeletal dysplasias, most notably **achondroplasia**, the most common form of short-limb dwarfism. These mutations result in impaired endochondral ossification by disrupting the normal growth plate function. While primarily a skeletal disorder, dysregulated FGFR3 signaling can also contribute to oncogenesis, particularly in cancers such as meningiomas and certain sarcomas. However, the most direct and well-established disease associated with FGFR3 mutations is **achondroplasia**.\n\n\\boxed{achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell growth and differentiation. Mutations in FGFR3 can lead to constitutive activation of downstream signaling, promoting uncontrolled cell proliferation. This contributes to the development of **Meningioma**, a type of brain tumor. FGFR3 mutations are commonly associated with meningiomas, particularly in the context of Neurofibromatosis type 2 (NF2), where loss of NF2 tumor suppressor function leads to activation of FGFR3 signaling. This pathway activation drives tumor growth by enhancing MAPK and PI3K/AKT signaling, promoting cell survival and proliferation. Thus, FGFR3 mutations are implicated in the pathogenesis of **Meningioma**.\n\n\\boxed{Meningioma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele in this pathway contributes to **Multiple Endocrine Neoplasia Type 2 (MEN2)**. RET is a receptor tyrosine kinase, and its activation through mutations leads to constitutive signaling via the PI3K-AKT-MTOR pathway, promoting uncontrolled cell growth and survival. This results in the development of tumors in multiple endocrine glands, including parathyroid, adrenal, and thyroid tissues. RET mutations are particularly associated with medullary thyroid carcinoma (MTC) and phaeochromocytoma. The involvement of PI3K and AKT further enhances oncogenic potential by driving cell proliferation, angiogenesis, and resistance to apoptosis. These molecular mechanisms underlie the pathogenesis of MEN2, a hereditary cancer syndrome. \\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase. This activation initiates the downstream signaling cascade: RET \u2192 PI3K \u2192 PIP3 \u2192 AKT \u2192 MTOR. This pathway is crucial for cell survival, proliferation, and metabolism. Mutations in RET can cause uncontrolled cell growth, leading to the development of tumors. Specifically, RET mutations are well-known contributors to medullary thyroid carcinoma (MTC). These mutations are often germline, leading to familial MTC, and can also occur somatically in sporadic cases. The activation of the PI3K-AKT-MTOR pathway promotes oncogenesis by enhancing cell survival and inhibiting apoptosis. Therefore, RET mutations are directly associated with the development of medullary thyroid carcinoma. \n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET pathway is a critical signaling cascade involved in cell growth, survival, and differentiation. Mutations in the RET gene, which encodes a receptor tyrosine kinase, can lead to constitutive activation of downstream effectors such as PI3K and AKT, ultimately activating MTOR. This results in uncontrolled cell proliferation and survival, contributing to tumorigenesis. Specifically, mutations in RET are well-known for their role in **multiple endocrine neoplasia type 2 (MEN2)**, a hereditary syndrome characterized by the development of medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid adenomas. RET mutations also contribute to other cancers, including lung and kidney carcinomas. The dysregulation of this pathway due to RET mutations disrupts normal cellular homeostasis, promoting malignant transformation. \\boxed{Multiple Endocrine Neoplasia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a key regulator of actin polymerization. It binds to monomeric actin (ACTB and ACTG1) and promotes the formation of filamentous actin, essential for cellular structures like the cytoskeleton. Mutations in PFN1 disrupt this process, leading to impaired actin dynamics. This contributes to neurodevelopmental disorders, particularly **familial hemiplegic migraine (FHM)**. PFN1 mutations are linked to altered calcium signaling and neuronal excitability, which underlie the migratory and neurological symptoms of FHM. The pathway involving actin monomers and filaments is critical for synaptic function and neuronal stability. Dysregulation due to PFN1 variants impairs these processes, resulting in episodic migraine with hemiplegia. Thus, the biological effect of the PFN1 allele is the development of **familial hemiplegic migraine**.\n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and promotes its incorporation into filamentous actin structures. This process is essential for cytoskeletal dynamics, cell motility, and intracellular trafficking. Mutations in PFN1 disrupt actin polymerization, leading to impaired cellular functions. This contributes to neurodevelopmental disorders, particularly cortical dysplasia and epilepsy. The disrupted actin dynamics affect neuronal migration and synapse formation, leading to structural and functional abnormalities in the brain. These abnormalities are associated with intellectual disability, seizures, and motor impairments. The specific PFN1 allele in question is linked to a subset of cases with progressive myoclonus epilepsy (PME) and other neurodevelopmental conditions. Therefore, the biological effect of this PFN1 allele is the disruption of actin dynamics, contributing to \\boxed{Progressive Myoclonus Epilepsy}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and facilitates its incorporation into filamentous actin structures. This process is essential for actin dynamics, which underpin various cellular functions including cytoskeletal organization, cell migration, and intracellular transport. Mutations in PFN1 disrupt this critical actin nucleation process, leading to impaired cellular motility and structural integrity. This dysfunction is implicated in neurodevelopmental disorders, particularly in the context of leukodystrophy. Specifically, PFN1 mutations are associated with **Eunell syndrome**, a rare genetic disorder characterized by progressive neurodegeneration, seizures, and intellectual disability. The disruption of actin filament assembly due to PFN1 dysfunction compromises neuronal development and myelination, contributing to the clinical manifestations of the disease. \\boxed{Eunell syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **PSEN1** gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of the amyloid precursor protein (APP). Mutations in **PSEN1** are a well-established cause of **early-onset familial Alzheimer's disease (AD)**. These mutations lead to increased production of amyloid-\u03b2 peptides, particularly the toxic A\u03b242 form, which aggregates into plaques in the brain. This pathological accumulation disrupts synaptic function, triggers neuroinflammation, and ultimately leads to neuronal death. The pathway described involves mitochondrial calcium dynamics and apoptosis, with **PSEN1** mutations indirectly contributing to mitochondrial dysfunction and the activation of the intrinsic apoptotic pathway via cytochrome c release and caspase activation. This ultimately results in neurodegeneration. Thus, the biological effect of **PSEN1** allele mutations is the progression of **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to abnormal cleavage of APP, resulting in the accumulation of amyloid-\u03b2 plaques in the brain, a hallmark of Alzheimer's disease. The pathway described involves calcium dysregulation via mitochondrial calcium uptake (MCU), leading to mitochondrial dysfunction and the release of cytochrome c, which activates the intrinsic apoptotic pathway through APAF1 and CASP9, ultimately inducing caspase-dependent apoptosis. This cascade contributes to neurodegeneration. Thus, the PSEN1 allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PSEN1 and PSEN2, which are key components of the gamma-secretase complex. Mutations in PSEN1 are well-documented to cause early-onset Alzheimer's disease (AD). These mutations lead to abnormal processing of the amyloid precursor protein (APP), resulting in increased production of toxic amyloid-beta peptides. The subsequent cascade includes mitochondrial dysfunction via altered calcium homeostasis through RYR3, MCU, and VDACs, leading to mitochondrial stress and release of cytochrome c. This activates the intrinsic apoptotic pathway via APAF1 and CASP9, ultimately leading to CASP3 and CASP7 activation, which induce cell death. This pathway is central to neurodegeneration in Alzheimer's disease. The PSEN1 allele thus contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key player in the ubiquitin-proteasome system, functioning as an E3 ubiquitin ligase. Its role in the pathway PRKN \u2192 PLCG1 \u2192 IP3 \u2192 ITPR \u2192 Ca\u00b2\u207a suggests involvement in intracellular calcium signaling, which is critical for neuronal function. Mutations in PRKN lead to impaired ubiquitination and degradation of proteins, disrupting calcium homeostasis. This disruption is linked to neurodegeneration. Specifically, PRKN mutations are a known cause of Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The resulting dysfunction in calcium signaling contributes to mitochondrial dysfunction, oxidative stress, and neuronal death. Thus, the biological effect of PRKN allele mutations is the disruption of calcium signaling, leading to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway plays a critical role in mitochondrial quality control through the ubiquitination and degradation of damaged mitochondria via autophagy (mitophagy). Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neurodegeneration. PRKN is a key gene in Parkinson's disease (PD) pathology. Loss-of-function mutations in PRKN are associated with early-onset PD, characterized by dopaminergic neuron loss. The pathway disruption leads to impaired calcium signaling via IP3 and ITPR, further exacerbating neuronal dysfunction. Thus, PRKN mutations directly contribute to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key player in the ubiquitin-proteasome system, facilitating protein degradation. Its pathway involves PLCG1, IP3, and calcium release via ITPR receptors. Mutations in PRKN disrupt this pathway, leading to the accumulation of damaged proteins and impaired mitochondrial function. This dysfunction is central to neurodegenerative processes. PRKN mutations are strongly associated with Parkinson's disease, as they impair autophagy and mitochondrial quality control, contributing to dopaminergic neuron loss. The loss-of-function mutations in PRKN are a monogenic cause of early-onset Parkinson's disease. This pathway's disruption also links to other neurodegenerative disorders, but its most well-documented consequence is Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in neuronal function. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long polyglutamine tract in the huntingtin protein. This results in protein misfolding, aggregation, and neurotoxicity. The disease associated with this mutation is Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway described includes components of the mitochondrial electron transport chain, particularly complex III, which is critical for ATP production. Impaired mitochondrial function is a known consequence of HTT mutations, further contributing to neuronal death. The involvement of genes such as UQCRFS1, CYTB, CYC1, and others highlights the disruption of mitochondrial energy metabolism in this disease. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose abnormal function is central to Huntington's disease. The pathway described includes components of complex III in the electron transport chain, involving genes like UQCRFS1, UQCRC1, and others, which are critical for mitochondrial function. Mutations in HTT lead to the production of an expanded polyglutamine tract in huntingtin, causing protein misfolding, aggregation, and neurotoxicity. This results in progressive degeneration of neurons, particularly in the striatum and cortex. The disease is autosomal dominant, with symptoms typically appearing in mid-adulthood. The HTT allele contributes to the pathogenesis of Huntington's disease by disrupting mitochondrial function and neuronal survival. The involvement of complex III components suggests a link between mitochondrial dysfunction and the neurodegenerative process. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form causes Huntington's disease. In the given pathway, HTT interacts with components of complex III (UQCRFS1, CYTB, CYC1, UQCRC1, UQCRC2, UQCRHL, UQCRH, UQCRB, UQCRQ, UQCR10, UQCR11), which is part of the mitochondrial electron transport chain. Mutations in HTT lead to the production of an abnormally long polyglutamine tract in the huntingtin protein, causing it to misfold and aggregate. These aggregates disrupt mitochondrial function, including oxidative phosphorylation and ATP production, and cause neuronal degeneration. This results in progressive motor, cognitive, and psychiatric symptoms. The pathway's involvement highlights the role of mitochondrial dysfunction in disease progression. The biological effect of the HTT allele is thus the development of Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, as part of the RET-RAS-RAF-MEK-ERK signaling pathway, plays a critical role in cell proliferation, differentiation, and survival. Mutations in RET, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, promoting uncontrolled cell growth. This contributes to the development of **multiple endocrine neoplasia type 2 (MEN2)**, a hereditary cancer syndrome. RET mutations are also implicated in **medullary thyroid carcinoma (MTC)**, which is a primary tumor in MEN2. Additionally, RET activation can drive **non-small cell lung cancer (NSCLC)** and **pancreatic neuroendocrine tumors** in some cases. The pathway's dysregulation leads to oncogenic transformation by sustaining proliferation signals and inhibiting apoptotic pathways. Thus, RET mutations are strongly associated with **medullary thyroid carcinoma (MTC)**, a hallmark of MEN2. \n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele in the pathway RET \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK is critical for cell growth and differentiation. Mutations in RET, particularly gain-of-function mutations, lead to constitutive activation of the RET receptor tyrosine kinase, which in turn activates downstream RAS and RAF signaling. This results in uncontrolled cell proliferation and survival, contributing to oncogenesis. RET mutations are most notably associated with **medullary thyroid carcinoma (MTC)**, a type of thyroid cancer. Additionally, RET mutations can also contribute to other cancers, including certain lung and gastrointestinal tumors. In particular, RET fusions or mutations are hallmark genetic alterations in MTC, and are also implicated in some cases of multiple endocrine neoplasia type 2 (MEN2). The activation of this pathway leads to aberrant MAPK signaling, promoting tumorigenesis. Therefore, the biological effect of a pathogenic RET allele is the initiation and progression of **medullary thyroid carcinoma**.\n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, which initiates the RET-RAS-RAF-MEK-ERK signaling pathway. This pathway is critical for cell proliferation, differentiation, and survival. Gain-of-function mutations in RET drive uncontrolled cell growth by continuously activating downstream effectors, leading to oncogenesis. This is most notably associated with **multiple endocrine neoplasia type 2 (MEN2)**. RET mutations are also implicated in **medullary thyroid carcinoma (MTC)** and **thyroid cancer**, as well as **pancreatic neuroendocrine tumors**. These mutations result in the inappropriate activation of the MAPK/ERK cascade, promoting tumor progression. The RET pathway is also linked to **non-small cell lung cancer (NSCLC)** in some cases. Thus, the biological effect of a pathogenic RET allele is the activation of the MAPK signaling pathway, contributing to **medullary thyroid carcinoma**. \n\n\\boxed{Medullary Thyroid Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol-3 kinase (PI3K), a key enzyme in the PI3K-AKT-MTOR signaling pathway. Activating mutations in PIK3CA lead to constitutive activation of this pathway, resulting in increased phosphorylation of AKT and subsequent activation of MTOR and S6K. This promotes cell growth, proliferation, and survival, while inhibiting apoptosis. The dysregulation of this pathway is implicated in multiple human cancers. Specifically, PIK3CA mutations are commonly found in cancers such as breast, endometrial, colorectal, and bladder cancer. These mutations drive tumor progression by enhancing oncogenic signaling and resistance to apoptosis. The PI3K-AKT-MTOR axis is a major driver in oncogenesis, making PIK3CA a critical gene in cancer development. Therefore, the biological effect of a pathogenic PIK3CA allele is the promotion of tumorigenesis.\n\n\\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K* -> PIP3 -> AKT -> MTOR -> S6K pathway is a central signaling cascade involved in cell growth, survival, and metabolism. The PIK3CA gene encodes the catalytic subunit of phosphoinositide-3-kinase (PI3K), which initiates this pathway by converting PIP2 to PIP3. Mutations in PIK3CA, such as activating mutations, lead to sustained activation of downstream effectors like AKT and MTOR, resulting in unchecked protein synthesis and cell proliferation. This dysregulation contributes to the development and progression of various cancers. Specifically, PIK3CA mutations are frequently observed in breast cancer, where they drive tumor growth by promoting cell survival and proliferation. These mutations are also implicated in other cancers, including ovarian, endometrial, and colorectal cancers. The constitutive activation of this pathway is a key driver in oncogenesis, making it a critical target for therapeutic intervention. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol-3 kinase (PI3K), a key enzyme in the PI3K-AKT-MTOR pathway. Mutations in PIK3CA, such as activating mutations, lead to constitutive activation of the PI3K pathway, resulting in increased production of PIP3 and subsequent activation of AKT and MTOR. This promotes cell survival, proliferation, and protein synthesis via S6K. The dysregulation of this pathway is strongly associated with uncontrolled cell growth and tumor formation. PIK3CA mutations are commonly found in various cancers, including colorectal, breast, endometrial, and ovarian cancers. These mutations contribute to oncogenesis by enhancing cell survival and resistance to apoptosis. The most well-documented disease linked to PIK3CA mutations is colorectal cancer. \\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated proteasomal degradation. Mutations in PRKN lead to impaired ubiquitination and proteasomal function, resulting in the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN mutations are a major cause of autosomal recessive Parkinson's disease (PD), with loss-of-function variants leading to early-onset PD. The pathway also involves UBE2L3 and UBE2L6, which are ubiquitin-conjugating enzymes, and SNCA, which is associated with Lewy body formation in PD. The interaction between these genes highlights the role of ubiquitin-mediated degradation in maintaining neuronal health. Dysfunction in this pathway disrupts protein quality control, contributing to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway includes UBCH7/8 (E2 conjugating enzymes) and alphaSynuclein (SNCA), which are involved in ubiquitination and protein misfolding. PRKN dysfunction leads to impaired degradation of misfolded proteins, including alpha-synuclein, contributing to neuronal toxicity. This disruption is a key factor in the pathogenesis of Parkinson's disease. The loss-of-function mutations in PRKN result in the accumulation of toxic proteins and mitochondrial dysfunction, leading to dopaminergic neuron loss. Therefore, the biological effect of PRKN allele mutations is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase that plays a critical role in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 (E2 conjugating enzymes) and alpha-Synuclein (SNCA), highlights its role in ubiquitination and protein quality control. Impaired PRKN function leads to the accumulation of misfolded proteins, including alpha-synuclein, contributing to neuronal dysfunction and degeneration. This is a key mechanism in Parkinson's disease. Mutations in PRKN reduce its ability to ubiquitinate and degrade damaged proteins, leading to the formation of Lewy bodies and progressive motor dysfunction. Thus, the PRKN allele is directly linked to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1-PRKN-MFN1/2 pathway is critical for mitochondrial quality control. PINK1, a mitochondrial kinase, stabilizes when mitochondria are damaged, recruiting parkin (PRKN) to ubiquitinate mitochondrial proteins, marking them for degradation. This process, known as mitophagy, removes dysfunctional mitochondria. Mutations in PINK1 or PRKN impair this pathway, leading to the accumulation of damaged mitochondria and neuronal damage. This dysfunction is strongly associated with Parkinson's disease. Mutations in PINK1 are one of the most common genetic causes of inherited Parkinson's, contributing to the loss of dopaminergic neurons. The pathway's role in maintaining mitochondrial health directly links PINK1 to neurodegeneration. Therefore, the biological effect of PINK1 mutations is the disruption of mitophagy, contributing to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1-PRKN-MFN1/2 pathway is critical for mitochondrial quality control. PINK1 encodes a kinase that stabilizes on damaged mitochondria, recruiting parkin (PRKN), an E3 ubiquitin ligase, to initiate mitophagy. MFN1 and MFN2 facilitate mitochondrial fusion, which is essential for maintaining mitochondrial function. Mutations in PINK1 or PRKN disrupt this pathway, leading to impaired mitophagy and accumulation of dysfunctional mitochondria. This contributes to neurodegeneration. The most well-documented disease associated with this pathway is Parkinson's disease. Loss-of-function mutations in PINK1 or PRKN are linked to early-onset Parkinson's, characterized by dopaminergic neuron loss. The dysfunction in mitochondrial quality control leads to oxidative stress, impaired energy production, and neuronal death, hallmark features of the disease. Therefore, the biological effect of this PINK1 allele is a key contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 and PRKN (parkin) work together in the ubiquitin-proteasome system to regulate mitochondrial function by promoting the degradation of damaged mitochondria through mitophagy. Mutations in PINK1 or PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal loss. This dysfunction is a key factor in neurodegenerative diseases. Specifically, mutations in PINK1 are strongly associated with Parkinson's disease, a disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. The PINK1-PRKN pathway is critical for maintaining mitochondrial health and preventing neurodegeneration. Therefore, defects in this pathway contribute to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-beta42, promoting amyloid plaque formation in the brain. The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) is implicated in neuronal transport and tau pathology, both of which are central to Alzheimer's disease progression. Disruptions in this pathway contribute to neurodegeneration by impairing axonal transport and increasing oxidative stress. Thus, the PSEN1 allele contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), leading to the production of amyloid-beta peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described\u2014PSEN1 \u2192 GSK3B -| (KIF5+KLC)\u2014suggests a role for PSEN1 in modulating GSK3B, a kinase involved in neurodegeneration and tau pathology. KIF5 and KLC are involved in intracellular transport, and their interaction may affect neuronal function. Dysregulation of this pathway due to PSEN1 mutations disrupts protein processing and transport, contributing to neuronal death. This strongly links the PSEN1 allele to Alzheimer's disease. The biological effect of this PSEN1 allele is the increased risk and early onset of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer's disease (AD). These mutations lead to altered gamma-secretase activity, resulting in increased production of toxic amyloid-beta peptides, which accumulate as plaques in the brain. This pathological accumulation is a hallmark of Alzheimer's disease and contributes to neuronal dysfunction and cognitive decline. The pathway involving PSEN1 \u2192 GSK3B and the kinesin-related proteins (KIF5 and KLC) likely modulates tau pathology and axonal transport, both of which are disrupted in AD. Therefore, the PSEN1 allele contributes to the development of Alzheimer's disease by disrupting key neurodegenerative processes.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a well-established cause of early-onset Alzheimer's disease (AD). The pathway described involves PSEN1 regulating GSK3B, which plays a role in neurodegeneration and tau phosphorylation. The interaction with KIF5 (kinesin family member 5) and KLC (kinesin light chain) suggests involvement in axonal transport, which is disrupted in neurodegenerative conditions. Impaired axonal transport and increased amyloid-beta production contribute to neuronal dysfunction and neurodegeneration. Thus, the PSEN1 allele contributes to the pathogenesis of Alzheimer's disease by disrupting these critical cellular processes. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the \u03b3-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP), leading to the production of \u03b2-amyloid peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 GSK3B -| (KIF5+KLC), suggests a regulatory interaction between PSEN1 and GSK3B, with KIF5 and KLC proteins potentially mediating transport or localization effects. Altered PSEN1 function disrupts \u03b3-secretase activity, increasing \u03b2-amyloid production and contributing to neuronal toxicity. This results in the characteristic pathological features of Alzheimer's disease, including amyloid plaques and neurofibrillary tangles. Therefore, the biological effect of the PSEN1 allele is the contribution to the development of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the gamma-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP), leading to the production of amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). These mutations disrupt the normal function of gamma-secretase, leading to increased production of toxic amyloid-beta species, which aggregate into plaques in the brain. This pathological process contributes to neuronal dysfunction and death, hallmark features of Alzheimer's disease. Additionally, the pathway involves GSK3B, KIF5 (kinesin family member 5), and KLC (kinesin light chain) proteins, which are implicated in intracellular transport and synaptic function, further supporting the role of this pathway in neurodegeneration. Consequently, the PSEN1 allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for mitochondrial quality control and protein degradation. Mutations in PRKN lead to impaired ubiquitin-mediated proteolysis, resulting in the accumulation of damaged proteins and dysfunctional mitochondria. This dysfunction contributes to neurodegeneration. PRKN mutations are a major cause of autosomal recessive Parkinson\u2019s disease (PD), specifically juvenile-onset PD. The pathway involving PRKN, along with UBCH7/8 and PAELR, underscores its role in ubiquitin-mediated degradation. Loss of PRKN function disrupts cellular clearance mechanisms, leading to neuronal loss, particularly in the substantia nigra. This genetic defect is associated with impaired mitophagy and increased oxidative stress, which are key pathological features of Parkinson\u2019s disease. Thus, the PRKN allele contributes to the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein quality control and mitochondrial function. Mutations in PRKN lead to loss of function, impairing ubiquitin-mediated degradation of damaged proteins and mitochondrial quality control. This contributes to the accumulation of dysfunctional proteins and mitochondria, leading to cellular stress and neurodegeneration. PRKN mutations are a primary cause of autosomal recessive Parkinson's disease (PD), specifically PARK2. The pathway involving PRKN, along with UBCH7/8 and PAELR, highlights its role in ubiquitin conjugation and protein degradation. Dysfunction in this pathway disrupts proteostasis, contributing to neuronal loss in PD. Therefore, PRKN alleles associated with loss of function are a key genetic contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 (E2 conjugating enzymes) and GPR37, is implicated in mitochondrial quality control and proteostasis. Loss-of-function PRKN alleles impair the ubiquitin-proteasome system, leading to the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neuronal degeneration, particularly in dopaminergic neurons. PRKN mutations are a major genetic cause of early-onset Parkinson's disease. The biological effect of PRKN dysfunction is neurodegeneration, primarily manifesting as Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the progression from the amyloid beta precursor protein (APP) to the formation of amyloid-beta (Abeta), which then activates NMDA receptors (via GRIN subunits). This leads to an influx of calcium ions (Ca2+), which are transported into mitochondria via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDACs). Excess mitochondrial calcium triggers the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c (CYCS), initiating apoptosis. This cascade is central to neurodegeneration. The accumulation of amyloid-beta and subsequent mitochondrial dysfunction are hallmarks of Alzheimer's disease. The involvement of NMDA receptors and calcium dysregulation further supports neuronal damage. Therefore, this pathway contributes to the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is central to the pathogenesis of Alzheimer's disease. The pathway begins with the cleavage of the amyloid beta precursor protein (APP), leading to the production of amyloid-beta (Abeta). This Abeta interacts with NMDA receptors (GRIN1, GRIN2A-D), triggering influx of calcium ions (Ca2+). Excess Ca2+ enters mitochondria via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDAC1-3), along with other solute carriers (SLC25A4-6, SLC25A31). This mitochondrial Ca2+ overload activates the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c (CYCS), initiating apoptosis. This cascade contributes to neurodegeneration. Therefore, this pathway is directly implicated in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as outlined in the pathway, involves the production of amyloid-beta (Abeta), which triggers NMDA receptor activation, leading to increased intracellular calcium via the mitochondrial calcium uniporter (MCU). This results in mitochondrial dysfunction, permeability transition pore (MPTP) opening, and release of cytochrome c (CYCS), promoting apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent neuronal damage are hallmark features of Alzheimer's disease. Mutations in APP can lead to increased Abeta production, exacerbating this process. The involvement of NMDA receptors, calcium dysregulation, and mitochondrial stress further supports the role of this pathway in Alzheimer's pathology. Thus, the APP allele contributes to the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) allele plays a critical role in thyroid hormone synthesis by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin (TG), forming monoiodo- (MIT) and diiodotyrosine (DIT) residues. These intermediates then couple to form triiodothyronine (T3) and thyroxine (T4). Mutations in TPO can impair this process, leading to reduced hormone production. This results in hypothyroidism, where the thyroid gland fails to produce sufficient thyroid hormones. TPO antibodies, often seen in autoimmune conditions, can further contribute to thyrotoxicosis by stimulating hormone release. However, the primary effect of a dysfunctional TPO allele is impaired thyroid hormone synthesis, leading to **hypothyroidism**. This is most notably associated with **Hashimoto's thyroiditis**, an autoimmune disorder where TPO antibodies attack the thyroid gland, causing inflammation and dysfunction. \n\n\\boxed{Hashimoto's thyroiditis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) gene plays a critical role in thyroid hormone synthesis by catalyzing the oxidation of iodide and the coupling of iodinated tyrosine residues on thyroglobulin (TG), forming intermediates like monoiodotyrosine (MIT) and diiodotyrosine (DIT), which later combine to form triiodothyronine (T3) and thyroxine (T4). Mutations in TPO can lead to impaired iodide oxidation and hormone synthesis. This dysfunction contributes to autoimmune thyroid diseases, particularly **Hashimoto's thyroiditis**, an inflammatory condition where the immune system attacks the thyroid gland. TPO antibodies are commonly found in patients with Hashimoto's, reflecting immune recognition of self-antigens due to TPO dysfunction. These mutations also increase the risk of **hypothyroidism** and may predispose individuals to **thyroid cancer**. The biological effect of the TPO allele is thus a key contributor to autoimmune thyroid disorders. \n\n\\boxed{Hashimoto's thyroiditis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a critical role in thyroid hormone synthesis by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin (TG), forming monoiodotyrosine (MIT) and diiodotyrosine (DIT). These intermediates then couple to form triiodothyronine (T3) and tetraiodothyronine (T4). Mutations in the TPO gene impair this process, leading to defective thyroid hormone production. This dysfunction results in hypothyroidism, as the thyroid gland cannot produce sufficient hormones. TPO mutations are a key genetic contributor to autoimmune thyroid disease, particularly Hashimoto's thyroiditis, where immune-mediated destruction of thyroid tissue further exacerbates hormone deficiency. The TPO allele's role in hormone synthesis directly links it to thyroid dysfunction. \\boxed{Hashimoto's thyroiditis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate, which activates carbamoyl-phosphate synthase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing ammonia detoxification. This results in hyperammonemia, a condition characterized by elevated ammonia levels in the blood. The primary disease associated with NAGS dysfunction is **N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. Patients typically present with neurological symptoms such as seizures, lethargy, and developmental delay due to toxic ammonia accumulation. This disorder is part of the broader category of urea cycle defects. The genetic defect in NAGS disrupts the urea cycle's functionality, leading to severe metabolic complications if left untreated. \\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, a key enzyme in the urea cycle that catalyzes the formation of N-acetylglutamate, which activates CPS1 (carbamoyl-phosphate synthase 1). Mutations in NAGS lead to reduced N-acetylglutamate levels, impairing CPS1 activity and resulting in reduced urea synthesis. This leads to hyperammonemia, a buildup of ammonia in the blood, which is toxic to the brain. The primary disease associated with NAGS mutations is **hyperammonemia due to N-acetylglutamate synthetase deficiency**, a rare autosomal recessive disorder. Affected individuals may present with neurological symptoms such as seizures, coma, or developmental delay. This condition is part of the broader group of urea cycle disorders. The NAGS allele contributes directly to this disease by disrupting the urea cycle's activation step. \n\n\\boxed{Hyperammonemia due to N-acetylglutamate synthetase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the synthesis of N-acetylglutamate, a key activator of carbamoyl-phosphate synthase 1 (CPS1) in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing the urea cycle and causing the accumulation of ammonia. This results in hyperammonemia, a life-threatening condition. The specific disease associated with NAGS mutations is **hyperammonemia due to N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. Affected individuals experience neurological symptoms such as lethargy, seizures, and developmental delay due to toxic levels of ammonia in the blood. The deficiency disrupts nitrogen metabolism, leading to systemic toxicity. Early diagnosis and management, including dietary restrictions and medication, are essential to prevent complications. \\boxed{Hyperammonemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy and neurodegeneration. Impaired autophagy due to ATXN3 dysfunction leads to the accumulation of misfolded proteins, exacerbating neuronal damage. This disruption of protein homeostasis and autophagy contributes to the progression of SCA2. Therefore, the biological effect of the ATXN3 allele is the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA processing and ubiquitin-mediated proteolysis. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive coordination difficulties due to selective degeneration of cerebellar neurons. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation. Impaired autophagy due to ATXN3 dysfunction contributes to the accumulation of misfolded proteins and neurotoxicity, exacerbating SCA2 pathology. The interaction with BECN1 and other autophagy-related genes suggests a role for ATXN3 in maintaining cellular homeostasis through autophagy. This highlights the connection between ATXN3 dysfunction and the progression of neurodegenerative disease.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in RNA processing and proteasomal degradation. Mutations in ATXN3, specifically expansions of the CAG repeat, lead to the accumulation of mutant ataxin-3 protein, which disrupts cellular functions, particularly in neurons. This dysfunction contributes to neurodegeneration. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy regulation. Impaired autophagy due to ATXN3 dysfunction leads to the accumulation of misfolded proteins and neuronal death. This is a hallmark of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor function. The genetic and pathway interactions underscore the role of ATXN3 in maintaining protein homeostasis and neuronal integrity. \n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele described is part of the BRAF-MEK-ERK signaling pathway, a key regulator of cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the ERK pathway, driving uncontrolled cell growth. This dysregulation is a hallmark of several cancers. Specifically, BRAF mutations are strongly associated with melanoma, where they occur in approximately 50% of cases. Additionally, BRAF mutations contribute to the development of other malignancies, including colon adenocarcinoma, lung cancer, and thyroid cancer. The persistent activation of the MAPK/ERK pathway due to mutant BRAF results in oncogenic transformation and tumor progression. The presence of this mutation also influences treatment response, as targeted therapies such as BRAF inhibitors are effective in BRAF-mutant tumors. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade involved in cell proliferation, differentiation, and survival. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, promoting cell growth. Mutations in BRAF, particularly the V600E hotspot mutation, lead to constitutive activation of this pathway, driving uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies, including colorectal cancer, non-small cell lung cancer, and thyroid cancer. The persistent activation of the MAPK/ERK pathway due to mutant BRAF contributes to tumor initiation and progression by promoting cell cycle progression and inhibiting apoptosis. Therefore, the biological effect of the BRAF allele is oncogenic, contributing to the development of **melanoma**. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade involved in cell proliferation, differentiation, and survival. Mutations in the BRAF gene, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway. This results in uncontrolled cell growth and resistance to apoptosis, contributing to oncogenesis. The BRAF-V600E mutation is a well-established driver mutation in several cancers. It is most commonly associated with melanoma, where it occurs in approximately 50% of cases. Additionally, this mutation is found in other malignancies, including thyroid cancer, colorectal cancer, and non-small cell lung cancer. The persistent activation of ERK due to the mutated BRAF leads to increased cell proliferation and tumor progression. Therefore, the biological effect of the BRAF allele, specifically the V600E mutation, is the promotion of tumorigenesis, primarily contributing to melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. In the given pathway, SMO activates GLI transcription factors, which regulate downstream genes such as GLI1, PTCH, HHIP, and BMP2/4. Mutations in SMO that result in constitutive activation of the pathway lead to uncontrolled GLI-mediated transcription, driving abnormal cell proliferation and differentiation. This dysregulation is implicated in several cancers, including basal cell carcinoma (BCC), the most common human malignancy associated with Hh pathway activation. Mutations in SMO, such as those seen in Gorlin syndrome, also contribute to the development of BCC and other developmental disorders. The pathway's involvement in stem cell maintenance and tissue patterning means its aberrant activation can lead to tumor formation and progression. Thus, SMO mutations are strongly associated with \\boxed{basal cell carcinoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The given pathway shows that SMO interacts with SUFU and KIF7, and GLI transcription factors regulate downstream targets such as BMP2/4, HHIP, GLI1, PTCH, and WNT genes. Mutations in SMO can lead to constitutive activation of the Hh pathway, promoting uncontrolled cell proliferation and tissue growth. This dysregulation is associated with several diseases, including basal cell carcinoma (BCC), the most common human malignancy. Activating mutations in SMO, such as those found in BCC, result in persistent Hh signaling, driving tumor growth. Additionally, SMO overactivity has been implicated in other cancers, such as medulloblastoma and some sarcomas. The pathway also intersects with Wnt signaling, further contributing to oncogenic processes. Therefore, the biological effect of an activating SMO allele is the promotion of tumor growth, primarily contributing to \\boxed{basal cell carcinoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway described indicates that SMO is activated, leading to the regulation of GLI transcription factors, which in turn modulate downstream targets such as BMP2/4, HHIP, GLI1, PTCH, and WNT genes. Aberrant activation of SMO, such as through mutations in PTCH1 (a negative regulator of SMO), results in constitutive Hh signaling. This dysregulation is commonly associated with basal cell carcinoma (BCC), a type of skin cancer. Mutations in SMO or its upstream regulators, like PTCH1, lead to uncontrolled cell proliferation and tumor formation, particularly in the skin. Additionally, SMO pathway activation has been implicated in other cancers, including medulloblastoma and certain pancreatic tumors. Therefore, the biological effect of an activating SMO allele is the promotion of uncontrolled cell growth, contributing to the development of basal cell carcinoma.\n\n\\boxed{Basal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway defined (APP \u2192 Abeta \u2192 CxIV \u2192 H2O) illustrates the amyloid-beta generation process. The amyloid-beta precursor protein (APP) is cleaved to produce amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The accumulation of Abeta plaques in the brain is a hallmark of Alzheimer's. The pathway also involves cytochrome c oxidase subunits, which are part of the mitochondrial electron transport chain. Dysregulation of this pathway can lead to mitochondrial dysfunction and oxidative stress, both of which are implicated in neurodegeneration. The conversion of APP to Abeta and its subsequent accumulation contribute to neuronal toxicity and cognitive decline. Therefore, the biological effect of this APP allele is the promotion of amyloid-beta accumulation, directly contributing to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the amyloid beta precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). This Abeta is then processed through CxIV (likely a typo or placeholder for a specific enzyme or protein) to produce water (H2O). This suggests a degradation or clearance pathway for Abeta. The presence of multiple cytochrome c oxidase (COX) subunits indicates a connection to mitochondrial function, as these subunits are components of complex IV in the electron transport chain. The involvement of APP and Abeta is strongly associated with the pathological processes in Alzheimer's disease, where abnormal accumulation of amyloid-beta leads to neurodegeneration. The pathway likely represents a mechanism by which Abeta is metabolized, and dysfunction in this pathway may contribute to the buildup of toxic Abeta plaques. Therefore, the biological effect of this APP allele is its contribution to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele involves the production of amyloid-beta (Abeta) peptides through the sequential cleavage of the APP protein. This process is critical in the pathogenesis of Alzheimer's disease. The pathway described, APP \u2192 Abeta \u2192 CxIV \u2192 H2O, highlights the conversion of APP into Abeta, which aggregates into plaques in the brain, a hallmark of Alzheimer's. While the subsequent steps involving CxIV (possibly a cofactor or chaperone) and the eventual production of water may reflect metabolic byproducts or degradation pathways, the key pathological contribution of the APP allele is the generation of Abeta peptides. These peptides disrupt neuronal function, trigger inflammatory responses, and contribute to neurodegeneration. Therefore, the APP allele's biological effect is central to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele, as part of the NRG (Neuregulin) signaling pathway, plays a critical role in cell growth, differentiation, and survival. ERBB4 is a receptor tyrosine kinase that binds Neuregulin ligands (NRG1-4), initiating intracellular signaling cascades, particularly the MAPK and PI3K/AKT pathways. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to oncogenesis. Specifically, alterations in ERBB4 have been implicated in various cancers, including breast cancer, where it can act as an oncogene by promoting cell proliferation and survival. Additionally, ERBB4 has been associated with neurodevelopmental disorders, such as autism spectrum disorder, due to its role in brain development. However, its most well-documented contribution is to cancer. The most characteristic disease associated with ERBB4 dysregulation is \\boxed{Breast Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular signaling pathways, particularly in neural development, myelination, and cell proliferation. The NRG (Neuregulin) family of ligands activates ERBB4, initiating downstream signaling events essential for proper neural function. Mutations or dysregulation of ERBB4 or its ligands have been implicated in various neurological and psychiatric disorders. Specifically, alterations in the ERBB4 allele have been associated with schizophrenia. This contribution arises from disrupted signaling in neural development and synaptic plasticity, which are critical for cognitive and emotional functions. Abnormal ERBB4 activity can lead to impaired myelination and disrupted connectivity in brain regions such as the prefrontal cortex and hippocampus, both of which are implicated in schizophrenia. Thus, ERBB4 dysfunction contributes to the pathophysiology of \\boxed{Schizophrenia}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular processes such as proliferation, differentiation, and survival. It is activated by ligands like the neuregulins (NRG1\u2013NRG4). Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. In particular, ERBB4 has been implicated in neurodevelopmental disorders, including schizophrenia, due to its role in brain development and synaptic function. Additionally, ERBB4 is involved in cancer progression, especially in breast and lung cancers, where it promotes cell growth and resistance to apoptosis. The interaction between ERBB4 and neuregulins is essential for proper neural development, and disruptions in this pathway are associated with cognitive and behavioral abnormalities. Therefore, mutations in ERBB4 are linked to schizophrenia. \n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation and neuronal function. The pathway indicates that ATXN1 interacts with RORA and KAT5, leading to the regulation of ITPR1, SLC1A6, and GRM1, which are involved in calcium signaling, neurotransmitter transport, and glutamate receptor activity. Mutations in ATXN1 are associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination. The expansion of the CAG repeat in ATXN1 results in the production of an abnormally long polyglutamine tract in ataxin-1, leading to protein misfolding, aggregation, and neuronal toxicity, particularly in the cerebellum. This contributes to the motor deficits observed in SCA1. The pathway highlights the role of ATXN1 in maintaining neuronal homeostasis and its disruption in disease.\n\n\\boxed{Spinocerebellar ataxia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN1 (ataxin 1) is a key gene in the spinocerebellar ataxia type 1 (SCA1) pathway. The pathway defines ATXN1 as interacting with RORA and KAT5, leading to the regulation of ITPR1, SLC1A6, and GRM1. Mutations in ATXN1, particularly expansions of its polyglutamine tracts, are the primary cause of SCA1, a neurodegenerative disorder characterized by progressive degeneration of cerebellar neurons. This results in impaired motor coordination, ataxia, and cognitive deficits. The interaction network suggests ATXN1's role in modulating calcium signaling (via ITPR1), glutamate neurotransmission (via GRM1), and ion homeostasis (via SLC1A6), all of which are disrupted in SCA1. The disease typically presents in mid-adulthood and is linked to the length of the polyglutamine stretch in ATXN1. The pathway highlights the molecular mechanisms underlying ATXN1-mediated neurodegeneration. \n\n\\boxed{Spinocerebellar ataxia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation and cellular processes such as RNA splicing and chromatin remodeling. The pathway described indicates that ATXN1 interacts with RORA and KAT5, which regulate the expression of genes like ITPR1, SLC1A6, and GRM1. Mutations in ATXN1 are associated with spinocerebellar ataxia type 1 (SCA1), an autosomal dominant neurodegenerative disorder characterized by progressive loss of coordination. The expansion of the polyglutamine tract in ataxin-1 leads to protein misfolding, aggregation, and neuronal toxicity, particularly in cerebellar Purkinje cells. This results in motor deficits, cognitive decline, and other neurological symptoms. The involvement of ATXN1 in modulating calcium signaling (via ITPR1) and glutamate receptor function (via GRM1) underscores its role in neuronal excitability and synaptic transmission. Thus, the ATXN1 pathway is central to the pathogenesis of \\boxed{Spinocerebellar Ataxia Type 1}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in cell cycle regulation by inhibiting the MDM2 protein, which normally promotes the degradation of TP53. This allows TP53 to remain stable and functional, enabling it to suppress cell proliferation and induce apoptosis in response to DNA damage. CDKN2A also directly inhibits CDKN1A, which is involved in the regulation of the cyclin D-CDK4/6-RB1-E2F pathway. Loss or mutation of CDKN2A disrupts this regulatory network, leading to unchecked cell proliferation. This contributes to the development of various cancers, particularly those involving the p53 pathway. The most well-known disease associated with CDKN2A dysfunction is melanoma, but it is also implicated in pancreatic cancer and other malignancies. Mutations in CDKN2A are among the most common genetic alterations in melanoma, contributing to its aggressive behavior and resistance to therapy. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in cell cycle regulation by inhibiting the MDM2 protein, which normally targets TP53 for degradation. By stabilizing TP53, CDKN2A ensures proper activation of the p53 pathway, leading to cell cycle arrest or apoptosis in response to DNA damage. CDKN2A also directly inhibits CDK4/6, preventing the phosphorylation of RB1 and thereby blocking the release of E2F transcription factors. This pathway is central to preventing uncontrolled cell proliferation. Loss or mutation of CDKN2A disrupts this regulatory network, leading to unchecked cell division and tumor formation. Mutations in CDKN2A are commonly associated with melanoma and are also implicated in other cancers such as pancreatic cancer. These mutations contribute to genomic instability and resistance to apoptosis, promoting tumorigenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of cyclin D-CDK4/6 complexes. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and destabilizes TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor-suppressive functions, including activation of CDKN1A and inhibition of CDK4/6, leading to cell cycle arrest. Loss or mutation of CDKN2A disrupts this pathway, resulting in unchecked cell proliferation and evasion of apoptosis. This contributes to uncontrolled cell growth, a hallmark of cancer. CDKN2A mutations are strongly associated with various cancers, particularly melanoma, pancreatic cancer, and some leukemias. The loss of CDKN2A function is a key driver in these diseases by allowing p53 inactivation and cyclin D-CDK4/6-mediated progression through the G1 phase of the cell cycle. \\boxed{Melanoma}"]]